0001410578-23-001384.txt : 20230530 0001410578-23-001384.hdr.sgml : 20230530 20230530161546 ACCESSION NUMBER: 0001410578-23-001384 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CureVac N.V. CENTRAL INDEX KEY: 0001809122 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39446 FILM NUMBER: 23976585 BUSINESS ADDRESS: STREET 1: PAUL-EHRLICH-STRABE 15 TUBINGEN CITY: BADEN-WURTTEMBERG STATE: 2M ZIP: 72076 BUSINESS PHONE: 49 7071 9883 0 MAIL ADDRESS: STREET 1: PAUL-EHRLICH-STRABE 15 TUBINGEN CITY: BADEN-WURTTEMBERG STATE: 2M ZIP: 72076 FORMER COMPANY: FORMER CONFORMED NAME: CureVac B.V. DATE OF NAME CHANGE: 20200410 6-K 1 cvac-20230331x6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2023

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

☒

Form 40-F

☐

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of March 31, 2023 and for the three month periods ended March 31, 2023 and 2022; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of March 31, 2023 and for the three month periods ended March 31, 2023 and 2022.

The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CUREVAC N.V.

	By:	/s/Alexander Zehnder
		Chief Executive Officer


Date: May 30, 2023

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2023 and for the three month periods ended March 31, 2023 and 2022
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations

EX-99.1 2 cvac-20230331xex99d1.htm EX-99.1

Exhibit 99.1

CureVac N.V.

Unaudited Interim Condensed Consolidated Financial

Statements

As of March 31, 2023 and December 31, 2022
and for the three months ended
March 31, 2023 and 2022

CureVac N.V.

Interim Condensed Consolidated Statements of Operations and

Other Comprehensive Income (Loss)


		Three months ended March 31,
	Note	2022	2023

(in thousands of EUR, except per share amounts)		(unaudited)
Revenue	3.1	24,373	7,129
Cost of sales	3.2	(37,232)	(20,634)
Selling and distribution expenses	3.3	(271)	(824)
Research and development expenses	3.4	(10,786)	(24,251)
General and administrative expenses	3.5	(24,566)	(23,287)
Other operating income	3.6	33,436	2,006
Other operating expenses		(222)	(494)
Operating loss		(15,268)	(60,355)
Finance income		2,021	3,888
Finance expenses		(1,942)	(951)
Loss before income tax		(15,189)	(57,418)
Income tax benefit/ (expense)	13	96	(1)
Net loss for the period		(15,093)	(57,419)
Other comprehensive income (loss):
Foreign currency adjustments		(55)	19
Total comprehensive loss for the period		(15,148)	(57,400)
Net loss per share (basic and diluted)		(0.08)	(0.27)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

CureVac N.V.

Interim Condensed Consolidated Statements of Financial Position


		December 31,	March 31,
	Note	2022	2023
(in thousands of EUR)			(unaudited)
Assets
Non-current assets
Intangible assets and goodwill	6.1	31,778	30,600
Property, plant and equipment	6.2	197,941	210,475
Right-of-use assets		43,761	42,688
Other assets		1,666	1,697
Deferred tax assets		1,297	1,296
Total non-current assets		276,443	286,756
Current assets
Assets held for sale	7	10,467	10,210
Inventories	8	23,989	24,678
Trade receivables	3.1	6,295	3,379
Contract assets		2,707	2,464
Other financial assets	10	4,487	3,069
Prepaid expenses and other assets	9	40,287	25,597
Cash and cash equivalents	10	495,797	617,519
Total current assets		584,029	686,916
Total assets		860,472	973,672
Equity and liabilities
Equity	4
Issued capital		23,400	26,862
Capital reserve		1,817,287	2,050,235
Treasury Shares		(1,481)	(344)
Accumulated deficit		(1,305,814)	(1,363,234)
Other comprehensive income		(139)	(120)
Total equity		533,253	713,399
Non-current liabilities
Lease liabilities		37,106	36,087
Contract liabilities	3.1	72,549	72,549
Provisions		61,320	61,320
Other liabilities		19	19
Total non-current liabilities		170,994	169,975
Current liabilities
Lease liabilities		4,980	5,058
Trade and other payables	11	73,463	14,973
Provisions		1,922	1,334
Other liabilities	12	40,491	37,715
Income taxes payable		610	607
Contract liabilities	3.1	34,759	30,611
Total current liabilities		156,225	90,298
Total liabilities		327,219	260,273
Total equity and liabilities		860,472	973,672

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

CureVac N.V.

Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity
for the three months ended March 31, 2023 and 2022


					Currency
	Issued	Capital	Treasury	Accumulated	translation	Total
(in thousands of EUR)	capital	reserve	Shares	deficit	reserve	equity
Balance as of January 1, 2022	22,454	1,728,658	(5,817)	(1,056,785)	(34)	688,476
Net loss	—	—	—	(15,093)	—	(15,093)
Other comprehensive income (loss)	—	—	—	—	(55)	(55)
Total comprehensive income (loss)	—	—	—	(15,093)	(55)	(15,148)
Share-based payments (net of taxes)	—	1,090	—	—	—	1,090
Exercise of options	—	(4)	—	—	—	(4)
Settlement of share-based payment awards	—	(2,277)	2,721	—	—	444
Balance as of March 31, 2022 (unaudited)	22,454	1,727,467	(3,096)	(1,071,878)	(89)	674,858


					Currency
	Issued	Capital	Treasury	Accumulated	translation	Total
(in thousands of EUR)	capital	reserve	Shares	deficit	reserve	equity
Balance as of January 1, 2023	23,400	1,817,287	(1,481)	(1,305,814)	(139)	533,253
Net loss	—	—	—	(57,419)	—	(57,419)
Other comprehensive income (loss)	—	—	—	—	19	19
Total comprehensive income (loss)	—	—	—	(57,419)	19	(57,400)
Share-based payments	—	1,578	—	—	—	1,578
Issuance of share capital (net of transaction costs)	3,453	232,387	—	—	—	235,840
Settlement of Share Based Payment awards	9	(1,017)	1,137	—	—	129
Balance as of March 31, 2023 (unaudited)	26,862	2,050,235	(344)	(1,363,234)	(120)	713,399

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

CureVac N.V.

Interim Condensed Consolidated Statements of Cash Flows


	For the three months ended March 31,
	2022	2023

(in thousands of EUR)	(unaudited)
Operating activities
Loss before income tax	(15,189)	(57,418)
Adjustments to reconcile loss before tax to net cash flows
Finance income	(2,021)	(3,888)
Finance expense	1,942	950
Depreciation and impairment of property, plant and equipment and right-of-use assets	9,077	5,853
Loss on disposal of fixed assets	—	239
Impairment of inventory and prepayments	15,944	1,362
Share-based payment expense	2,273	1,578
Non-cash income from release of provisions	(31,858)	(588)

Working capital changes
Decrease / (increase) in assets held for sale	—	257
Decrease / (increase) in trade receivables and contract assets	(9,521)	3,159
Decrease / (increase) in inventory	14,099	(2,050)
Decrease / (increase) in other assets	(23,093)	17,229
Receipts from grants from government agencies and similar bodies	—	—
(Decrease) / increase in trade and other payables, other liabilities and contract liabilities	(96,834)	(67,668)
(Decrease) / increase in other current financial liabilities	—	—
Decrease / (increase) in deferred taxes	—	2
Income taxes paid	—	(4)
Interest received	—	2,034
Interest paid	(1,330)	(633)
Net cash flow (used in) operating activities	(136,511)	(99,586)

Investing activities
Purchase of property, plant and equipment	(16,737)	(13,028)
Purchase of intangible assets	(448)	(134)
Net cash flow (used in) investing activities	(17,185)	(13,162)

Financing activities
Payments on lease obligations	(900)	(1,260)
Proceeds from the issuance of Shares (net of transaction costs)	—	235,840
Payment on / proceeds from treasury shares/exercise of options	440	129
Net cash flow provided by financing activities	(460)	234,709
Net increase (decrease) in cash and cash equivalents	(154,156)	121,961
Currency translation gains (losses) on cash and cash equivalents	895	(239)
Cash and cash equivalents, beginning of period	811,464	495,797
Cash and cash equivalents, end of period	658,203	617,519

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

1. Corporate Information

CureVac N.V. (“CureVac” or “CV” or the “Company”) is the parent company of CureVac Group (“Group”) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.

The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company’s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH & Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 43 – 46 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.

2. Basis of preparation

The interim condensed consolidated financial statements for the three months ended March 31, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on May 22, 2023. The Group’s interim condensed consolidated financial statements are presented in Euros (“EUR”). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.

New standards, interpretations and amendments adopted by the Group

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three months ended March 31, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Impact of COVID-19 and the Russia-Ukraine Conflict

As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company’s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group’s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group’s laboratory and production operations.

The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group’s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.

3. Notes to the consolidated financial statements

3.1 Revenue from contract with customers

The Group recognized the following revenues:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Belgium
GSK	23,746	6,473
Switzerland
CRISPR	180	209
Netherlands
Genmab	447	447
Total	24,373	7,129

Of these revenues, all of which were recognized over time as part of collaboration agreements, during the three months ended March 31, 2023 EUR 4,148k (March 31, 2022: EUR 18,243k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below), (ii) EUR 132k (March 31, 2022: EUR 103k) related to delivery of products and (iii) EUR 2,849k (March 31, 2022: EUR 6,027k) were recognized from those research and development services considered distinct within the agreements.

Of the total revenues recognized, in the three months ended March 31, 2023, EUR 6,473k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (“GSK I”) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac’s second-generation COVID-19 vaccine candidate, CV2CoV (“GSK II”). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the three months ending March 31, 2023, also includes recognition of EUR 423k of the milestone amount (March 31, 2022: EUR 4,725k). The remaining EUR 3,321k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the three months ended March 31, 2022, revenue consisted of EUR 23,746k primarily recognized from the upfront payments under both collaboration agreements with GSK.

The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:


		Upfront and	Upfront and	Revenue recognized from
		milestones payments included	milestones payments included	upfront and milestones payments
	Upfront and milestone	in contract	in contract	for three months ended
	payments	liabilities at	liabilities at	March 31,
Customer	March 31, 2023	December 31, 2022	March 31, 2023	2022	2023

		(EUR k)	(EUR k)	(EUR k)
GSK	EUR 205,000k (EUR 10,000k milestone payment included)	102,804	99,180	17,719	3,624
CRISPR	USD 3,000k (EUR 2,524k)*	929	852	77	77
Genmab	USD 10,000k (EUR 8,937k)*	3,575	3,128	447	447
Total		107,308	103,160	18,243	4,148

* Translated at the currency exchange rate prevailing on the transaction date.

Contract balances:


	December 31,	March 31,
	2022	2023
	EUR k	EUR k
Trade receivables	6,295	3,379
Contract assets	2,707	2,464
Contract liabilities	107,308	103,160

Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.

3.2 Cost of sales

The cost of sales consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(7,937)	(8,188)
Materials	(22,828)	(4,534)
Third-party services	(964)	(5,453)
Maintenance and lease	(231)	(580)
Amortization and depreciation	(5,168)	(1,170)
Other	(104)	(710)
Total	(37,232)	(20,634)

For the three months ended March 31, 2023, cost of sales decreased in comparison to corresponding period in 2022. This decline was primarily attributable to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them.

3.3 Selling and distribution expenses

Selling and distribution expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(197)	(716)
Amortization and depreciation	(17)	—
Other	(57)	(108)
Total	(271)	(824)

Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023 of EUR 675k (March 31, 2022: EUR 129k) and share-based payment expense of EUR 41k (March 31, 2022: EUR 68k).

3.4 Research and development expenses

R&D expenses consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Materials	(17,287)	(3,489)
Personnel	(7,054)	(11,037)
Amortization and depreciation	(1,013)	(1,725)
Patents and fees to register a legal right	(1,855)	(857)
Third-party services	16,800	(4,692)
Maintenance and lease	(36)	(1,766)
Other	(341)	(684)
Total	(10,786)	(24,251)

During the three months ended March 31, 2023, research and development expenses increased in comparison to the same period of 2022, as the prior year period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR 6,800k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group’s committed capacity at Novartis (see Note 3.6 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category.

As of March 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.

Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023 of EUR 10,885k (March 31, 2022: EUR 6,864k) and share-based payment expense of EUR 152k (March 31, 2022: EUR 190k).

3.5 General and administrative expenses

General and administrative expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(9,781)	(9,098)
Maintenance and lease	(1,300)	(1,301)
Third-party services	(5,283)	(7,002)
Legal and other professional services	(2,325)	(1,629)
Amortization and depreciation	(2,938)	(3,106)
Other	(2,939)	(1,152)
Total	(24,566)	(23,287)

Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023, of EUR 7,768k (March 31, 2022: EUR 7,803k) and share-based payment expense of EUR 1,330k (March 31, 2022: EUR 1,978k). During the three months ended March 31, 2023, third-party services expenses increased, compared to the same period of 2022, mainly due to higher consulting services.

3.6 Other operating income


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Compensation for CMO/Material transfer	33,012	1,544
Sale of equipment	310	308
Grants and other cost reimbursements from government agencies and similar bodies	69	2
Other	45	152
Total	33,436	2,006

In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the three months ended March 31, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the three months ended March 31, 2022 (see Note 3.4).

During the three months ended March 31, 2023 and 2022, income from grants with government agencies and similar bodies resulted from the following:

Coalition for Epidemic Preparedness Innovations (CEPI)

In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.

For the three months ended March 31, 2023, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 2k (March 31, 2022: EUR 6k) as “other operating income”. As of March 31, 2023, EUR 307k in grant funds received have been deferred and are presented within other liabilities (December 31, 2022: EUR 309k).

Bill & Melinda Gates Foundation (BMGF)

For the three months ended March 31, 2023, CureVac recognized EUR 0k (March 31, 2022: EUR 63k) from the amortization of the grants on a straight-line basis into other operating income. As of March 31, 2023, EUR 1,712k in grant funds received have been deferred and presented within other liabilities (December 31, 2022: EUR 1,712k).

4. Issued Capital and Reserves

According to the Company’s articles of association, the Company’s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a nominal value of EUR 0.12.

As of March 31, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.

All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders’ equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company’s articles of association.

In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to USD 600.0 million. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 17.5 million in net proceeds; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program amounts to $497.5 million.

In February 2023, the Group completed a follow-on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Group from these transactions were EUR 219,832k. Additional offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.

The number of shares issued and outstanding developed as follows:


Common shares issued and outstanding at December 31, 2022		194,997,091
At-the-market offering program issuances		1,748,218
Share issuances as part of the public offering		27,027,028
Share issuances for exercises between Jan to Mar 2023		112,089
Treasury shares		(32,913)
Common shares issued and outstanding at March 31, 2023		223,851,513

5. Share-based payments

During the three months ended March 31, 2023 and 2022, the Group recognized share-based based payments expenses of EUR 1,578k and EUR 2,273k, respectively, as follows:

Three months ended March 31,


	2022	2023
	EUR k	EUR k
Research and development expenses	189	152
Selling and distribution expenses	67	41
General and administrative expenses	1,978	1,330
Other operating expenses	37	55
Total	2,273	1,578

Expense recognized for the equity-settled programs was as follows:

Three months ended March 31,


Program	2022	2023
	EUR k	EUR k
LTIP Stock Options	1,824	975
RSU Supervisory Board	37	55
New VSOP	103	57
Prior VSOP	92	(51)
LTIP RSUs	216	542
Total	2,273	1,578

On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the Group’s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 options during 2022.

On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options granted to the COO were exercised at that date. The CDO has left the Group and, under the terms of his LTIP agreement, his options had expired as of December 31, 2022.

On March 1, 2021, CureVac granted 2,000 options to a key employee and on January 1, 2022, CureVac granted 9,500 options to a key employee. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.

On March 1, 2022, CureVac granted 130,000 options to the Executive Board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.

On April 1, 2022, CureVac granted 700 options to a key employee. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.

The expenses recognized for employee services received under the LTIP Stock Options during the three months ended March 31, 2023, is in an amount of EUR 975k (2022; EUR 1,824k) and is included in general and administrative expenses and selling and distribution expenses.

In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, the group awarded 10,956 RSUs to Supervisory Board members and on December 23, 2021, the group awarded 63,095 RSUs to the Executive Board and various key employees. Up to March 31, 2023, 47,424 RSU’s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient’s costs are classified.

On January 01, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses. For the three months period ended March 31, 2023, all RSUs were settled.

On January 31, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO) and 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses.

On June 22, 2022, the group awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. On November 30, 2022, the group awarded further 7,633 RSU awards to key employees who joined the Group during fiscal 2022. The related RSU expense is recorded in the functional cost category to which the award recipient’s costs are classified. Up to March 31, 2023, 73,056 RSUs were settled.

Effective July 1, 2022 (‘closing date’), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (‘Frame Pharmaceuticals’), now CureVac Netherlands BV. On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees. The related RSU expense is recorded in the functional cost category to which the award recipients’ costs are classified.

The expenses recognized for employee services received under the LTIP RSUs during the three months ended March 31, 2023, is in an amount of EUR 542k (2022: EUR 216k) and is included in research and development expenses, general and administrative expenses and selling and distribution expenses.

The remaining expense of EUR 57k (2022: EUR 103k) results from grants under the New VSOP and the consideration of the Prior VSOP program leads to an earning of EUR 51k (2022: expense of EUR 92k) in the three-month period ended March 31, 2023.

As the CEO left as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.

Exercise of options

Under the New VSOP plan, 36,516 options were exercised within the first three months of 2023 at a weighted average share price of USD 10.42.

6. Fixed Assets

6.1 Intangible assets

During the three months ended March 31, 2023, the Group acquired intangible assets of EUR 134k (three months ended March 31, 2022: EUR 448k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those.

6.2 Property, plant and equipment

During the three months ended March 31, 2023, the increase in property, plant and equipment was attributable to the purchase of technical equipment and machines and other equipment of EUR 3,206k (March 31, 2022: EUR 1,551k) as well as additional amounts recognized as construction in progress of EUR 12,631k (March 31, 2022: EUR 20,533k) primarily related to the Company-owned GMP IV facility EUR 11,845k.

7. Assets held for sale

In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO-Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell. Criteria for the determination of the fair value were defined based on certain sales scenarios considering different

sales campaigns. All sales activities are scheduled for 2023 and as of March 31, 2023 Assets held for sale with a net book value of EUR 257k were sold through an external service provider.

8. Inventories

The inventories include only raw materials and supplies amounting to EUR 24,678k (December 31, 2022: EUR 23,989k), which are recoverable under the Company’s agreements with its collaboration partners. During the three months ended March 31, 2023, the increase in inventory of EUR 688k is due primarily to the purchases of raw material.

9. Prepaid expenses and other assets (current)

Prepaid expenses and other current assets as of March 31, 2023 amounted to EUR 25,597k (December 31, 2022: 40,287k) and mainly include receivables for the GSK compensation of EUR 3,658k (December 31, 2022; EUR 5,595k). For more details, refer to note 3.6. In addition, other assets include tax claims against the tax authorities of EUR 8,540k (December 31, 2022: EUR 24,840k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.

10. Financial assets and financial liabilities

Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.

Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the three months ended March 31, 2023 and 2022.

11. Trade and other payables

Trade and other payables are all due within one year amounting to EUR 14,973k (December 31, 2022: EUR 73,463k). During the three months ended March 31, 2023, the decrease of EUR 58,490k in trade and other payables was primarily due payments to raw material suppliers for invoices received before December 31, 2022.

12. Other liabilities and provisions

During the three months ended March 31, 2023, the decrease of EUR 2,776k in other liabilities was primarily due to lower accruals for outstanding invoices. During the three months ended March 31, 2023, the decrease of EUR 588k in provisions was primarily due to a consumption of the CRO provision for onerous losses.

13. Income tax

For the three months ended March 31, 2023 and 2022, the Group recorded a consolidated income tax expense (March 31, 2022: income tax benefit) of EUR 1k (March 31, 2022: EUR 96k), respectively. The consolidated income tax expense (March 31, 2022: income tax benefit) for the three months ended March 31, 2023, resulted from income tax expense from CureVac Swiss AG of EUR 1k.

14. Disclosure of financial instruments and risk management

As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the three months ended March 31, 2023, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.

Refer to note 16 to the consolidated financial statements as of December 31, 2022 for additional information on the Group’s risk management activities. As of March 31, 2023, the Group held cash and cash equivalents of USD 76,186k and CHF 124k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds.

15. Earnings per share

Earnings per share is calculated pursuant to IAS 33 Earnings per Share by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.

The weighted number of shares outstanding for the three months ended March 31, 2023 was 211,444,899 (March 31, 2022: 186,993,831). This has led to a basic loss per share for the three months ended March 31, 2023 and 2022 of EUR 0.27 and EUR 0.08, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the three months ended March 31, 2023 and 2022.

16. Related party disclosures

Dietmar Hopp

During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH & Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group’s largest shareholder, purchased EUR 100,000k of the Group’s common shares at a price of USD 16.00 per share.

Antony Blanc

In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfill a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac N.V., Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid in 2023 until March 2023 an amount of EUR 21k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.

BePharBel Manufacturing S.A.

In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group’s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean Stéphenne, Chairman of our Supervisory Board, holds directly and indirectly 15.61% of BePharBel Manufacturing’s equity and is a director of BePharBel Manufacturing, and Baron Jean Stéphenne’s son, Vincent Stéphenne, holds 1.43% of BePharBel Manufacturing’s equity and is a managing director of BePharBel Manufacturing.

Franz-Werner Haas

In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

Alexander Zehnder

In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.

Barker BioMedical GmbH

In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was entered into. Barker BioMedical GmBH is a wholly-owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V.. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

Craig Tooman

In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

17. Subsequent events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company identified no subsequent event that requires disclosure in the financial statements.

EX-99.2 3 cvac-20230331xex99d2.htm EX-99.2

Exhibit 99.2

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes to the financial statements, which are included in this Report of Foreign Private Issuer on Form 6-K. In addition, this information should also be read in conjunction with the information contained in our Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission on April 25, 2023, or the Annual Report, including the consolidated annual financial statements as of and for the year ended December 31, 2022 and their accompanying notes included therein.

Forward-Looking Statements

This Report of Foreign Private Issuer on Form 6-K contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of CureVac N.V. The words “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of CureVac N.V. with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of CureVac N.V. to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, among others, our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs, the timing of and our ability to obtain and maintain regulatory approval for our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates and cost associated with the cancellation of manufacture and supply agreements in the event of termination of our research and development programs, the exercise by the Bill & Melinda Gates Foundation of withdrawal rights, our and our collaborators’ ability to obtain, maintain, defend and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection, the rate and degree of market acceptance of our products, our ability to commercialize our product candidates, if approved, our ability and the potential to successfully manufacture our drug substances and delivery vehicles for preclinical use, for clinical trials and on a larger scale for commercial use, if approved, general economic, political, demographic and business conditions in the United States and Europe, the impact of unstable market and economic conditions such as rising inflation and interest rates and the conflict involving Russia and Ukraine on our business, our ability to implement our growth strategy, our ability to compete and conduct our business in the future, our ability to enroll patients for our clinical trials, the availability of qualified personnel and the ability to retain such personnel, regulatory developments and changes in the United States, Europe and countries outside of Europe including tax matters, our ability to overcome the challenges posed by pandemics (such as COVID-19), to the conduct of our business and other various other factors, whether referenced or not referenced in this Report of Foreign Private Issuer on Form 6-K, that may affect our financial condition, liquidity and results of operations. Various other risks and uncertainties may affect CureVac and its results of operations, as described in reports filed by CureVac with the Securities and Exchange Commission from time to time, including its Annual Report. CureVac does not assume any obligation to update these forward-looking statements.

Unless otherwise indicated or the context otherwise requires, all references in this Report of Foreign Private Issuer on Form 6-K to “CureVac” or the “Company,” “we,” “our,” “ours,” “ourselves,” “us” or similar terms refer to CureVac N.V. together with its subsidiaries.

Overview

We are a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneer in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a targeted approach to optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology and molecular therapy.

In prophylactic vaccines, we are advancing our second-generation mRNA backbone against coronavirus (SARS-CoV-2) and a range of infectious diseases, including influenza, in collaboration with GlaxoSmithKline Biologicals SA (“GSK”).

COVID-19 Program (second-generation mRNA backbone)

The collaboration on COVID-19 vaccine candidates with GSK, was initiated in April 2021, and aims to research, develop and manufacture mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants.

CV2CoV was introduced as the first representative of our joint COVID-19 vaccine program based on our second-generation backbone. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the original SARS-CoV-2 virus, formulated within Lipid Nanoparticles, or LNPs. On June 30, 2021, we published preclinical data in Nature Communications demonstrating full protection by CV2CoV and our first-generation vaccine candidate CVnCoV, from lethal infection caused by SARS-CoV-2 ancestral strain BavPat1 or the Beta variant (B.1.351) in a transgenic mouse model. On August 4, 2022, we further published in the journal Vaccines data from a preclinical study in rats, showing that CV2CoV is able to induce high levels of antigen production in an in vitro setup as well as strong and dose-dependent immune responses in vivo. In a subsequent Nature publication issued on November 18, 2021, we further presented preclinical data investigating immune responses as well as the protective efficacy of CV2CoV in comparison to CVnCoV, against SARS-CoV-2 challenge in non-human primates. A direct comparison of CV2CoV with a licensed mRNA vaccine in non-human primates was able to show that neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of the licensed mRNA vaccine were highly comparable. On April 21, 2022, the preclinical data for CV2CoV and the second-generation mRNA backbone was extended by a study conducted in collaboration with the Friedrich-Loeffler-Institute, comparing immune responses and protective efficacy of monovalent and bivalent mRNA vaccines encoding Beta and/or Delta variants, primarily in a transgenic mouse model and a Wistar rat model. On March 30, 2022, we announced the start of a Phase 1 clinical trial with CV2CoV. The Phase 1 dose-escalation study is being conducted at clinical sites in the United States and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV2CoV in the dose range of 2µg to 20µg.

Within the joint vaccine program with GSK, we also extended our technology platform to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We announced the start of a Phase 1 clinical trial with a chemically modified COVID-19 mRNA vaccine candidate based on our second-generation backbone, CV0501, on August 18, 2022. CV0501 specifically targets the Omicron BA.1 variant. The study is being conducted at clinical sites in the United States, Australia, and the Philippines and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 3µg to 200µg.

On January 6, 2023, we announced that the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the COVID-19 program. In January and April 2023, we also announced positive preliminary data from the CV0501 Phase 1 trial. The data are based on cohort sizes of up to 20 participants in the younger adults age group (age 18-64) and 10 participants in the older adults age group (age ≥65). Reported safety data cover the fully recruited dose groups of 3, 6, 12, 25, 50, 100 and 200µg in the younger adult age group and 12, 25, 50, 100 and 200µg in the older adult age group. CV0501 was shown to be generally well tolerated. Immunogenicity data in both age groups showed relevant titers of neutralizing antibodies beginning at the lowest tested dose. On day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against the Omicron BA.1 variant of 8.1. in younger adults and 13.3 in older adults. The data read-out for both age groups are currently being finalized. A Phase 2 clinical study, expected to start later in 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants. A pivotal Phase 3 trial may be initiated in 2024, contingent on discussion with regulatory authorities.

Seasonal Flu Program (second-generation mRNA backbone)

Influenza was disclosed as the first indication from the initial collaboration we started with GSK in July 2020, which focuses on the development of new products for different targets in the field of infectious diseases.

The first non-COVID-19 vaccine candidate within the broader infectious disease program applying our second-generation backbone we tested in collaboration with GSK is the influenza candidate, CVSQIV, a differentiated multivalent vaccine candidate featuring multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February 10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity and immunogenicity of CVSQIV in the dose range of 3µg to 28µg. Preliminary safety data reported on April 28, 2022, showed a benign reactogenicity profile across the tested dose groups.

In line with the mRNA development strategy to also test chemically modified mRNA and similar to the setup of the COVID-19 vaccine program, CureVac and GSK announced the start of a Phase 1 dose-escalation study with a chemically modified influenza vaccine candidate, Flu-SV-mRNA, on August 18, 2022. The candidate is a monovalent candidate. The Phase 1 dose-escalation study is being conducted in Canada, Spain and Belgium to evaluate the safety, reactogenicity and immunogenicity of Flu-SV-mRNA.

On January 6, 2023, the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the seasonal flu vaccine program. In the Phase 1 study of the monovalent Flu-SV-mRNA, expressing an H1N1 hemagglutinin antigen (subtype of influenza A), five doses ranging from 2 to 54μg with up to 25 subjects per dose cohort were evaluated in younger adults (age 18-45). In this age group, preliminary safety and reactogenicity data showed that the monovalent Flu-SV-mRNA candidate was generally well tolerated with no safety concerns observed to date across all tested dose levels. A single dose of Flu-SV-mRNA (dose level undisclosed) was assessed for safety and reactogenicity in older adults (age 60-80) and was also observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. Immunogenicity of the monovalent Flu-SV-mRNA was assessed in parallel with a licensed seasonal flu vaccine comparator in both age groups. In younger adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA increased up to approximately 3.3 times those elicited by the licensed flu vaccine comparator in younger adults. In older adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA were approximately 2.3 times those elicited by the licensed flu vaccine comparator. In the same age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.

The vaccine candidate for future clinical development is expected to target all four strains recommended by the World Health Organization (WHO) for influenza vaccines. Dosing of the first participant in a Phase 1/2 study for multivalent vaccine candidates was announced on May 8, 2023.

COVID-19 candidate CVnCoV (first-generation mRNA backbone)

On October 12, 2021, we announced the strategic decision to withdraw our first-generation COVID-19 vaccine candidate, CVnCoV, from the approval process with the European Medicines Agency, or EMA, and to focus our COVID-19 vaccine program on the development of second-generation mRNA vaccine candidates in collaboration with GSK. The decision was aligned with the evolving dynamics of the pandemic response toward greater need for more differentiated vaccines. The rolling submission with the EMA was originally initiated in February 2021 to assess CVnCoV’s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, the EMA informed us that it would not start reviewing the provided CVnCoV data packages before 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. By this time, we expected candidates from the second-generation vaccine program to be progressing through clinical development. Consequently, CVnCoV was also withdrawn from a rolling submission with Swissmedic, Switzerland’s authority responsible for the authorization and supervision of therapeutic products, initiated in April 2021, to review the safety, efficacy and pharmaceutical quality of CVnCoV as a prerequisite for market authorization.

All clinical studies with first-generation candidate, CVnCoV, have completed the scheduled safety follow-up times for all trial participants as per the respective trial protocols. These include a Phase 1 study in Germany (initiated in June 2020), a Phase 2a study in Peru and Panama (initiated in September 2020), the Phase 2b/3 (HERALD) study in Europe and Latin America (initiated in December 2020), a Phase 3 study in healthcare workers in Germany (initiated in December 2020), and a Phase 3 study in participants with comorbidities in Belgium (initiated in April 2021).

Data analyses of the Phase 2b/3 (HERALD) study and Phase 3 study in healthcare workers in Germany have been finalized. Primary data of the Phase 2b/3 (HERALD) trial was published in The Lancet Infectious Diseases (“The Lancet”) on November 23, 2021. Data of an interim analysis of the Phase 1 trial in Germany was published in Wiener klinische Wochenschrift on August 10, 2021. Safety and immunogenicity data of the Phase 2a clinical trial in Peru and Panama was published in Vaccine: X on July 1, 2022. Neutralizing antibody data against the ancestral strain and the beta variant after a third dose of CVnCoV in the same trial were published in Vaccines on March 25, 2022.

Previously announced studies to be initiated with CVnCoV, including a Phase 2 clinical trial, focusing on immunogenicity in older adults above the age of 65 years old compared to younger adults and a flu-co-administration study, planned to be initiated together with Bayer AG to assess compatibility with established seasonal vaccines in an older population, were cancelled.

To assess the benefit of booster vaccinations, CVnCoV was also included in the Cov-Boost trial sponsored by the University of Southampton, UK. The Cov-Boost trial started in June 2021 across 18 sites in the United Kingdom and dosed overall 2,878 participants with a third dose vaccine. Initial results from the Cov-Boost trial were published in The Lancet on December 2, 2021.

Our pivotal Phase 2b/3 trial for CVnCoV, which included approximately 40,000 participants, reported interim analysis outcomes on May 28, 2021, and on June 16, 2021. In the highly dynamic variant environment, the HERALD trial met the prespecified success criteria for efficacy against symptomatic COVID-19 of any severity and for efficacy against moderate-to-severe COVID-19, as defined in the protocol. Vaccine efficacy against COVID-19 of any severity was 48.2% in the overall primary efficacy analysis set of SARS-CoV-2 naive participants, and 52.5% in those aged 18–60 years. Vaccine efficacy against moderate-to-severe COVID-19 was 70.7% overall and 77.2% in participants aged 18–60 years. There were too few participants aged 61 years or older who developed COVID-19 to allow a meaningful estimate of efficacy in this age group. HERALD was conducted in an unprecedented evolving landscape with an increasing number of SARS-CoV-2 variants adding additional challenges to the assessment of COVID-19 vaccine candidates. About 50% of cases of COVID-19 in our trial were caused by variants of concern, 35% were caused by variants of interest, as classified by WHO in September 2021, and about 3% were caused by wild-type, with the remaining 11% caused by other variants.

Beyond the GSK COVID-19 and general infectious disease collaboration, our next advanced prophylactic vaccine program, CV7202, is being developed for prophylactic vaccination against rabies. CV7202 is an mRNA based on our first-generation backbone that encodes the rabies virus glycoprotein, RABV-G, formulated with Lipid Nanoparticles. Safety, reactogenicity, and immunogenicity of CV7202 was investigated in a Phase 1 clinical trial that has completed the scheduled follow-up time for all trial participants as per trial protocol. In January 2021, we published data from our Phase 1 trial of CV7202 in Vaccine. CV7202 induced adaptive immune response as shown by rabies-specific virus-neutralizing antibodies above the World Health Organization thresholds considered to be protective, after the second dose in all subjects, at the lowest 1μg and 2μg dose levels. We also showed that the lowest dose levels (1μg and 2μg mRNA) were generally well tolerated. We are currently assessing the path forward for advancing CV7202.

Oncology

In oncology, we plan to build a meaningful portfolio and create long-term value to accelerate growth beyond the recent progress in prophylactic vaccines. Developing new oncology candidates is characterized by similar medical challenges as in infectious diseases, including selection and accessibility of disease-relevant antigens, enhancing antigen-induced immune activation, and triggering immune responses led by a strong induction of tumor-killing T cells.

Taking advantage of recent technology platform advances, particularly our second-generation mRNA backbone in COVID-19 and flu, we are evaluating targeted expansions of our unique mRNA approaches for the development of cancer vaccines. This targeted expansion is based on three strategic pillars:

1.Validation and optimization of our broad mRNA technology approach for T cell mediated tumor control

2.Build-up of a pipeline of cancer vaccine candidates targeting antigens predicted to be immunogenic and presented on tumors in cancer patients

3.Addition of complementary platform technologies for validation and optimization of vaccine design focusing on T cell activation

A key component to deliver on this strategy is the build-up of a powerful antigen discovery engine. To gain access to state-of-the-art antigen discovery technologies we announced a partnership with Belgium-based company myNEO NV (“myNEO”) on May 25, 2022, and the acquisition of Netherlands-based Frame Cancer Therapeutics (“Frame”) on June 8, 2022.

Together with immunotherapy company myNEO, we aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing.

With the acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types, we complement existing in-house expertise to identify and validate promising antigens for mRNA cancer vaccine candidates. The former Frame Cancer Therapeutics site was inaugurated as CureVac Netherlands and will further develop the proprietary technology platform, which has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.

The field of immuno-therapy has advanced with the progression of available technologies to extract data from patient samples, such as next-generation sequencing. Conventional approaches have so far focused on the exome, the protein-coding part of the genome, which represents only about 1.5% of the total genetic information. More recently, breakthrough developments in sequencing capacity have enabled the extraction of vastly larger amounts of data that allows us to utilize the remaining 98.5% of genetic information. The technologies brought in house with the acquisition of Frame Cancer Therapeutics are based on whole-genome-sequencing for every patient sample combined with short as well as long-range RNA sequencing to map the full inventory of genomic changes. More specifically, downstream of the sequencing, a software package integrates all the data to retrieve the exact changes in the DNA of the tumor cells compared to healthy cells. Correlation of this data with changes in the RNA transcription of the tumor results in entirely new and potentially antigenic tumor antigens that we plan to test as targets for a portfolio of new cancer vaccine candidates. These new antigens are not only entirely foreign to the body but are also uniquely expressed in the tumor and not in healthy tissue. In their foreignness, these constructs are expected to raise stronger immune responses than antigens derived from exome-based conventional approaches.

The highly synergistic antigen discovery technologies of Frame Cancer Therapeutics and myNEO are expected to significantly accelerate CureVac’s oncology strategy to build a meaningful portfolio of new cancer vaccine candidates. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone. To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we expect to initiate a proof-of-principle study in the second quarter of 2023, assessing an mRNA construct encoding eight epitopes from tumor associated antigens in patients with surgically resected Glioblastoma Multiforme.

In our oncology strategy, we are committed to drive innovation by also leveraging The RNA Printer®, CureVac’s automated end-to-end manufacturing solution for GMP-grade mRNA vaccines and therapeutics. The highly standardized system is expected to allow for rapid and highly flexible availability of mRNA to screen new targets and transition promising mRNA product candidates more efficiently into the clinic. Designed for small-scale quantities, the automated GMP-grade output of The RNA Printer® is designed to open avenues for personalized mRNA-based cancer therapies. The system is currently undergoing regulatory approval processes to obtain its first manufacturing licenses.

Our clinical oncology candidate, CV8102, is a complex of single-stranded non-coding RNA, which has been optimized to maximize activation of cellular receptors that normally detect viral pathogens entering the cells (such as toll-like receptor 7, or TLR7, toll-like receptor 8, or TLR8, and retinoic acid inducible gene I, or RIG-I pathways), mimicking a viral infection of the tumor. Clinical data support the hypothesis that CV8102 is able to recruit and activate antigen-presenting cells at the site of injection to present tumor antigens released from tumor cells to T cells in the draining lymph node. This potentially leads to activation of tumor-specific T cells, which can kill tumor cells at the injected site, but also at distant non-injected tumor lesions or metastases. CV8102 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with anti-PD 1 antibodies. The trial consists of two parts. The first dose-escalating part assesses CV8102 in 58 patients with solid tumors, namely cutaneous melanoma, adenoid cystic carcinoma, squamous cell carcinoma of skin, and squamous cell carcinoma of head and neck, or HNSCC. As of June 21, 2021, in the single-agent cohort, we observed one patient with a complete response and two patients with a partial response according to Response Evaluation Criteria In Solid Tumors, RECIST, 1.1. In addition, twelve patients experienced a best response of stable disease. In the PD 1 combination cohort, one PD 1 refractory melanoma patient experienced a partial response according to RECIST 1.1. In addition, three patients experienced a best response of stable disease. On November 10, 2021, we added an extensive analysis of immune cell activation. The data showed efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma. Serial tumor biopsies from individual patients demonstrated increased infiltration of T cells in the micro-environment of injected as well as non-injected tumors.

In February 2021, we initiated an expansion of our Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600μg dose in 40 patients with advanced melanoma. On November 11, 2022, we presented preliminary data from the expansion study. As of August 30, 2022, preliminary efficacy was observed in the cohort of 30 patients treated in combination with anti-PD-1 antibodies, 40% of whom were pretreated with anti-CTLA-4 antibodies. In this anti-PD-1 combination cohort, five out of 30 patients (17%) experienced a partial response according to RECIST 1.1. Responses appeared durable for up to one year from the start of treatment. No objective responses were observed in the 10 patients of the single-agent cohort, 50% of whom were pretreated with anti-CTLA-4 antibodies. Analysis of immune cell activation confirmed that CV8102 single agent or combination treatment, after the first dose, activated systemic pathways of immune response. Preliminary analysis of the tumor microenvironment in a subgroup of patients showed the positive outcome of increased infiltration of T cells, following intra-tumoral injection in 4 out of 8 (single agent cohort) and 10 out of 18 (anti- PD1 combination cohort) analyzed paired biopsy samples.

Final study results are expected to be submitted for publication in a peer reviewed journal in the first half of 2023. A scientific paper assessing the mode of action and efficacy of CV8102 for local immunotherapy in preclinical models was published on November 2, 2022, in Cancer Immunology, Immunotherapy.

In the context of our strategic focus on antigen discovery and hence the development of mRNA-based cancer vaccine candidates that target tumor-specific antigens, the clinically validated immuno-modulatory characteristics of CV8102 represent a potentially complementary technology. We would therefore only consider a potential further clinical development of CV8102 based on an integration into our cancer vaccine developments, for example, as a potential immuno-modulatory adjunct to a defined mRNA cancer vaccine candidate.

Molecular Therapies

In molecular therapies, we published preclinical mouse data in liver fibrosis in the Journal of Hepatology in August 2021. Progression of liver fibrosis is associated with the gradual decrease of hepatocyte nuclear factor 4 alpha, or HNF4 alpha, an important regulator and key factor in liver metabolism. In the published study, four independent mouse models of the disease were treated with mRNA encoding HNF4A. The treatment was able to restore HNF4A levels and thereby significantly reduced liver injury. The study was conducted in collaboration with the REBIRTH-Research Center for Translational Regenerative Medicine and Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Hannover (Germany). It provides the first preclinical data demonstrating the therapeutic applicability of mRNA encoded HNF4A in the treatment of liver fibrosis and cirrhosis.

We further expect to publish data from our collaboration with the Schepens Eye Research Institute.

On September 26, 2022, CureVac AG entered into a plan of merger with CureVac Beteiligungsverwaltungs AG, with CureVac SE as the surviving entity and both CureVac AG and CureVac Beteiligungsverwaltungs AG as disappearing entities

Key Factors Affecting Our Results of Operations

We believe that the most significant factors affecting our results of operations include:

Research and Development Expenses

Our ability to successfully pioneer a robust mRNA technology platform and develop innovative product candidates will be the primary factor affecting our future growth and development. Our approach to the discovery and development of product candidates based on mRNA technology is still being demonstrated. As such, we do not know whether we will be able to successfully develop any products. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.

All of the product candidates are still in development, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Due to our accelerated efforts to develop our first-generation backbone COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October 2021 notification to the European Commission, or EC, of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April 2021, we entered into a collaboration agreement with GSK for the development of a broad COVID-19 vaccine program based on our second-generation backbone. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our COVID-19 vaccine program based on the second-generation backbone and presently in the Phase 1 clinical trial, as announced on March 30, 2022. Within this COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation backbone vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID Products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation backbone vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generation backbone for our COVID-19 vaccine candidates, such as for our second-generation backbone COVID-19 vaccine candidates or may pursue new indications with our technology platform.

We have historically funded the research and development expenses primarily through public offerings of our common stock, private placements of equity securities, convertible loans, grants from government agencies and similar bodies and payments for collaborative research and development services with strategic partners. In addition, we signed an advance purchase agreement, or APA, with the EC that provided substantial support for our efforts to advance our first-generation backbone vaccine candidate, CVnCoV. In October 2021, we notified the European Commission of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA.

Our and Our Collaborators’ Ability to Commercialize Our Product Candidates

Our ability to generate revenue from our product candidates depends on our and our collaborators’ ability to successfully advance clinical trials for our product candidates and receive regulatory approval, particularly in the United States, Europe, and other major markets.

We believe that our broad portfolio of product candidates with both novel and validated targets enhances the likelihood that our research and development efforts will yield successful product candidates. Nonetheless, we cannot be certain if any of our product candidates will receive regulatory approvals. Even if such approvals are granted, we will thereafter need to maintain manufacturing and supply arrangements and engage in extensive marketing prior to generating any revenue from such products, and the ultimate commercial success of our products will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.

The competitive environment is also an important factor with the commercial success of our product candidates, and our ability to successfully commercialize a product candidate will depend on whether there are competing product candidates being developed or already marketed by other companies.

We currently do not have any product candidates that have received regulatory approval. As such, we have not incurred any material commercialization expenses in connection with an approved product candidate. In February 2021, we initiated a rolling submission for our first generation COVID-19 vaccine candidate, CVnCoV, with the EMA, which was designed to allow the EMA to assess CVnCoV’s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, EMA informed us that the EMA would not start reviewing our submission for CVnCoV before the beginning of 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. Data on the efficacy of CVnCoV was generated and published in June 2021. This efficacy data did not live up to our pre-trial expectations and fell behind the efficacy of competing COVID-19 vaccine products. The application for the marketing authorization for CVnCoV was withdrawn in early October 2021, as a necessary reaction to the efficacy data as well as the concerns and uncertainties resulting from such data on the granting of a marketing authorization and the expected concerns of prescribers and patients about using a COVID-19 vaccine with a lower efficacy compared to the vaccines already available on the market. After the withdrawal of the application for a marketing authorization for CVnCoV, we have focused our efforts on second-generation mRNA vaccines. The decision is aligned with the evolving dynamics of the pandemic response toward greater need for differentiated vaccines with the gradual transition from an acute pandemic to an endemic SARS-CoV-2 environment. In connection with the regulatory approval process, and in preparation for the commercialization of a second-generation COVID-19 vaccine, we expect our expenses related to commercialization to significantly decrease in the short-term due to our past commercialization efforts for CVnCoV. However, we expect that our expenses related to commercialization will significantly increase in the long term if a second-generation COVID-19 vaccine candidate reaches late clinical stages, but we expect that this increase in expenses will be mitigated by the GSK COVID Agreement, as described below. As part of the commercialization process of CVnCoV, we also entered into strategic partnerships with Bayer for the development, production and distribution of CVnCoV. In addition, pursuant to a preliminary agreement regarding the secondary manufacturing of CVnCoV we entered into with GSK, GSK would have supported the secondary manufacturing of up to 100 million doses of CVnCoV in 2021. Additionally, we also partnered with Fareva, Rentschler Biopharma SE, and Novartis AG, among others, to develop an integrated European manufacturing network. Due to our decision to withdraw CVnCoV from the regulatory approval process and focus our efforts on second-generation mRNA vaccine, separate agreements with Celonic and Wacker were terminated.

Our Collaborations, Related License Agreements and Advance Purchase Agreements

Our results of operations have been, and we expect them to continue to be, affected by our contractual collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, our future results of operation may be affected by future advance purchase agreements for our COVID-19 vaccine candidates. To date, our revenues have been recognized pursuant to license and collaboration agreements, which include upfront payments for licenses or options to obtain licenses, milestone payments, payments for product sales and payments for research and development services. Grants from government agencies or similar bodies are recognized as other operating income or as a reduction to depreciation and amortization expense recognized from assets purchased under the associated arrangements.

We have entered into strategic collaborations and license agreements with third parties. In addition, on November 30, 2020, we entered into an advance purchase agreement, or APA, with the European Commission, which provided for the advance purchase by the commission of our first-generation vaccine candidate, CVnCoV. In October 2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA. As part of our business development strategy, we aim to increase the number of our strategic collaborations in order to derive further value from our platform and more fully exploit the potential of our collaboration and license agreements. Relatedly, on April 8, 2022, we received a letter from the Federal Republic of Germany's counsel confirming that the CureVac-GSK Consortium (as defined below), was awarded with the Pandemic Preparedness Agreement (as defined below).

Certain key terms of our current material collaboration and license agreements, our advance purchase agreement with the EC, the CureVac-GSK Consortium and the Pandemic Preparedness Agreement ("PPA") are summarized below.

GlaxoSmithKline

In July 2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. The 2020 GSK Agreement was amended and restated in April 2021, September 2021, February 2022 and March 2022.

GSK paid us an upfront payment of €120 million and is required to pay us a manufacturing capacity reservation fee of €30 million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between €28 million to €45 million in development milestone payments, €32 million to €35 million in regulatory milestone payments and €70 million to €100 million in commercial milestone payments, depending on the product. Under the 2020 GSK Agreement, we granted GSK an exclusive option to add additional products in the field of infectious diseases to the license granted under the 2020 GSK Agreement and, upon each exercise of such option, GSK is required to compensate us for certain development costs and pay any accrued milestone payments. Additionally, GSK has the right to replace products licensed under the 2020 GSK Agreement and, if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are additionally eligible to receive tiered royalty payments ranging from single-digit to low-teens percentages on net sales, subject to certain customary reductions. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with performing our obligations under the 2020 GSK Agreement, and we are eligible to receive up to €20,000 in reimbursements for expenses incurred by recording or registering the licenses granted under the 2020 GSK Agreement. We retain the right to commercialize products developed under the 2020 GSK Agreement in Germany, Austria and Switzerland, as GSK’s exclusive distributor in these markets. Under any such distribution agreement to be entered into between us and GSK, we will be required to purchase supply from GSK and pay GSK a low thirties percentage royalty on net sales. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities set forth in updated development plans. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly.

Additionally, in April 2021, we entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV 2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID 19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV 2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021, February 2022 and March 2022, and further amended to update the research and development plan in August 2022. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by us, GSK or jointly.

Under the GSK COVID Agreement, GSK paid us an upfront payment of €75 million. We and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID Products, other than Combination Products (as defined therein), under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from sub-teen to mid-teen percentages on net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement we have the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if we exercise such right, our sales of GSK COVID Products, other than Combination Products will be subject to the profit share and we will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries.

Genmab

In December 2019, we entered into a Collaboration and License Agreement, which we refer to as the Genmab Agreement, with Genmab A/S to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab’s proprietary antibody technology for the treatment of human diseases. We will collaborate on research to identify an initial product candidate designed to express a certain Genmab proprietary antibody, and we will contribute a portion of the overall costs for the development of such product candidate, until submission of an IND. Genmab will thereafter be responsible for the development and commercialization of the product candidate. Under the Genmab Agreement we further grant Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under our mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.

Under the terms of the Genmab Agreement, Genmab paid us a $10 million upfront fee and made a €20 million equity investment in March 2020. Genmab will be obligated to pay us a $0.5 million reservation fee upon the selection of each additional product concept for development under the Genmab Agreement and $5 million upon selection of a product targeting Genmab’s proprietary antibody for further development and commercialization. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid single-digit to low teens percentage tiered royalty on aggregate net sales of licensed products, on a per-product basis and subject to certain customary reductions. If Genmab grants a sublicense to the initial product candidate developed under the Genmab Agreement before a certain milestone event, Genmab must pay us a one-time $10 million payment. We are responsible for any payments to third parties related to the LNP technology we license to Genmab for use in relation to the initial product candidate developed under the Genmab Agreement and a portion of such payments with respect to LNP technology used in the additional product concepts. We retain an option to participate in development and commercialization of one of the potential additional mRNA antibody product concepts under predefined terms and conditions. In the event we exercise such right, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of March 31, 2023, we have received $1 million in development cost reimbursements and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.

Arcturus

In January 2018, we entered into a Development and Option Agreement, which we refer to as the Arcturus Agreement, with Arcturus, which provides us with access to Arcturus LNP formulation technology which we use in combination with our mRNA technology. We paid Arcturus an upfront fee of $5 million and must pay an extension fee of $1 million if we exercise our option to extend the initial term of the Arcturus Agreement beyond July 2023. We are required to reimburse Arcturus for certain costs incurred in connection with development activities and provide certain FTE funding. We are additionally required to pay up to an aggregate of $5 million in connection with our acceptance of the irrevocable offer to obtain licenses for further development and commercialization of selected targets. As of March 31, 2023, we have not exercised our option to extend and accept any such irrevocable offer. Under each license agreement to be entered into in connection with our acceptance of the irrevocable offer, we will additionally be required to make certain royalty payments, which are not in excess of 10% on net sales of licensed products, and pay Arcturus up to $6 million in development milestone payments, $9 million in regulatory milestone payments and $8 million in commercial milestone payments. As of March 31, 2023, we have made payments totaling $5.5 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations, and we have not accepted the irrevocable offer with respect to any target and therefore have not paid any acceptance fees or made any milestone or royalty payments to Arcturus.

Acuitas

In April 2016, we entered into a Development and Option Agreement, which as amended we refer to as the Acuitas Agreement, with Acuitas, which provides us with access to Acuitas LNP formulation technology that we use in combination with our mRNA technology. We are required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement and to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option to obtain a license for further development and commercialization with respect to a selected target, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million upfront fee in connection with an amendment to the Acuitas Agreement dated July 2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we are required to pay an exchange fee of $3 million. We additionally paid Acuitas a $3 million upfront fee in connection with an amendment to the Acuitas Agreement dated December 2020 and are required to pay an additional $250,000 in April 2023 for certain options not yet exercised. Under each license agreement in connection with our exercise of our option, we will additionally be required to make low single-digit percentage tiered royalty payments and must pay up to between $1.1 million and $9 million in development milestone payments, $1.3

million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of March 31, 2023, we have exercised our option to obtain a non-exclusive license to 17 targets, subject to customary closing conditions. As of March 31, 2023, we have paid Acuitas $8.0 million in reservation and option exercise fees and $1.25 million for certain options not yet exercised and have made payments totaling $8.8 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations.

For each option that we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned target, all based on the same form agreement, which we refer to as the Acuitas License Agreements. We are required to pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and between $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement. We must pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under each Acuitas License Agreement after a certain milestone event. Additionally, we are obligated to pay Acuitas a low single-digit percentage royalty on net sales of licensed products. As of March 31, 2023, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, and have not made any royalty payments.

CRISPR Therapeutics

In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics which, as amended by an amendment entered into in June 2020, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics an exclusive worldwide license to use our improved Cas9 constructs for the development and commercialization of three of its in vivo gene-editing programs for certain diseases.

CRISPR Therapeutics paid us an upfront one-time technology access fee of $3 million, and we are eligible to receive up to $13 million in development milestone payments, $33 million in regulatory milestone payments and $133 million in commercial milestone payments, as well as mid-single-digit percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. Additionally, CRISPR Therapeutics will make payments to us for services provided by us in conjunction with research programs under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the CRISPR Therapeutics Agreement, CRISPR Therapeutics must pay us a low teens to mid-twenties percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of March 31, 2023, we have received €4.3 million in payments and we have invoiced €3.0 million for the supply of materials and FTE cost, development reimbursements and upfront one-time technology access fee and no milestone, royalty or sublicense fee payments.

Bill & Melinda Gates Foundation

In May 2014, we were awarded a grant from the Bill & Melinda Gates Foundation for the development of a vaccine for rotaviruses, as amended in November 2020, for up to $2.8 million in funding. As of March 31, 2023, we have received $3.0 million in funding under the agreement. In March 2015, the Bill & Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility. We entered into a Global Access Commitments Agreement with the Bill & Melinda Gates Foundation in February 2015 pursuant to which we are required to take certain actions to support the Bill & Melinda Gates Foundation mission. In connection with the investment by the Bill & Melinda Gates Foundation, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill & Melinda Gates Foundation. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits.

In November 2016, in connection with the Global Access Commitments Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill & Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of March 31, 2023, we have received $0.7 million in funding under the picornaviruses grant agreement. The term of the picornavirus grant expired in June 2022; however, our global access commitments survive. In November 2017, we were awarded two additional grants each for up to $1.9 million and $1.5 million in funding from the Bill & Melinda Gates Foundation for the development of a universal influenza and a malaria vaccine, respectively. By an amendment entered into November 2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of March 31, 2023, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement. The malaria grant agreement expired in December 2022 and the universal influenza grant agreement expired in March 2022. We and the Bill & Melinda Gates Foundation are currently assessing options to continue the influenza grant agreement.

Coalition for Epidemic Preparedness Innovations

In February 2019, we entered into a framework partnership agreement, which as amended we refer to as the CEPI Agreement, with the Coalition for Epidemic Preparedness, or CEPI, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products, as well as certain additional intellectual property licensed to us. In connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase 1 clinical trial for our first-generation COVID-19 vaccine candidate, CVnCoV. The CEPI Agreement terminated in February 2022, except with respect to certain ongoing projects, which are contemplated to be completed in December 2023. CEPI agreed to contribute up to $34 million in funding for projects undertaken under the CEPI Agreement and an additional $15.3 million in connection with development of CVnCoV. As of March 31, 2023, we have received €27.1 million in funding for projects undertaken under the CEPI Agreement. Following the completion of the CEPI Agreement, CEPI requested a partial reimbursement of $1.0 million for unspent funds.

Tesla Automation

In November 2015, we entered into a development and intellectual property agreement with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, which we refer to as the Tesla Automation Agreement, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of March 31, 2023, we have paid Tesla Automation €20 million to €21 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.

Research and Option Agreement with myNEO

On May 12, 2022, we entered into a Research and Option Agreement (“R&O”) with myNEO, pursuant to which we will both collaborate to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer and melanoma (the “Main Indications”) and potentially other indications. We are required to use commercially reasonable efforts to develop at least one product for each of the Main Indications, to file marketing approval applications for such products and commercialize such products in at least one of certain countries. Under the R&O, myNEO will own all intellectual property rights generated solely by myNEO or jointly with us during the first three phases of the R&D plan (the “R&D Project IP”). We receive a non-exclusive, royalty-free, non-assignable, sublicensable, worldwide license under certain patents and know-how owned by myNEO and R&D Project IP to the extent required to perform our research and development obligations under the agreement until the completion of a certain phase of the R&D plan. We were also granted an exclusive option to acquire all of myNEO’s rights under certain R&D Project IP relating to certain target lists, which we exercised on April 12, 2023. myNEO receives a non-exclusive, royalty-free, perpetual license back to such IP to make, use or sell certain targets in the field of patient-specific vaccines. Under the R&O, myNEO agrees to work exclusively with us to develop and validate shared antigens for the Main Indications until the earlier of the date of the first phase I clinical trial for either Main Indication or 24 months after we exercised our option.

Under the R&O, we paid myNEO an upfront one-time technology access fee of €138,000 and myNEO is eligible to receive up to €17.5 million in research and development milestone payments with respect to the Main Indications, up to €175,000 in research and development milestone payments with respect to indications other than the Main Indications, up to €30 million in commercial milestone payments with respect to the Main Indications and up to €7.5 million in commercial milestone payments with respect to indications other than the Main Indications, as well as low single-digit percentage royalties on the net sales of licensed products in the Main Indications and sub single-digit percentage royalties on the net sales of licensed products for indications other than the Main Indications. Our royalty obligations continue on a product-by-product and country-by-country basis until the earlier of the date when there are no valid patent claims covering such licensed product in such country and 10 years following the date of first commercial sale of such licensed product in such country.

Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate

On November 30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an upfront payment of €450 million. Such upfront payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the upfront payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October 2021, we notified

the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would only return the unspent amount of the upfront payment. In the context of the APA, “spent” means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March 8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the upfront payment. Due to the termination of the APA, we will not receive any further payments related to the APA.

In other respects, upon the EC’s request, we will transfer any raw materials and/or primary components paid for with the upfront payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expired at the end of 2022 and an amount of €4.1 million is accrued as of March 31, 2023, for the related amount due to be remitted to the EC.

Acquisition of Frame Pharmaceuticals

June 8, 2022, we entered into a Share Purchase Agreement (“SPA”), to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., domiciled in Amsterdam, the Netherlands, a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), organized and existing under the laws of the Netherlands, focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. Under the SPA, the total consideration for the purchase was €34 million, conditioned on certain development milestone payments, as described therein. This acquisition serves to complement and strengthen our discovery capabilities to identify and validate promising neoantigens for our mRNA cancer vaccine programs and could strongly increase the likelihood of developing highly effective cancer vaccines for patients.

CureVac-GSK Consortium Agreement

The Federal Republic of Germany, represented by the Vaccine Production Taskforce on behalf of the Federal Ministry of Health, called for tenders relating to pandemic preparedness, which we refer to as the Tender Procedure. The Tender Procedure resulted in framework agreements for the provision to the Federal Republic of Germany of production capacities and, upon demand, the production and supply of mRNA vaccines (referred to as lot 1) and vector- or protein-based vaccines (referred to as lot 2). Because neither we nor GSK were alone in a position to provide the full range of services requested by the Federal Republic of Germany under the Tender Procedure, we established a consortium with GSK (referred to as the CureVac-GSK Consortium) for the purpose of participating in the Tender Procedure, entering into a framework agreement for the provision of production capacities and, upon demand, the production and supply of mRNA vaccines (lot 1), which we refer to as a Pandemic Preparedness Agreement.

The CureVac-GSK Consortium submitted an application and offer under the Tender Procedure for the award of a Pandemic Preparedness Agreement. On April 8, 2022, the Federal Republic of Germany sent a letter confirming that the CureVac-GSK Consortium had been awarded a Pandemic Preparedness Agreement. Following a qualification phase of a maximum of two years from the award date, the Pandemic Preparedness Agreement grants the government access to a manufacturing capacity of 80 million doses of mRNA-based vaccine per year until 2029, subject to extension. Under the contract, after successful achievement of pandemic preparedness by the end of the qualification phase, the contract will enter into a stand-by phase during which the government will pay the CureVac-GSK Consortium an annual stand-by fee. During the stand-by phase, the CureVac-GSK Consortium is required to maintain a manufacturing capacity of 80 million doses of mRNA-based vaccine per year at constant readiness. The Pandemic Preparedness Agreement is subject to termination by the Federal Republic of Germany or the CureVac-GSK Consortium if, among other things, by the end of the qualification phase the CureVac-GSK Consortium does not have an mRNA-based vaccine for which a marketing authorization (which may be temporary) for the German market has been granted.

Pandemic Preparedness Agreement with the Federal Republic of Germany

On February 20, 2022, the CureVac-GSK Consortium submitted its best and final offer in the Tender Procedure for the conclusion of framework agreements for the provision of production capacities and, on demand, for the production and supply of mRNA vaccines (lot 1). On April 8, 2022, the CureVac-GSK Consortium received a letter from the Federal Republic of Germany’s counsel confirming that the CureVac-GSK Consortium had been awarded a Pandemic Preparedness Agreement. Pursuant to the Pandemic Preparedness Agreement, the CureVac-GSK Consortium will have to achieve, within a two years’ time frame beginning from the award of the Pandemic Preparedness Agreement, a state in which it is considered qualified to provide manufacturing capacities in Germany for 160 million doses of mRNA vaccine per year, including procurement of the required nonproduct specific manufacturing licenses and insurances and to have achieved “pandemic preparedness,” which means, inter alia, that we maintain the GMP IV facility in a stand-by mode that can be activated for manufacture of a so-called selected vaccine at any time and that the CureVac-GSK Consortium is complying with the material requirements set out in the Pandemic Preparedness Plan (in particular with the requirements regarding the assurance of a supplier network and the availability of the critical supplier products).

If qualification and pandemic preparedness is achieved by the end of the two years’ time frame beginning from the award of the Pandemic Preparedness Agreement (and if the Pandemic Preparedness Agreement is not terminated because the CureVac-GSK Consortium does not have an mRNA-based vaccine for which a marketing authorization for the (at least temporary) placing on the

German market has been granted at this time), the CureVac-GSK Consortium will receive a stand-by fee which will be shared between us and GSK in accordance with the agreement governing the CureVac-GSK Consortium. The phase following the qualification phase (stand-by phase) during which pandemic preparedness is to be maintained is for five years, it being understood that this term may be extended by mutual agreement up to three times for a subsequent one-year renewal term.

At any time during the stand-by phase, in case there is a public health emergency, the Federal Republic of Germany may exercise its preferred purchase right and/or its preferred manufacturing right. If the preferred purchase right is exercised the CureVac-GSK Consortium will have to deliver up to 80 million doses of the mRNA vaccine of the CureVac-GSK Consortium, and if the preferred manufacturing right is exercised the CureVac-GSK Consortium will have to act as a contract manufacturer and manufacture a third party’s mRNA vaccine in our GMP IV facility. However, there are strict and narrow requirements to be fulfilled before the Federal Republic of Germany may exercise the preferred manufacturing right.

Financial Operations Overview

Revenue

To date, our revenues have consisted of up-front licensing payments, milestone payments, product sales and compensation for research and development services, all of which relate to our license and collaboration agreements. Certain of these payments are initially recorded on our statement of financial position and are subsequently recognized as revenue in accordance with our accounting policy as described further in note 3 to our audited consolidated financial statements included in the Annual Report.

Cost of Sales

Cost of sales consists primarily of personnel costs, costs for materials and third party services, including any relating to written-off inventory, as well as maintenance and lease costs, and depreciation and amortization. Costs of sales includes costs of product sales, idle production costs and costs from set-up and quality assurance activities for our production processes, including those relating to pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues. See “Research and Development Expenses” below for additional information on recognition of costs relating to pre-launch products.

Selling and Distribution Expenses

Selling and distribution expenses primarily consist of personnel expenses which include salary and salary-related expenses and expenses from share-based compensation.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research and preclinical and clinical development activities, including our product discovery efforts and certain activities relating to the design of GMP-manufacturing facilities. Research and development expenses contain wages and salaries, share-based compensation, fringe benefits and other personnel costs, the costs of clinical testing and the associated clinical production costs, research material production costs, fees for contractual partners, consultants and other third parties, fees to register legal rights, amortization of licensed software and intellectual property as well as costs for plant and facilities. Research and development expenses contain costs for independent research and development work as well as work carried out in the context of collaboration and licensing agreements; such expenses include all costs related to research and development services delivered under our collaboration arrangements. Additionally, prior to initial regulatory approval, if any, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin, as the underlying costs will not be included in cost of sales as they will have been recognized in research and development expense in the period incurred.

We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generations of our COVID-19 vaccine candidates, such as for our second-generation COVID-19 vaccine candidates or may pursue new indications with our technology platform.

General and Administrative Expenses

General and administrative expenses generally include wages and salaries, share-based compensation, fringe benefits and other personnel costs of our senior management and administrative personnel, costs for professional services, including legal, audit and consulting services and costs of facilities and office expenses.

Results of Operations

Comparison of the Three Months Ended March 31, 2022 Compared to Three Months Ended March 31, 2023

We have based the following discussion of our financial condition and results of operations on our unaudited interim condensed consolidated financial statements for the three months ended March 31, 2022 and 2023 and the notes thereto, included elsewhere in this Report of Foreign Private Issuer on Form 6-K.

Our historical results for the three months ended March 31, 2022 and 2023 are not necessarily indicative of results to be expected for a full year or any other interim period.

The following table summarizes our consolidated results of operations for the three months ended March 31, 2022 and 2023:


	For the Three Months Ended
	March 31,
	2022	2023

(in thousands of euros, except per share data)	(unaudited)
Statement of Operations and Comprehensive Income (Loss) Data:
Revenue	24,373	7,129
Cost of sales	(37,232)	(20,634)
Selling and distribution expenses	(271)	(824)
Research and development expenses	(10,786)	(24,251)
General and administrative expenses	(24,566)	(23,287)
Other operating income	33,436	2,006
Other operating expenses	(222)	(494)
Operating loss	(15,268)	(60,355)
Finance income	2,021	3,888
Finance expenses	(1,942)	(951)
Loss before income tax	(15,189)	(57,418)
Income tax benefit (expense)	96	(1)
Net loss for the period	(15,093)	(57,419)
Other comprehensive income (loss):
Foreign currency adjustments	(55)	19
Total comprehensive loss for the period	(15,148)	(57,400)
Net loss per share (basic and diluted)	(0.08)	(0.27)

Revenue

Revenue was €7.1 million for the three months ended March 31, 2023, representing a decrease of €17.3 million, or 71%, from €24.4 million for the three months ended March 31, 2022. The decrease was primarily driven by lower sales to GSK due to changes in the timeline of certain projects.

Cost of Sales

Cost of sales was €20.6 million for the three months ended March 31, 2023, representing a decrease of €16.6 million, or 45%, from €37.2 million for the three months ended March 31, 2022. The decrease was primarily attributable to a decrease in write-offs of raw materials, which were in prior periods procured for manufacturing products to sell to GSK.


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Personnel	(7,937)	(8,188)
Materials	(22,828)	(4,534)
Third party services	(964)	(5,453)
Maintenance and lease	(231)	(580)
Amortization and depreciation	(5,168)	(1,170)
Other	(104)	(710)
Total	(37,232)	(20,634)

Selling and Distribution Expenses

Selling and distribution expenses were €0.8 million for the three months ended March 31, 2023, representing an increase of €0.5 million, or 204%, from €0.3 million for the three months ended March 31, 2022. The increase was primarily attributable to higher personnel expenses due to an increased business development workforce.


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Personnel	(197)	(716)
Amortization and depreciation	(17)	—
Other	(57)	(108)
Total	(271)	(824)

Research and Development Expenses

Research and development costs were €24.3 million for the three months ended March 31, 2023, representing an increase of €13.5 million, or 125%, from €10.8 million for the three months ended March 31, 2022. The increase was primarily attributable to prior year impacts caused by (i) the reversal of provision for onerous contracts in the amount of €6.8 million as a result of more participants leaving the clinical trials, prior to completion, than originally estimated; and (ii) renegotiations of contracts with CROs. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at CMO.


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Materials	(17,287)	(3,489)
Personnel	(7,054)	(11,037)
Amortization and depreciation	(1,013)	(1,725)
Patents and fees to register a legal right	(1,855)	(857)
Third party services	16,800	(4,692)
Maintenance and lease	(36)	(1,766)
Other	(341)	(684)
Total	(10,786)	(24,251)

The following table reflects our research and development costs for each of our programs for the three months ended March 31, 2022 and 2023:


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Key Programs (CV8102, CV7202, CV2CoV and CVnCoV)
CV8102	(537)	(450)
CV7202	(39)	(13)
Second Generation Covid (CV2CoV and CV0501)	(3,055)	(7,226)
CVnCoV	6,117	2,625
Other Research and Development Programs	(2,080)	(5,853)
Unallocated costs(1)	(11,192)	(13,334)
Total	(10,786)	24,251

(1)	Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third party service expenses and certain material expenses.

We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates.

Considering that, our research and development expenses primarily relate to the following key programs:

●

Our modified mRNA vaccine candidate against SARS-CoV-2, CV0501, a monovalent construct, developed in collaboration with GSK. A Phase 1 study was initiated in August 2022. We reported positive preliminary data in early 2023. A Phase 2 clinical study, expected to start later in 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants. Novel cancer vaccine candidates based on differentiated antigen discovery technologies and bioinformatics to target antigens that are overexpressed in tumor tissues with no or little expression on healthy tissues. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone. To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we expect to initiate a proof-of-principle study in the second quarter of 2023, assessing an mRNA construct encoding eight epitopes from tumor associated antigens in patients with surgically resected Glioblastoma Multiforme.

●

Our oncology program, CV8102, which is currently in a Phase 1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD1 and an expansion of the Phase 1 study to evaluate the safety, tolerability and efficacy of CV8102 at a 600μg dose in patients with PD-1 refractory melanoma – also as a monotherapy and in combinations with anti-PD-1 antibodies.

●

Our vaccine program, CV7202, which is currently in a Phase 1 clinical trial as a vaccine candidate for rabies.

General and Administrative Expenses

General and administrative expenses were €23.3 million for the three months ended March 31, 2023, representing a decrease of €1.3 million, or 5%, from €24.6 million for the three months ended March 31, 2022. The decrease was primarily attributable to less legal services and lower share-based payment expenses.


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Personnel	(9,781)	(9,098)
Maintenance and lease costs	(1,300)	(1,301)
Third party services	(5,283)	(7,002)
Legal and other professional services	(2,325)	(1,629)
Amortization and depreciation	(2,938)	(3,106)
Other	(2,939)	(1,152)
Total	(24,566)	(23,287)

Other Operating Income

Other operating income was €2.0 million for the three months ended March 31, 2023, representing a decrease of €31.4 million, or 94%, from €34.4 million for the three months ended March 31, 2022. The decrease was primarily attributable to the impacts of the amendments to the 2020 GSK Agreement and the GSK Covid Agreement, under which CureVac was entitled to further compensation by GSK for set-up activities undertaken by CureVac (€20.5 million) and for reimbursement of prepayments (€12.0 million).

Other Operating Expense

Other operating expense was €0.5 million for the three months ended March 31, 2023, representing an increase of €0.3 million, or 123%, from €0.2 million for the three months ended March 31, 2022. Other operating expense related primarily to compensation expense of our Supervisory Board.

Finance Income

Finance income was €3.9 million for the three months ended March 31, 2023, representing an increase of €1.9 million, or 92%, from €2.0 million for the three months ended March 31, 2022. The increase was primarily attributable to positive interest on cash investments.

Finance Expenses

Finance expenses were €1.0 million for the three months ended March 31, 2023, representing a decrease of €1.0 million, or 51%, from €1.9 million for the three months ended March 31, 2022. The decrease was primarily attributable to less foreign exchange losses and no negative interest on cash.

Income Tax Expense

An income tax expense of €0.5 thousand was generated for the three months ended March 31, 2023, representing a decrease of €96.7 thousand, from an income tax benefit of €96.2 thousand generated for the three months ended March 31, 2022. The decrease to an expense was primarily attributable to the income tax expense of CureVac Swiss AG.

Liquidity and Capital Resources

Our financial condition and liquidity is and will continue to be influenced by a variety of factors, including:

●

our ability to generate cash flows from our operations;

●

future indebtedness and the interest we are obligated to pay on this indebtedness;

●

the availability of public and private debt and equity financing;

●

changes in exchange rates which will impact our generation of cash flows from operations when measured in euros; and

●

our capital expenditure requirements.

Overview

Since inception, we have incurred significant operating losses. For the three months ended March 31, 2022 and 2023, we incurred net losses of €15.1 million and €57.4 million, respectively. To date, we have financed our operations primarily through the IPO in August 2020, follow-on public offerings, private placements of equity securities, issuance of convertible debt, grants from government agencies and similar bodies and payments for collaborative research and development services. Our cash and cash equivalents as of March 31, 2023 were €617.5 million. Our primary cash needs are to fund our non-clinical and clinical development programs, for working capital requirements and for capital expenditures. We believe our existing cash, cash equivalents, borrowings available to us, receipts from grants and short-term investments will enable us to fund our operating expenses and capital expenditure requirements at least through the middle of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

In February 2023, we sold an additional 27,027,028 common shares in an underwritten public offering at an offering price of $9.25 per share raising $234.2 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses payable by us.

In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Securities LLC, as sales agents, to establish an at-the-market offering (“ATM Program”), pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. For the three months ended March 31, 2023, we issued 1,748,218 common shares through the ATM program and the remaining value authorized for sale under the at-the-market program is $497.5 million.

Comparative Cash Flows

Comparison of the three months ended March 31, 2022 and 2023

The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated:


	For the Three Months Ended
	March 31,
	2022	2023

	(in thousands of euros)
	(unaudited)
Net cash flow from (used in):
Operating activities	(136,511)	(99,586)
Investing activities	(17,185)	(13,162)
Financing activities	(460)	234,709
Effect of currency translation gains on cash and cash equivalents	895	(239)
Overall cash inflow	(153,261)	121,722

Operating Activities

Net cash used in operating activities for the three months ended March 31, 2023 was €99.6 million as compared to net cash used in operating activities of €136.5 million for the three months ended March 31, 2022. The decrease in net cash used in operating activities was primarily attributable to less prepayments for service agreements with Contract Research Organizations and Contract Manufacturing Organizations.

Investing Activities

Net cash used in investing activities for the three months ended March 31, 2023 was €13.2 million as compared to net cash used in investing activities of €17.2 million for the three months ended March 31, 2022. The change in cash flows from investing activities was primarily attributable to a decrease in purchases of property, plant and equipment for manufacturing facilities and intangible assets.

Financing Activities

Net cash provided by financing activities was €234.7 million for the three months ended March 31, 2023 as compared to net cash used by financing activities of €0.5 million for the three months ended March 31, 2022. The increase in cash flow provided by financing activities was mainly attributable to the raising of cash in the public offering conducted in February 2023.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for those noncancellable contractual obligations from certain of our arrangements with contract manufacturing organizations disclosed in “Liquidity and Capital Resources”.”

Safe Harbor

See “Forward-Looking Statements.”

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or the IFRS, as issued by the International Accounting Standards Board, or IASB. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our

assets, liabilities and shareholders’ equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted.

Our significant accounting policies that we believe to be critical to the judgments and estimates used in the preparation of our financial statements are included in “note 2 — Significant accounting policies” and “note 10 — Share-based payments” to our consolidated financial statements included in the Annual Report.

Recent Accounting Pronouncements

We have applied, in our audited consolidated financial statements for the year ended December 31, 2022, new standards and amendments as issued by IASB and that are mandatory as of January 1, 2022. See note 2 to our audited consolidated financial statements included in the Annual Report.

We have applied, in our unaudited interim condensed consolidated financial statements for the three months ended March 31, 2023, new standards and amendments as issued by IASB and as issued by IASB and that are mandatory as of January 1, 2022. See note 2 to our unaudited interim condensed consolidated financial statements included elsewhere in this Report of Foreign Private Issuer on Form 6-K for further information on these new standards and amendments.

GRAPHIC 4 cvac-20230331xex99d1001.jpg GRAPHIC begin 644 cvac-20230331xex99d1001.jpg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end EX-101.SCH 5 cvac-20230331.xsd EX-101.SCH 00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Interim Condensed Consolidated Statements of Financial Position link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details) link:presentationLink link:calculationLink link:definitionLink 40309 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Share-based payments - Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Trade and other payables (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Other liabilities and provisions (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Share-based payments (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40308 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40310 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Share-based payments - Equity-settled programs (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Share-based payments (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fixed Assets - Intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Prepaid expenses and other assets (current) (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Related party disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Corporate Information link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of preparation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Notes to the consolidated financial statements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Issued Capital and Reserves link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Share-based payments link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Assets held for sale link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Prepaid expenses and other assets (current) link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Financial assets and financial liabilities link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Trade and other payables link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Other liabilities and provisions link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Income tax link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Disclosure of financial instruments and management of financial risks link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Related party disclosures link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Basis of preparation (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Notes to the consolidated financial statements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Issued Capital and Reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Assets held for sale (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Financial assets and financial liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cvac-20230331_cal.xml EX-101.CAL EX-101.DEF 7 cvac-20230331_def.xml EX-101.DEF EX-101.LAB 8 cvac-20230331_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Entity Addresses, Address Type [Axis] Address Type [Domain] Business Contact Document Information [Line Items] Document and Entity Information Document Type Document Registration Statement Document Annual Report Document Transition Report Document Shell Company Report Entity Registrant Name Document Period End Date Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Contact Personnel Name Country Region Contact Personnel Email Address Title of 12(b) Security Trading Symbol Security Exchange Name Entity File Number Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Filer Category Entity Interactive Data Current Entity Emerging Growth Company Entity Ex Transition Period Document Accounting Standard Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag ICFR Auditor Attestation Flag Amendment Description Entity Voluntary Filers Entity Public Float Auditor Name Auditor Firm ID Auditor Location Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Total revenues Revenue Total revenues Revenue recognized Cost of sales. Cost of sales Sales and marketing expense Selling and distribution expenses Research and development expense Research and development expenses General and administrative expense General and administrative expenses Miscellaneous other operating income Other operating income Total Miscellaneous other operating expense Other operating expenses Profit (loss) from operating activities Operating loss Finance income Finance income Finance costs Finance expenses Profit (loss) before tax Loss before income tax Loss before income tax Tax expense (income) Income tax benefit/ (expense) Profit (loss) Net loss for the period Net loss Other comprehensive income [abstract] Other comprehensive income (loss): Other comprehensive income, net of tax, exchange differences on translation Foreign currency adjustments Comprehensive income Total comprehensive income (loss) Total comprehensive loss for the period Basic earnings (loss) per share Net loss per share basic Diluted earnings (loss) per share Net loss per share diluted Interim Condensed Consolidated Statements of Financial Position AssetsAbstract Assets NoncurrentAssets Non-current assets Intangible assets and goodwill Intangible assets and goodwill Property, plant and equipment Ending balance Beginning balance Property, plant and equipment Right-of-use assets Right-of-use assets Other assets. Other assets Net deferred tax assets Deferred tax assets Total non-current assets Total non-current assets CurrentAssetsAbstract Current assets Non-current assets or disposal groups classified as held for sale or as held for distribution to owners Assets held for sale Written down value of equipment Current inventories Inventories Current trade receivables Trade receivables Current contract assets Contract assets Contract assets Other current financial assets Other financial assets Current prepayments and other current assets Prepaid expenses and other assets Prepaid expenses and other current assets Cash and cash equivalents. Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Current assets Total current assets Assets Total assets EquityAndLiabilitiesAbstract Equity and liabilities Equity [abstract] Equity Issued capital. Issued capital Capital reserve. Capital reserve Treasury shares. Treasury Shares Retained earnings Accumulated deficit Accumulated other comprehensive income Other comprehensive income Equity. Balance at the end Balance at the beginning Total equity NoncurrentLiabilitiesAbstract Non-current liabilities Non-current lease liabilities Lease liabilities Non-current contract liabilities Contract liabilities Non-current provisions Provisions Other non-current liabilities. Other liabilities Other liabilities (non-current) Non-current liabilities Total non-current liabilities Current liabilities [abstract] Current liabilities Current lease liabilities Lease liabilities Trade and other current payables Trade and other payables Current provisions Provisions Other current liabilities Other liabilities Other liabilities (current) Current tax liabilities Income taxes payable Current contract liabilities Contract liabilities Current liabilities Total current liabilities Liabilities Total liabilities Equity and liabilities Total equity and liabilities Interim Condensed Consolidated Statements of Changes in Shareholders' Equity Statement of changes in equity [table] Retrospective application and retrospective restatement [axis] Currently stated [member] Effects from the first-time adoption of IFRS 9 Effects from the first-time adoption of IFRS 15 Previously stated Components of equity [axis] Equity [member] Issued capital Capital reserve Treasury share Treasury share Accumulated deficit Currency translation reserve Statement of changes in equity [line items] Statement of changes in equity The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. Net Loss Net loss Other comprehensive income Other comprehensive income (loss) Issue of equity Issuance of share capital (net of transaction costs) Shares issued on exercise of option Exercise of options Amount of Share-based payment expense (incl. deferred taxes) Share-based payment expense (incl. deferred taxes) Share-based payments (net of taxes) The amount of share based payment awards settled in cash. Settlement Of Share Based Payment Awards , Amount Settlement of share-based payment awards Increase (decrease) through treasury share transactions, equity Repurchase of common shares Interim Condensed Consolidated Statements of Cash Flows Cash flows from (used in) operating activities [abstract] Operating activities Adjustments to reconcile profit (loss) [abstract] Adjustments to reconcile loss before tax to net cash flows Adjustments for finance income Finance income Adjustments for finance costs Finance expense Adjustments for depreciation and amortisation expense Depreciation and impairment of property, plant and equipment and right-of-use assets Adjustments for losses (gains) on disposal of non-current assets Loss on disposal of fixed assets Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment Impairment of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment Loss on disposal of fixed assets Amount of transfer to assets held for sale. Adjustments Transfer To Asset Held For Sale Impairment of assets held for sale Impairments of inventory and prepayments Impairments of inventory and prepayments Impairment of inventory and prepayments Adjustments for share-based payments Share-based payment expense Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments For Non Cash Income From Release Of Provisions Non-cash income from release of provisions Adjustments for provisions Releases in provision for onerous contracts No definition available. Changes in Working Capital [Abstract] Working capital changes Amount of adjustments for decrease increase in asset held for sale. Adjustments For Decrease Increase in Asset Held for Sale Decrease / (increase) in asset held for sale Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners Decrease / (increase) in assets held for sale Adjustments for decrease (increase) in trade and other receivables Decrease / (increase) in trade receivables and contract assets Adjustments for decrease (increase) in inventories Decrease / (increase) in inventory Adjustments for decrease (increase) in other assets Decrease / (increase) in other assets Amount of increase (decrease) in prepaid expenses, and assets classified as other. Ifrs Increase (Decrease) in Prepaid Expense and Other Assets Decrease / (increase) in prepaid expenses and other assets The cash inflow from government grants and similar bodies. Receipts from Government Grants Classified as Operating Activities Receipts from grants from government agencies and similar bodies Grant amount received/eligible to receive Adjustments for increase (decrease) in trade and other payables (Decrease) / increase in trade and other payables, other liabilities and contract liabilities Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities. Adjustments For Increase Decrease In Other Current Financial And Other Liabilities (Decrease) / increase in other current financial liabilities Adjustments for deferred tax expense Decrease / (increase) in deferred taxes Income taxes paid, classified as operating activities Income taxes paid Interest received, classified as operating activities Interest received Interest paid, classified as operating activities Interest paid Cash flows from (used in) operating activities Net cash flow (used in) operating activities Cash flows from (used in) investing activities [abstract] Investing activities Purchase of property, plant and equipment, classified as investing activities Purchase of property, plant and equipment Purchase of intangible assets, classified as investing activities Purchase of intangible assets Proceeds from government grants, classified as investing activities Proceeds from asset-related grants Purchase of other long-term assets, classified as investing activities Purchases of financial assets Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Acquisition of subsidiary, net of cash acquired The net cash flow from sale / purchase of other financial assets classified as investing activities. Proceeds from (Payments For) Sale of Other Financial Assets, Investing Activities Proceeds from sale of other financial assets Cash flows from (used in) investing activities Net cash flow (used in) investing activities Cash flows from (used in) financing activities [abstract] Financing activities Payments of lease liabilities, classified as financing activities Payments on lease obligations Amount of Proceed From Issuing Other Equity Instrument Proceed From Issuing Other Equity Instrument Payment on / Proceeds from Treasury Shares Proceeds from issuing shares Cash received from issuance of shares Proceeds from the issuance of shares (net of transaction costs) The cash inflow from at the market shares issued during the period. Ifrs Stock Issued During Period Value New Issues Proceeds from at-the-market offering program (net of transaction costs) The cash inflow or outflow from the exercise of options. Proceeds Or Payments From Exercise Of Options Payments from the exercise of options The cash inflow or outflow from the exercise of options and treasury shares. Payment on Proceeds From Treasury Shares and Exercise Of Options Amount of proceed from issuing other equity instrument or exercise of options. Proceed From Issuing Other Equity Instrument Or Exercise of Options Payment on / proceeds from treasury shares/exercise of options Proceeds from exercise of options Proceeds from the exercise of options Proceeds on exercise of options. Proceeds On Exercise Of Options Proceeds on exercise of options The cash inflow from borrowings obtained. [Refer: Borrowings] Proceeds from (Repayments of) borrowings, classified as financing activities Proceeds from (repayment of) the EIB loan Proceeds from issue of bonds, notes and debentures Proceeds from the convertible loan Payments to acquire or redeem entity's shares Payment on treasury shares Proceeds from issuing other equity instruments Payment on treasury shares Repayments of bonds, notes and debentures Repayments of convertible loan Cash flows from (used in) financing activities Net cash flow provided by financing activities Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Net increase (decrease) in cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Currency translation gains (losses) on cash and cash equivalents No definition available. Corporate Information The entire disclosure on corporate information. Corporate Information [Text Block] Corporate Information The disclosure of the basis used for the preparation of the financial statement. Basis of preparation The disclosure of the basis used for the preparation of the financial statement. Disclosure of Basis of Preparation Explanatory [Text Block] Basis of preparation EX-101.PRE 9 cvac-20230331_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2023
Document and Entity Information
Document Type	6-K
Entity Registrant Name	CureVac N.V.
Document Period End Date	Mar. 31, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001809122
Amendment Flag	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)
Revenue	€ 7,129	€ 24,373
Cost of sales	(20,634)	(37,232)
Selling and distribution expenses	(824)	(271)
Research and development expenses	(24,251)	(10,786)
General and administrative expenses	(23,287)	(24,566)
Other operating income	2,006	33,436
Other operating expenses	(494)	(222)
Operating loss	(60,355)	(15,268)
Finance income	3,888	2,021
Finance expenses	(951)	(1,942)
Loss before income tax	(57,418)	(15,189)
Income tax benefit/ (expense)	(1)	96
Net loss for the period	(57,419)	(15,093)
Other comprehensive income (loss):
Foreign currency adjustments	19	(55)
Total comprehensive loss for the period	€ (57,400)	€ (15,148)
Net loss per share basic	€ (0.27)	€ (0.08)
Net loss per share diluted	€ (0.27)	€ (0.08)

XML 12 R3.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Financial Position - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Non-current assets
Intangible assets and goodwill	€ 30,600	€ 31,778
Property, plant and equipment	210,475	197,941
Right-of-use assets	42,688	43,761
Other assets	1,697	1,666
Deferred tax assets	1,296	1,297
Total non-current assets	286,756	276,443
Current assets
Assets held for sale	10,210	10,467
Inventories	24,678	23,989
Trade receivables	3,379	6,295
Contract assets	2,464	2,707
Other financial assets	3,069	4,487
Prepaid expenses and other assets	25,597	40,287
Cash and cash equivalents	617,519	495,797
Total current assets	686,916	584,029
Total assets	973,672	860,472
Equity
Issued capital	26,862	23,400
Capital reserve	2,050,235	1,817,287
Treasury Shares	(344)	(1,481)
Accumulated deficit	(1,363,234)	(1,305,814)
Other comprehensive income	(120)	(139)
Total equity	713,399	533,253
Non-current liabilities
Lease liabilities	36,087	37,106
Contract liabilities	72,549	72,549
Provisions	61,320	61,320
Other liabilities	19	19
Total non-current liabilities	169,975	170,994
Current liabilities
Lease liabilities	5,058	4,980
Trade and other payables	14,973	73,463
Provisions	1,334	1,922
Other liabilities	37,715	40,491
Income taxes payable	607	610
Contract liabilities	30,611	34,759
Total current liabilities	90,298	156,225
Total liabilities	260,273	327,219
Total equity and liabilities	€ 973,672	€ 860,472

XML 13 R4.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Changes in Shareholders' Equity - EUR (€)	Issued capital	Capital reserve	Treasury share	Accumulated deficit	Currency translation reserve	Total
Balance at the beginning at Dec. 31, 2021	€ 22,454,000	€ 1,728,658,000	€ (5,817,000)	€ (1,056,785,000)	€ (34,000)	€ 688,476,000
Net loss				(15,093,000)		(15,093,000)
Other comprehensive income (loss)					(55,000)	(55,000)
Total comprehensive income (loss)				(15,093,000)	(55,000)	(15,148,000)
Exercise of options		(4,000)				(4,000)
Share-based payments (net of taxes)		1,090,000				1,090,000
Settlement of share-based payment awards		(2,277,000)	2,721,000			444,000
Balance at the end at Mar. 31, 2022	22,454,000	1,727,467,000	(3,096,000)	(1,071,878,000)	(89,000)	674,858,000
Balance at the beginning at Dec. 31, 2022	23,400,000	1,817,287,000	(1,481,000)	(1,305,814,000)	(139,000)	533,253,000
Net loss				(57,419,000)		(57,419,000)
Other comprehensive income (loss)					19,000	19,000
Total comprehensive income (loss)				(57,419,000)	19,000	(57,400,000)
Issuance of share capital (net of transaction costs)	3,453,000	232,387,000				235,840,000
Share-based payments (net of taxes)		1,578,000				1,578,000
Settlement of share-based payment awards	9,000	(1,017,000)	1,137,000			129,000
Balance at the end at Mar. 31, 2023	€ 26,862,000	€ 2,050,235,000	€ (344,000)	€ (1,363,234,000)	€ (120,000)	€ 713,399,000

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

XML 14 R5.htm IDEA: XBRL DOCUMENT

Interim Condensed Consolidated Statements of Cash Flows € in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023 EUR (€)	Mar. 31, 2022 EUR (€)
Operating activities
Loss before income tax	€ (57,418)	€ (15,189)
Adjustments to reconcile loss before tax to net cash flows
Finance income	(3,888)	(2,021)
Finance expense	950	1,942
Depreciation and impairment of property, plant and equipment and right-of-use assets	5,853	9,077
Loss on disposal of fixed assets	239
Impairment of inventory and prepayments	1,362	15,944
Share-based payment expense	1,578	2,273
Non-cash income from release of provisions	(588)	(31,858)
Working capital changes
Decrease / (increase) in assets held for sale	257
Decrease / (increase) in trade receivables and contract assets	3,159	(9,521)
Decrease / (increase) in inventory	(2,050)	14,099
Decrease / (increase) in other assets	17,229	(23,093)
(Decrease) / increase in trade and other payables, other liabilities and contract liabilities	(67,668)	(96,834)
Decrease / (increase) in deferred taxes	2
Income taxes paid	(4)
Interest received	2,034
Interest paid	(633)	(1,330)
Net cash flow (used in) operating activities	(99,586)	(136,511)
Investing activities
Purchase of property, plant and equipment	(13,028)	(16,737)
Purchase of intangible assets	(134)	(448)
Net cash flow (used in) investing activities	(13,162)	(17,185)
Financing activities
Payments on lease obligations	(1,260)	(900)
Proceeds from the issuance of shares (net of transaction costs)	235,840
Payment on / proceeds from treasury shares/exercise of options	129	440
Net cash flow provided by financing activities	234,709	(460)
Net increase (decrease) in cash and cash equivalents	121,961	(154,156)
Currency translation gains (losses) on cash and cash equivalents	(239)	895
Cash and cash equivalents, beginning of period	495,797	811,464
Cash and cash equivalents, end of period	€ 617,519	€ 658,203

XML 15 R6.htm IDEA: XBRL DOCUMENT

Corporate Information

3 Months Ended

Mar. 31, 2023

Corporate Information

Corporate Information

1. Corporate Information

XML 16 R7.htm IDEA: XBRL DOCUMENT

Basis of preparation

3 Months Ended

Mar. 31, 2023

Basis of preparation

Basis of preparation

2. Basis of preparation

The interim condensed consolidated financial statements for the three months ended March 31, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.

New standards, interpretations and amendments adopted by the Group

Impact of COVID-19 and the Russia-Ukraine Conflict

XML 17 R8.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements

3 Months Ended

Mar. 31, 2023

Notes to the consolidated financial statements

Notes to the consolidated financial statements

3. Notes to the consolidated financial statements

3.1 Revenue from contract with customers

The Group recognized the following revenues:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Belgium
GSK	23,746	6,473
Switzerland
CRISPR	180	209
Netherlands
Genmab	447	447
Total	24,373	7,129


		Upfront and	Upfront and	Revenue recognized from
		milestones payments included	milestones payments included	upfront and milestones payments
	Upfront and milestone	in contract	in contract	for three months ended
	payments	liabilities at	liabilities at	March 31,
Customer	March 31, 2023	December 31, 2022	March 31, 2023	2022	2023

		(EUR k)	(EUR k)	(EUR k)
GSK	EUR 205,000k (EUR 10,000k milestone payment included)	102,804	99,180	17,719	3,624
CRISPR	USD 3,000k (EUR 2,524k)*	929	852	77	77
Genmab	USD 10,000k (EUR 8,937k)*	3,575	3,128	447	447
Total		107,308	103,160	18,243	4,148

* Translated at the currency exchange rate prevailing on the transaction date.

Contract balances:


	December 31,	March 31,
	2022	2023
	EUR k	EUR k
Trade receivables	6,295	3,379
Contract assets	2,707	2,464
Contract liabilities	107,308	103,160

Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.

3.2 Cost of sales

The cost of sales consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(7,937)	(8,188)
Materials	(22,828)	(4,534)
Third-party services	(964)	(5,453)
Maintenance and lease	(231)	(580)
Amortization and depreciation	(5,168)	(1,170)
Other	(104)	(710)
Total	(37,232)	(20,634)

3.3 Selling and distribution expenses

Selling and distribution expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(197)	(716)
Amortization and depreciation	(17)	—
Other	(57)	(108)
Total	(271)	(824)

3.4 Research and development expenses

R&D expenses consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Materials	(17,287)	(3,489)
Personnel	(7,054)	(11,037)
Amortization and depreciation	(1,013)	(1,725)
Patents and fees to register a legal right	(1,855)	(857)
Third-party services	16,800	(4,692)
Maintenance and lease	(36)	(1,766)
Other	(341)	(684)
Total	(10,786)	(24,251)

As of March 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.

3.5 General and administrative expenses

General and administrative expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(9,781)	(9,098)
Maintenance and lease	(1,300)	(1,301)
Third-party services	(5,283)	(7,002)
Legal and other professional services	(2,325)	(1,629)
Amortization and depreciation	(2,938)	(3,106)
Other	(2,939)	(1,152)
Total	(24,566)	(23,287)

3.6 Other operating income


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Compensation for CMO/Material transfer	33,012	1,544
Sale of equipment	310	308
Grants and other cost reimbursements from government agencies and similar bodies	69	2
Other	45	152
Total	33,436	2,006

During the three months ended March 31, 2023 and 2022, income from grants with government agencies and similar bodies resulted from the following:

Coalition for Epidemic Preparedness Innovations (CEPI)

Bill & Melinda Gates Foundation (BMGF)

XML 18 R9.htm IDEA: XBRL DOCUMENT

Issued Capital and Reserves

3 Months Ended

Mar. 31, 2023

Issued Capital and Reserves

Issued Capital and Reserves

4. Issued Capital and Reserves

As of March 31, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.

The number of shares issued and outstanding developed as follows:


Common shares issued and outstanding at December 31, 2022		194,997,091
At-the-market offering program issuances		1,748,218
Share issuances as part of the public offering		27,027,028
Share issuances for exercises between Jan to Mar 2023		112,089
Treasury shares		(32,913)
Common shares issued and outstanding at March 31, 2023		223,851,513

XML 19 R10.htm IDEA: XBRL DOCUMENT

Share-based payments

3 Months Ended

Mar. 31, 2023

Share-based payments

Share-based payments

5. Share-based payments

During the three months ended March 31, 2023 and 2022, the Group recognized share-based based payments expenses of EUR 1,578k and EUR 2,273k, respectively, as follows:

Three months ended March 31,


	2022	2023
	EUR k	EUR k
Research and development expenses	189	152
Selling and distribution expenses	67	41
General and administrative expenses	1,978	1,330
Other operating expenses	37	55
Total	2,273	1,578

Expense recognized for the equity-settled programs was as follows:

Three months ended March 31,


Program	2022	2023
	EUR k	EUR k
LTIP Stock Options	1,824	975
RSU Supervisory Board	37	55
New VSOP	103	57
Prior VSOP	92	(51)
LTIP RSUs	216	542
Total	2,273	1,578

As the CEO left as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.

Exercise of options

Under the New VSOP plan, 36,516 options were exercised within the first three months of 2023 at a weighted average share price of USD 10.42.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Fixed Assets

3 Months Ended

Mar. 31, 2023

Fixed Assets

Fixed Assets

6. Fixed Assets

6.1 Intangible assets

6.2 Property, plant and equipment

XML 21 R12.htm IDEA: XBRL DOCUMENT

Assets held for sale

3 Months Ended

Mar. 31, 2023

Assets held for sale

Assets held for sale

7. Assets held for sale

sales campaigns. All sales activities are scheduled for 2023 and as of March 31, 2023 Assets held for sale with a net book value of EUR 257k were sold through an external service provider.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2023

Inventories

Inventories

8. Inventories

XML 23 R14.htm IDEA: XBRL DOCUMENT

Prepaid expenses and other assets (current)

3 Months Ended

Mar. 31, 2023

Prepaid expenses and other assets (current)

Prepaid expenses and other assets (current)

9. Prepaid expenses and other assets (current)

XML 24 R15.htm IDEA: XBRL DOCUMENT

Financial assets and financial liabilities

3 Months Ended

Mar. 31, 2023

Financial assets and financial liabilities

Financial assets and financial liabilities

10. Financial assets and financial liabilities

XML 25 R16.htm IDEA: XBRL DOCUMENT

Trade and other payables

3 Months Ended

Mar. 31, 2023

Trade and other payables.

Trade and other payables

11. Trade and other payables

XML 26 R17.htm IDEA: XBRL DOCUMENT

Other liabilities and provisions

3 Months Ended

Mar. 31, 2023

Other liabilities and provisions

Other liabilities and provisions

12. Other liabilities and provisions

XML 27 R18.htm IDEA: XBRL DOCUMENT

Income tax

3 Months Ended

Mar. 31, 2023

Income tax

Income tax

13. Income tax

XML 28 R19.htm IDEA: XBRL DOCUMENT

Disclosure of financial instruments and management of financial risks

3 Months Ended

Mar. 31, 2023

Disclosure of financial instruments and management of financial risks

Disclosure of financial instruments and management of financial risks

14. Disclosure of financial instruments and risk management

XML 29 R20.htm IDEA: XBRL DOCUMENT

Earnings per share

3 Months Ended

Mar. 31, 2023

Earnings per share

Earnings per share

15. Earnings per share

XML 30 R21.htm IDEA: XBRL DOCUMENT

Related party disclosures

3 Months Ended

Mar. 31, 2023

Related party disclosures

Related party disclosures

16. Related party disclosures

Dietmar Hopp

Antony Blanc

BePharBel Manufacturing S.A.

Franz-Werner Haas

In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

Alexander Zehnder

Barker BioMedical GmbH

Craig Tooman

In Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

XML 31 R22.htm IDEA: XBRL DOCUMENT

Subsequent events

3 Months Ended

Mar. 31, 2023

Subsequent events

Subsequent events

17. Subsequent events

XML 32 R23.htm IDEA: XBRL DOCUMENT

Basis of preparation (Policies)	3 Months Ended
Basis of preparation (Policies)	Mar. 31, 2023
Basis of preparation
Basis of preparation	The interim condensed consolidated financial statements for the three months ended March 31, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on May 22, 2023. The Group’s interim condensed consolidated financial statements are presented in Euros (“EUR”). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.
New standards, interpretations and amendments adopted by the Group	New standards, interpretations and amendments adopted by the Group The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three months ended March 31, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.
Impact of COVID-19 and the Russia-Ukraine Conflict	Impact of COVID-19 and the Russia-Ukraine Conflict As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company’s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group’s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group’s laboratory and production operations. The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group’s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.

XML 33 R24.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements (Tables)

3 Months Ended

Mar. 31, 2023

Notes to the consolidated financial statements

Schedule of revenue from contract with customers recognized


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Belgium
GSK	23,746	6,473
Switzerland
CRISPR	180	209
Netherlands
Genmab	447	447
Total	24,373	7,129

Summary of upfront payments and related revenues recognized


		Upfront and	Upfront and	Revenue recognized from
		milestones payments included	milestones payments included	upfront and milestones payments
	Upfront and milestone	in contract	in contract	for three months ended
	payments	liabilities at	liabilities at	March 31,
Customer	March 31, 2023	December 31, 2022	March 31, 2023	2022	2023

		(EUR k)	(EUR k)	(EUR k)
GSK	EUR 205,000k (EUR 10,000k milestone payment included)	102,804	99,180	17,719	3,624
CRISPR	USD 3,000k (EUR 2,524k)*	929	852	77	77
Genmab	USD 10,000k (EUR 8,937k)*	3,575	3,128	447	447
Total		107,308	103,160	18,243	4,148

* Translated at the currency exchange rate prevailing on the transaction date.

Schedule of contract balances


	December 31,	March 31,
	2022	2023
	EUR k	EUR k
Trade receivables	6,295	3,379
Contract assets	2,707	2,464
Contract liabilities	107,308	103,160

Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses

The cost of sales consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(7,937)	(8,188)
Materials	(22,828)	(4,534)
Third-party services	(964)	(5,453)
Maintenance and lease	(231)	(580)
Amortization and depreciation	(5,168)	(1,170)
Other	(104)	(710)
Total	(37,232)	(20,634)

Selling and distribution expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(197)	(716)
Amortization and depreciation	(17)	—
Other	(57)	(108)
Total	(271)	(824)

R&D expenses consists of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Materials	(17,287)	(3,489)
Personnel	(7,054)	(11,037)
Amortization and depreciation	(1,013)	(1,725)
Patents and fees to register a legal right	(1,855)	(857)
Third-party services	16,800	(4,692)
Maintenance and lease	(36)	(1,766)
Other	(341)	(684)
Total	(10,786)	(24,251)

General and administrative expenses consist of the following:


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Personnel	(9,781)	(9,098)
Maintenance and lease	(1,300)	(1,301)
Third-party services	(5,283)	(7,002)
Legal and other professional services	(2,325)	(1,629)
Amortization and depreciation	(2,938)	(3,106)
Other	(2,939)	(1,152)
Total	(24,566)	(23,287)

Schedule of other operating income


	Three months ended March 31,
	2022	2023
	EUR k	EUR k
Compensation for CMO/Material transfer	33,012	1,544
Sale of equipment	310	308
Grants and other cost reimbursements from government agencies and similar bodies	69	2
Other	45	152
Total	33,436	2,006

XML 34 R25.htm IDEA: XBRL DOCUMENT

Issued Capital and Reserves (Tables)

3 Months Ended

Mar. 31, 2023

Issued Capital and Reserves

Schedule of total shares


Common shares issued and outstanding at December 31, 2022		194,997,091
At-the-market offering program issuances		1,748,218
Share issuances as part of the public offering		27,027,028
Share issuances for exercises between Jan to Mar 2023		112,089
Treasury shares		(32,913)
Common shares issued and outstanding at March 31, 2023		223,851,513

XML 35 R26.htm IDEA: XBRL DOCUMENT

Share-based payments (Tables)

3 Months Ended

Mar. 31, 2023

Share-based payments

Schedule of share-based payments expenses

Three months ended March 31,


	2022	2023
	EUR k	EUR k
Research and development expenses	189	152
Selling and distribution expenses	67	41
General and administrative expenses	1,978	1,330
Other operating expenses	37	55
Total	2,273	1,578

Schedule for expense recognized for the equity-settled programs

Three months ended March 31,


Program	2022	2023
	EUR k	EUR k
LTIP Stock Options	1,824	975
RSU Supervisory Board	37	55
New VSOP	103	57
Prior VSOP	92	(51)
LTIP RSUs	216	542
Total	2,273	1,578

XML 36 R27.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Revenue from contract with customers (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Notes to the consolidated financial statements
Total revenues	€ 7,129	€ 24,373
Research services combined with an IP license
Notes to the consolidated financial statements
Total revenues	4,148	18,243
Product
Notes to the consolidated financial statements
Total revenues	132	103
Research and development services
Notes to the consolidated financial statements
Total revenues	2,849	6,027
Belgium \| GSK
Notes to the consolidated financial statements
Total revenues	6,473	23,746
Switzerland \| CRISPR
Notes to the consolidated financial statements
Total revenues	209	180
Netherlands \| Genmab
Notes to the consolidated financial statements
Total revenues	€ 447	€ 447

XML 37 R28.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Additional Information (Details) € in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 EUR (€)
Notes to the consolidated financial statements
Proceeds from the issuance of shares (net of transaction costs)	€ 235,840	$ 17.5
Revenue recognized	7,129		€ 24,373
Milestone revenues
Notes to the consolidated financial statements
Revenue recognized	423		4,725
Additional development milestone payments			€ 10,000
Development milestone payment included in contract liabilities	€ 3,321

XML 38 R29.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license € in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023 EUR (€)	Mar. 31, 2022 EUR (€)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Notes to the consolidated financial statements
Upfront and milestones payments included in contract liabilities	€ 103,160			€ 107,308
Revenue recognized from upfront payments	4,148	€ 18,243
GSK
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	205,000
Upfront and milestones payments included in contract liabilities	99,180			102,804
Revenue recognized from upfront payments	3,624	17,719
CRISPR
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	2,524		$ 3,000
Upfront and milestones payments included in contract liabilities	852			929
Revenue recognized from upfront payments	77	77
Genmab
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	8,937		$ 10,000
Upfront and milestones payments included in contract liabilities	3,128			€ 3,575
Revenue recognized from upfront payments	447	€ 447
Minimum \| GSK
Notes to the consolidated financial statements
Upfront and milestone payments received or receivable	€ 10,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Contract balances (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Notes to the consolidated financial statements
Trade receivables	€ 3,379	€ 6,295
Contract assets	2,464	2,707
Contract liabilities	€ 103,160	€ 107,308

XML 40 R31.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Cost of sales (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Notes to the consolidated financial statements
Impairment of assets held for sale			€ 19,064
Cost of sales
Notes to the consolidated financial statements
Personnel	€ (8,188)	€ (7,937)
Materials	(4,534)	(22,828)
Third-party services	(5,453)	(964)
Maintenance and lease	(580)	(231)
Amortization and depreciation	(1,170)	(5,168)
Other	(710)	(104)
Total	€ (20,634)	€ (37,232)

XML 41 R32.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Selling and distribution expenses (Details) - Selling and distribution expenses - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Notes to the consolidated financial statements
Personnel	€ (716)	€ (197)
Amortization and depreciation		(17)
Other	(108)	(57)
Total	(824)	(271)
Salary and salary-related expenses	675	129
Expenses from share-based payments	€ 41	€ 68

XML 42 R33.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Research and development expenses (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Notes to the consolidated financial statements
Estimated contract termination provisions			€ 25,059
Research and development expenses
Notes to the consolidated financial statements
Materials	€ 3,489	€ 17,287
Personnel	(11,037)	(7,054)
Amortization and depreciation	(1,725)	(1,013)
Patents and fees to register a legal right	(857)	(1,855)
Third-party services	(4,692)	16,800
Maintenance and lease	(1,766)	(36)
Other	(684)	(341)
Total	(24,251)	(10,786)
Reversal of provision of onerous contracts	6,800
Expenses from share-based payments	152	190
Salary and salary-related expenses	€ 10,885	€ 6,864

XML 43 R34.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - General and administrative expenses (Details) - General and administrative expenses - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Notes to the consolidated financial statements
Personnel	€ (9,098)	€ (9,781)
Maintenance and lease	(1,301)	(1,300)
Third-party services	(7,002)	(5,283)
Legal and other professional services	(1,629)	(2,325)
Amortization and depreciation	(3,106)	(2,938)
Other	(1,152)	(2,939)
Total	(23,287)	(24,566)
Salary and salary-related expenses	7,768	7,803
Expenses from share-based payments	€ 1,330	€ 1,978

XML 44 R35.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Notes to the consolidated financial statements
Compensation for CMO/Materials transfer	€ 1,544	€ 33,012
Sale of equipment	308	310
Grants and other reimbursements from government agencies and similar bodies	2	69
Other	152	45
Total	€ 2,006	€ 33,436

XML 45 R36.htm IDEA: XBRL DOCUMENT

Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details) € in Thousands, $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2022 EUR (€)	May 31, 2020 USD ($)	Jan. 31, 2020 USD ($)
Notes to the consolidated financial statements
Reversal of provision recognized				€ 25,059
GSK [Member]
Notes to the consolidated financial statements
Compensation consist for set-up activities			€ 20,500
Reimbursement of prepayments			12,000
Coalition for Epidemic Preparedness Innovations
Notes to the consolidated financial statements
Income from release of governmental contract liabilities	€ 2		6
Maximum grant \| $						$ 15,300	$ 8,300
Grants received and deferred	307				€ 309
Bill & Melinda Gates Foundation (BMGF)
Notes to the consolidated financial statements
Income from release of governmental contract liabilities	€ 0	$ 1,712	€ 63
Grants received and deferred					€ 1,712

XML 46 R37.htm IDEA: XBRL DOCUMENT

Issued Capital and Reserves - Overview and General Remarks (Details) - Mar. 31, 2023 $ in Millions	€ / shares	USD ($) shares
Issued Capital and Reserves
Remaining authorized for sale value \| $		$ 497.5
Common shares
Issued Capital and Reserves
Number of shares authorized		386,250,000
Notional value per share \| € / shares	€ 0.12
Preferred shares
Issued Capital and Reserves
Number of shares authorized		386,250,000
Notional value per share \| € / shares	€ 0.12
Number of shares issued		0

XML 47 R38.htm IDEA: XBRL DOCUMENT

Issued Capital and Reserves - At-the-market offering (Details) $ / shares in Units, € in Thousands, $ in Thousands	1 Months Ended			3 Months Ended
	Feb. 28, 2023 EUR (€) shares	Feb. 28, 2023 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Mar. 31, 2023 EUR (€) shares	Mar. 31, 2023 USD ($) shares
Issued Capital and Reserves
Cash received from issuance of shares				€ 235,840	$ 17,500
Shares issued as part of the at-the-market offering program				1,748,218	1,748,218
ATM Offering Program
Issued Capital and Reserves
Aggregate gross proceeds \| $			$ 600,000
Shares issued as part of the at-the-market offering program				1,748,218	1,748,218
Follow-on public offering, incl. Greenshoe
Issued Capital and Reserves
Cash received from issuance of shares \| $		$ 219,832
Shares issued as part of the at-the-market offering program	27,027,028	27,027,028
Additional offering costs recognized as reduction to capital reserve \| €	€ 14,580
Price per shares issued in follow-on public offering \| $ / shares		$ 9.25

XML 48 R39.htm IDEA: XBRL DOCUMENT

Issued Capital and Reserves - Impact of share split (Details)	3 Months Ended
	Mar. 31, 2023 shares
Issued Capital and Reserves
Common shares issued and outstanding beginning	194,997,091
Treasury shares	(32,913)
Share issuances for exercises	112,089
Shares issued as part of the at-the-market offering program	1,748,218
Common shares issued and outstanding ending	223,851,513
Public Offering
Issued Capital and Reserves
Share issuances for exercises	27,027,028

XML 49 R40.htm IDEA: XBRL DOCUMENT

Share-based payments - Expenses (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based payments
Research and development expenses	€ 152	€ 189
Selling and distribution expenses	41	67
General and administrative expenses	1,330	1,978
Other operating expenses	55	37
Total	€ 1,578	€ 2,273

XML 50 R41.htm IDEA: XBRL DOCUMENT

Share-based payments - Equity-settled programs (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based payments
Total	€ 1,578	€ 2,273
LTIP
Share-based payments
Total	975	1,824
RSU Supervisory Board
Share-based payments
Total	55	37
New VSOP
Share-based payments
Total	57	103
Prior VSOP
Share-based payments
Total	(51)	92
LTIP RSU
Share-based payments
Total	€ 542	€ 216

XML 51 R42.htm IDEA: XBRL DOCUMENT

Share-based payments (Details) € in Thousands															1 Months Ended	3 Months Ended			12 Months Ended
Share-based payments (Details) € in Thousands	Nov. 30, 2022 Option	Sep. 22, 2022 Option	Jun. 22, 2022 Option	Apr. 01, 2022 EUR (€)	Mar. 01, 2022 Option	Jan. 31, 2022 Option	Jan. 01, 2022 Option	Dec. 23, 2021 Option	Aug. 01, 2021 Option	Jul. 01, 2021 Option	Mar. 01, 2021 Option	Jan. 24, 2021 Option	Dec. 01, 2020 Option	Nov. 16, 2020 Option	May 31, 2022 Option	Mar. 31, 2023 EUR (€) Option shares	Mar. 31, 2023 $ / shares	Mar. 31, 2022 EUR (€)	Dec. 31, 2022 EUR (€) Option
Share-based payments
Share-based based payments expenses \| €																€ 1,578		€ 2,273
Number of RSUs settled \| shares																73,056
LTIP Stock Options
Share-based payments
Number of RSU's awarded																			1,824
Number of RSUs settled \| shares																47,424
Expenses recognized \| €																€ 975
Expenses recognized with RSU \| €																542			€ 216
Prior VSOP
Share-based payments
Expenses recognized \| €																€ 51			92
New VSOP
Share-based payments
Number of options exercised																36,516
Average share price \| $ / shares																	$ 10.42
Expenses recognized \| €																€ 57			€ 103
Chief Scientific Officer \| LTIP Stock Options
Share-based payments
Number of share options granted				700										266,155
Number of options exercised															6,303
Chief Business Officer and Chief Commercial Officer \| LTIP Stock Options
Share-based payments
Number of share options granted													266,156			0
Chief Operating Officer
Share-based payments
Number of RSU's awarded							36,000
Number of awards granted						5,000
Chief Operating Officer \| LTIP Stock Options
Share-based payments
Number of share options granted										20,000
Number of options exercised																0
Chief Development Officer \| LTIP Stock Options
Share-based payments
Number of share options granted									30,000
Members of executive board and various key employees
Share-based payments
Number of RSU's awarded			193,340
Members of executive board and various key employees \| LTIP Stock Options
Share-based payments
Number of awards granted								63,095
Key employees
Share-based payments
Number of RSU's awarded	7,633
Key employees \| LTIP Stock Options
Share-based payments
Number of share options granted							9,500				2,000
Number of options exercised																0
Executive board members \| LTIP Stock Options
Share-based payments
Number of share options granted					130,000
Number of options exercised																0
Supervisory board members
Share-based payments
Number of RSU's awarded			37,868
Supervisory board members \| LTIP Stock Options
Share-based payments
Number of RSU's awarded												10,956
Chief Business Officer
Share-based payments
Number of RSU's awarded		89,655				30,000

XML 52 R43.htm IDEA: XBRL DOCUMENT

Fixed Assets - Intangible assets (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Acquisition costs \| licenses, software and prepayments [Member]
Fixed Assets
Additions	€ 134	€ 448

XML 53 R44.htm IDEA: XBRL DOCUMENT

Fixed Assets - Property, plant and equipment (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fixed Assets
Beginning balance	€ 197,941
Ending balance	210,475
Assets under construction
Fixed Assets
Additions	12,631	€ 20,533
Company-owned GMP IV facility
Fixed Assets
Additions	11,845
Acquisition costs \| Technical equipment and machines
Fixed Assets
Additions	€ 3,206	€ 1,551

XML 54 R45.htm IDEA: XBRL DOCUMENT

Assets held for sale (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
Assets held for sale (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets held for sale
Gross book value of CMO-Equipment held for sale		€ 29,531
Impairment of assets held for sale		19,064
Inventories fair value costs to sell		10,467
Written down value of equipment	€ 10,210	€ 10,467
Assets held for sale with a net book value sold	€ 257

XML 55 R46.htm IDEA: XBRL DOCUMENT

Inventories (Details) - EUR (€) € in Thousands	3 Months Ended
Inventories (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventories
Raw materials	€ 24,678	€ 98
Increase in inventory	€ 688

XML 56 R47.htm IDEA: XBRL DOCUMENT

Prepaid expenses and other assets (current) (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Prepaid expenses and other current assets
Prepaid expenses and other current assets	€ 25,597	€ 40,287
Prepayments for compensation	3,658	5,595
Tax claims	€ 8,540	€ 24,840

XML 57 R48.htm IDEA: XBRL DOCUMENT

Financial assets and financial liabilities (Details) - EUR (€)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Financial assets and financial liabilities
Transfer from Level 1 to Level 2, Assets	€ 0	€ 0
Transfer from Level 2 to Level 1, Assets	0	0
Transfer from Level 1 to Level 2, Liabilities	0	0
Transfer from Level 2 to Level 1, Liabilities	0	0
Transfers into Level 3, Assets	0	0
Transfers out of Level 3, Assets	0	0
Transfers into Level 3, Liabilities	0	0
Transfers out of Level 3, Liabilities	€ 0	€ 0

XML 58 R49.htm IDEA: XBRL DOCUMENT

Trade and other payables (Details) - EUR (€) € in Thousands	3 Months Ended
Trade and other payables (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Dec. 31, 2022
Trade and other payables.
Trade and other payables	€ 14,973	€ 73,463
Amount of decrease in trade and other payables	€ 58,490

XML 59 R50.htm IDEA: XBRL DOCUMENT

Other liabilities and provisions (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Other liabilities and provisions
Decrease in other liabilities	€ 2,776
Decrease in provisions	588
Other liabilities (non-current)	19		€ 19
Other liabilities (current)	37,715		€ 40,491
Other operating income related the grants from government agencies and similar bodies	€ 2	€ 69

XML 60 R51.htm IDEA: XBRL DOCUMENT

Income tax (Details) - EUR (€) € in Thousands	3 Months Ended
Income tax (Details) - EUR (€) € in Thousands	Mar. 31, 2023	Mar. 31, 2022
Income tax
Income tax benefit/ (expense)	€ (1)	€ 96
CureVac AG
Income tax
Income tax benefit/ (expense)	€ 1

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

XML 61 R52.htm IDEA: XBRL DOCUMENT

Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details) - Mar. 31, 2023 - Foreign currency risk - Cash and cash equivalents SFr in Thousands, $ in Thousands	USD ($)	CHF (SFr)
USD
Disclosure of financial instruments and management of financial risks
Exposure in (foreign) currency \| $	$ 76,186
CHF
Disclosure of financial instruments and management of financial risks
Exposure in (foreign) currency \| SFr		SFr 124

XML 62 R53.htm IDEA: XBRL DOCUMENT

Earnings per share (Details) - € / shares	3 Months Ended
Earnings per share (Details) - € / shares	Mar. 31, 2023	Mar. 31, 2022
Earnings per share
Weighted number of shares outstanding	211,444,899	186,993,831
Net loss per share basic	€ (0.27)	€ (0.08)

XML 63 R54.htm IDEA: XBRL DOCUMENT

Related party disclosures (Details) € in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
Related party disclosures (Details) € in Thousands	May 31, 2022 EUR (€)	Aug. 31, 2020 $ / shares shares	Mar. 31, 2023 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2019 loan	Sep. 30, 2021 EUR (€)
Related party disclosures
Expenses to handle future service agreement			€ 51
Dietmar Hopp
Related party disclosures
Number of convertible loans \| loan					2
Number of shares issued \| shares		100,000
Price per share \| $ / shares		$ 16.00
Clarentis SRL
Related party disclosures
Contractual obligation amount						€ 100
BePharBel Manufacturing S.A
Related party disclosures
Settlement amount	€ 3,900
Amount paid				€ 4,016
Baron Jean Stephenne
Related party disclosures
Equity interest held			15.61%
Vincent Stphenne
Related party disclosures
Equity interest held			1.43%
Antony Blanc \| Clarentis SRL
Related party disclosures
Consulting fees			€ 21

XML 64 cvac-20230331x6k_htm.xml IDEA: XBRL DOCUMENT 0001809122 2023-01-01 2023-03-31 0001809122 cvac:DietmarHoppMember 2020-08-01 2020-08-31 0001809122 currency:USD cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember 2023-03-31 0001809122 currency:CHF cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember 2023-03-31 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-03-31 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-03-31 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-03-31 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-03-31 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-03-31 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-03-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2023-01-01 2023-03-31 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2023-01-01 2023-03-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2022-01-01 2022-03-31 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2022-01-01 2022-03-31 0001809122 country:NL cvac:GenmabMember 2023-01-01 2023-03-31 0001809122 country:CH cvac:CrisprMember 2023-01-01 2023-03-31 0001809122 country:BE cvac:GlaxosmithklineMember 2023-01-01 2023-03-31 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2023-01-01 2023-03-31 0001809122 cvac:ResearchAndDevelopmentServicesMember 2023-01-01 2023-03-31 0001809122 cvac:MilestoneRevenuesMember 2023-01-01 2023-03-31 0001809122 cvac:IfrsProductMember 2023-01-01 2023-03-31 0001809122 country:NL cvac:GenmabMember 2022-01-01 2022-03-31 0001809122 country:CH cvac:CrisprMember 2022-01-01 2022-03-31 0001809122 country:BE cvac:GlaxosmithklineMember 2022-01-01 2022-03-31 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-03-31 0001809122 cvac:ResearchAndDevelopmentServicesMember 2022-01-01 2022-03-31 0001809122 cvac:IfrsProductMember 2022-01-01 2022-03-31 0001809122 cvac:BepharbelManufacturingS.aMember 2021-01-01 2021-12-31 0001809122 cvac:VincentStphenneMember 2023-01-01 2023-03-31 0001809122 cvac:BaronJeanStephenneMember 2023-01-01 2023-03-31 0001809122 cvac:DietmarHoppMember 2020-08-31 0001809122 ifrs-full:PreferenceSharesMember 2023-03-31 0001809122 ifrs-full:OrdinarySharesMember 2023-03-31 0001809122 cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember cvac:LongTermIncentivePlanMember 2023-01-01 2023-03-31 0001809122 cvac:ChiefScientificOfficerMember cvac:LongTermIncentivePlanMember 2022-04-01 2022-04-01 0001809122 cvac:ExecutiveBoardMembersMember cvac:LongTermIncentivePlanMember 2022-03-01 2022-03-01 0001809122 cvac:KeyEmployeesMember cvac:LongTermIncentivePlanMember 2022-01-01 2022-01-01 0001809122 cvac:ChiefDevelopmentOfficerMember cvac:LongTermIncentivePlanMember 2021-08-01 2021-08-01 0001809122 srt:ChiefOperatingOfficerMember cvac:LongTermIncentivePlanMember 2021-07-01 2021-07-01 0001809122 cvac:KeyEmployeesMember cvac:LongTermIncentivePlanMember 2021-03-01 2021-03-01 0001809122 cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember cvac:LongTermIncentivePlanMember 2020-12-01 2020-12-01 0001809122 cvac:ChiefScientificOfficerMember cvac:LongTermIncentivePlanMember 2020-11-16 2020-11-16 0001809122 srt:ChiefOperatingOfficerMember cvac:LongTermIncentivePlanMember 2023-01-01 2023-03-31 0001809122 cvac:KeyEmployeesMember cvac:LongTermIncentivePlanMember 2023-01-01 2023-03-31 0001809122 cvac:ExecutiveBoardMembersMember cvac:LongTermIncentivePlanMember 2023-01-01 2023-03-31 0001809122 cvac:ChiefScientificOfficerMember cvac:LongTermIncentivePlanMember 2022-05-01 2022-05-31 0001809122 cvac:KeyEmployeesMember 2022-11-30 2022-11-30 0001809122 cvac:ChiefBusinessOfficerMember 2022-09-22 2022-09-22 0001809122 cvac:SupervisoryBoardMembersMember 2022-06-22 2022-06-22 0001809122 cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember 2022-06-22 2022-06-22 0001809122 cvac:ChiefBusinessOfficerMember 2022-01-31 2022-01-31 0001809122 srt:ChiefOperatingOfficerMember 2022-01-01 2022-01-01 0001809122 cvac:SupervisoryBoardMembersMember cvac:LongTermIncentivePlanMember 2021-01-24 2021-01-24 0001809122 srt:ChiefOperatingOfficerMember 2022-01-31 2022-01-31 0001809122 cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember cvac:LongTermIncentivePlanMember 2021-12-23 2021-12-23 0001809122 cvac:CurevacSwissAgMember 2023-01-01 2023-03-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2023-03-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2022-12-31 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2022-12-31 0001809122 cvac:VirtualSharesProgramIMember 2023-01-01 2023-03-31 0001809122 cvac:VirtualSharesProgramIiMember 2023-01-01 2023-03-31 0001809122 cvac:VirtualSharesProgramIMember 2022-01-01 2022-12-31 0001809122 cvac:VirtualSharesProgramIiMember 2022-01-01 2022-12-31 0001809122 ifrs-full:TreasurySharesMember 2023-03-31 0001809122 ifrs-full:RetainedEarningsMember 2023-03-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-03-31 0001809122 ifrs-full:IssuedCapitalMember 2023-03-31 0001809122 ifrs-full:CapitalReserveMember 2023-03-31 0001809122 ifrs-full:TreasurySharesMember 2022-12-31 0001809122 ifrs-full:RetainedEarningsMember 2022-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001809122 ifrs-full:IssuedCapitalMember 2022-12-31 0001809122 ifrs-full:CapitalReserveMember 2022-12-31 0001809122 ifrs-full:TreasurySharesMember 2022-03-31 0001809122 ifrs-full:RetainedEarningsMember 2022-03-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-03-31 0001809122 ifrs-full:IssuedCapitalMember 2022-03-31 0001809122 ifrs-full:CapitalReserveMember 2022-03-31 0001809122 ifrs-full:TreasurySharesMember 2021-12-31 0001809122 ifrs-full:RetainedEarningsMember 2021-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001809122 ifrs-full:IssuedCapitalMember 2021-12-31 0001809122 ifrs-full:CapitalReserveMember 2021-12-31 0001809122 ifrs-full:RetainedEarningsMember 2023-01-01 2023-03-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-03-31 0001809122 ifrs-full:RetainedEarningsMember 2022-01-01 2022-03-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-03-31 0001809122 cvac:BepharbelManufacturingS.aMember 2022-05-01 2022-05-31 0001809122 2022-03-31 0001809122 2021-12-31 0001809122 ifrs-full:GrossCarryingAmountMember cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember 2023-01-01 2023-03-31 0001809122 ifrs-full:ConstructionInProgressMember 2023-01-01 2023-03-31 0001809122 cvac:CompanyOwnedGmpIvFacilityMember 2023-01-01 2023-03-31 0001809122 ifrs-full:GrossCarryingAmountMember cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember 2022-01-01 2022-03-31 0001809122 ifrs-full:ConstructionInProgressMember 2022-01-01 2022-03-31 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2023-01-01 2023-03-31 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2022-01-01 2022-03-31 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember ifrs-full:BottomOfRangeMember 2023-03-31 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-03-31 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-03-31 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2023-03-31 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2023-03-31 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-12-31 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-12-31 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-12-31 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-12-31 0001809122 cvac:PublicOfferingMember 2023-01-01 2023-03-31 0001809122 ifrs-full:TreasurySharesMember 2023-01-01 2023-03-31 0001809122 ifrs-full:IssuedCapitalMember 2023-01-01 2023-03-31 0001809122 ifrs-full:CapitalReserveMember 2023-01-01 2023-03-31 0001809122 ifrs-full:TreasurySharesMember 2022-01-01 2022-03-31 0001809122 ifrs-full:CapitalReserveMember 2022-01-01 2022-03-31 0001809122 2021-01-01 2021-12-31 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2023-03-31 0001809122 cvac:DietmarHoppMember 2019-01-01 2019-12-31 0001809122 cvac:AntonyBlancMember cvac:ClarentisSrlMember 2023-01-01 2023-03-31 0001809122 cvac:SellingAndDistributionExpensesMember 2023-01-01 2023-03-31 0001809122 cvac:SellingAndDistributionExpensesMember 2022-01-01 2022-03-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2020-05-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2020-01-31 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001809122 cvac:IfrsCostOfSalesMember 2023-01-01 2023-03-31 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001809122 cvac:IfrsCostOfSalesMember 2022-01-01 2022-03-31 0001809122 2022-01-01 2022-12-31 0001809122 cvac:AtMarketOfferingProgramMember 2023-01-01 2023-03-31 0001809122 cvac:FollowOnPublicOfferingMember 2023-02-28 0001809122 cvac:MilestoneRevenuesMember 2023-03-31 0001809122 cvac:ClarentisSrlMember 2021-09-30 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2023-01-01 2023-03-31 0001809122 cvac:NewVirtualStockOptionsPlanMember 2023-01-01 2023-03-31 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2023-01-01 2023-03-31 0001809122 cvac:IfrsRestrictedStockUnitMember 2023-01-01 2023-03-31 0001809122 cvac:PriorVirtualStockOptionsPlanMember 2022-01-01 2022-03-31 0001809122 cvac:NewVirtualStockOptionsPlanMember 2022-01-01 2022-03-31 0001809122 cvac:LongTermIncentivePlanMember 2022-01-01 2022-03-31 0001809122 cvac:LongTermIncentivePlanAndRestrictedStockUnitMember 2022-01-01 2022-03-31 0001809122 cvac:IfrsRestrictedStockUnitMember 2022-01-01 2022-03-31 0001809122 cvac:LongTermIncentivePlanMember 2023-01-01 2023-03-31 0001809122 cvac:LongTermIncentivePlanMember 2022-01-01 2022-12-31 0001809122 cvac:GlaxosmithklineMember 2022-01-01 2022-03-31 0001809122 2023-03-31 0001809122 2022-12-31 0001809122 cvac:AtMarketOfferingProgramMember 2021-09-01 2021-09-30 0001809122 2022-01-01 2022-03-31 0001809122 cvac:FollowOnPublicOfferingMember 2023-02-01 2023-02-28 0001809122 cvac:MilestoneRevenuesMember 2022-01-01 2022-03-31 iso4217:EUR iso4217:USD shares iso4217:USD shares cvac:loan iso4217:EUR shares cvac:Option pure iso4217:CHF 6-K CureVac N.V. 2023-03-31 --12-31 2023 Q1 0001809122 false

0.12

98000

24373000

7129000

37232000

20634000

271000

824000

10786000

24251000

24566000

23287000

33436000

2006000

222000

494000

-15268000

-60355000

2021000

3888000

1942000

951000

-15189000

-57418000

-96000

1000

-15093000

-57419000

-55000

19000

-15148000

-57400000

-0.08

-0.27

31778000

30600000

197941000

210475000

43761000

42688000

1666000

1697000

1297000

1296000

276443000

286756000

10467000

10210000

23989000

24678000

6295000

3379000

2707000

2464000

4487000

3069000

40287000

25597000

495797000

617519000

584029000

686916000

860472000

973672000

23400000

26862000

1817287000

2050235000

1481000

344000

-1305814000

-1363234000

-139000

-120000

533253000

713399000

37106000

36087000

72549000

61320000

19000

170994000

169975000

4980000

5058000

73463000

14973000

1922000

1334000

40491000

37715000

610000

607000

34759000

30611000

156225000

90298000

327219000

260273000

860472000

973672000

22454000

1728658000

-5817000

-1056785000

-34000

688476000

-15093000

-55000

-15093000

-55000

-15148000

1090000 1090000

-4000

-2277000 2721000 444000

22454000

1727467000

-3096000

-1071878000

-89000

674858000

23400000

1817287000

-1481000

-1305814000

-139000

533253000

-57419000

19000

-57419000

19000

-57400000

1578000 1578000

3453000

232387000

235840000

9000 -1017000 1137000 129000

26862000

2050235000

-344000

-1363234000

-120000

713399000

-15189000

-57418000

2021000

3888000

1942000

950000

9077000

5853000

-239000

15944000 1362000

2273000

1578000

31858000 588000 257000

-9521000

3159000

14099000

-2050000

-23093000

17229000

-96834000

-67668000

2000

4000

2034000

1330000

633000

-136511000

-99586000

16737000

13028000

448000

134000

-17185000

-13162000

900000

1260000

235840000

440000 129000

-460000

234709000

-154156000

121961000

895000

-239000

811464000

495797000

658203000

617519000

1. Corporate InformationCureVac N.V. (“CureVac” or “CV” or the “Company”) is the parent company of CureVac Group (“Group”) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company’s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH & Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 43 – 46 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini. 2. Basis of preparationThe interim condensed consolidated financial statements for the three months ended March 31, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on May 22, 2023. The Group’s interim condensed consolidated financial statements are presented in Euros (“EUR”). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.New standards, interpretations and amendments adopted by the GroupThe accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three months ended March 31, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.Impact of COVID-19 and the Russia-Ukraine ConflictAs the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company’s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group’s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group’s laboratory and production operations.The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group’s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.

The interim condensed consolidated financial statements for the three months ended March 31, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on May 22, 2023. The Group’s interim condensed consolidated financial statements are presented in Euros (“EUR”). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.

New standards, interpretations and amendments adopted by the GroupThe accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three months ended March 31, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Impact of COVID-19 and the Russia-Ukraine ConflictAs the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company’s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group’s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group’s laboratory and production operations.The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group’s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.

3. Notes to the consolidated financial statements3.1 Revenue from contract with customersThe Group recognized the following revenues:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Belgium</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">GSK</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 23,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 6,473</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Switzerland</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">CRISPR</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 180</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 209</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Netherlands</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Genmab</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 447</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 447</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,373</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,129</td></tr></table>Of these revenues, all of which were recognized over time as part of collaboration agreements, during the three months ended March 31, 2023 EUR 4,148k (March 31, 2022: EUR 18,243k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below), (ii) EUR 132k (March 31, 2022: EUR 103k) related to delivery of products and (iii) EUR 2,849k (March 31, 2022: EUR 6,027k) were recognized from those research and development services considered distinct within the agreements.Of the total revenues recognized, in the three months ended March 31, 2023, EUR 6,473k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (“GSK I”) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac’s second-generation COVID-19 vaccine candidate, CV2CoV (“GSK II”). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the three months ending March 31, 2023, also includes recognition of EUR 423k of the milestone amount (March 31, 2022: EUR 4,725k). The remaining EUR 3,321k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the three months ended March 31, 2022, revenue consisted of EUR 23,746k primarily recognized from the upfront payments under both collaboration agreements with GSK.The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">Upfront and</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">Upfront and</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">Revenue recognized from</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">milestones payments included</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">milestones payments included</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"> upfront and milestones payments </td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;">Upfront and milestone </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">in contract</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">in contract</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">for three months ended</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;">payments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> liabilities at</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> liabilities at</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Customer</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">(EUR k)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">(EUR k)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">(EUR k)</td></tr><tr><td style="vertical-align:bottom;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;">GSK </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;background:#cceeff;margin:0pt;padding:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 102,804</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 99,180</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 17,719</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 3,624</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;">CRISPR </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;margin:0pt;padding:0pt;">USD 3,000k (EUR 2,524k)*</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 929</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 852</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 77</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 77</td></tr><tr><td style="vertical-align:bottom;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;">Genmab </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;background:#cceeff;margin:0pt;padding:0pt;">USD 10,000k (EUR 8,937k)*</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 3,575</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 3,128</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 447</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 447</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 107,308</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 103,160</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,243</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,148</td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div>* Translated at the currency exchange rate prevailing on the transaction date.Contract balances:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;">December 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;">Trade receivables</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 6,295</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"> 3,379</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;">Contract assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> 2,707</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,464</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;">Contract liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 107,308</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"> 103,160</td></tr></table>Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.3.2 Cost of salesThe cost of sales consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (7,937)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (8,188)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> (22,828)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"> (4,534)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (964)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (5,453)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Maintenance and lease</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> (231)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"> (580)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (5,168)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (1,170)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (104)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (710)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (37,232)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (20,634)</td></tr></table>For the three months ended March 31, 2023, cost of sales decreased in comparison to corresponding period in 2022. This decline was primarily attributable to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them.3.3 Selling and distribution expensesSelling and distribution expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (197)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (716)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (17)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (57)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (271)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (824)</td></tr></table>Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023 of EUR 675k (March 31, 2022: EUR 129k) and share-based payment expense of EUR 41k (March 31, 2022: EUR 68k).3.4 Research and development expensesR&D expenses consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (17,287)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (3,489)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (7,054)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (11,037)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,013)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (1,725)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Patents and fees to register a legal right</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (1,855)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (857)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 16,800</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (4,692)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Maintenance and lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (36)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (1,766)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (341)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (684)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (10,786)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,251)</td></tr></table>During the three months ended March 31, 2023, research and development expenses increased in comparison to the same period of 2022, as the prior year period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR 6,800k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group’s committed capacity at Novartis (see Note 3.6 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category.As of March 31, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023 of EUR 10,885k (March 31, 2022: EUR 6,864k) and share-based payment expense of EUR 152k (March 31, 2022: EUR 190k).3.5 General and administrative expensesGeneral and administrative expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (9,781)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (9,098)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Maintenance and lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> (1,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> (1,301)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (5,283)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (7,002)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Legal and other professional services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> (2,325)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> (1,629)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (2,938)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (3,106)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,939)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,152)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,566)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (23,287)</td></tr></table>Personnel expenses mainly include salary and salary-related expenses, during the three months ended March 31, 2023, of EUR 7,768k (March 31, 2022: EUR 7,803k) and share-based payment expense of EUR 1,330k (March 31, 2022: EUR 1,978k). During the three months ended March 31, 2023, third-party services expenses increased, compared to the same period of 2022, mainly due to higher consulting services.3.6 Other operating income<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Compensation for CMO/Material transfer</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 33,012</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 1,544</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Sale of equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 310</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 308</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 69</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 2</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,436</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,006</td></tr></table>In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the three months ended March 31, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the three months ended March 31, 2022 (see Note 3.4).During the three months ended March 31, 2023 and 2022, income from grants with government agencies and similar bodies resulted from the following:Coalition for Epidemic Preparedness Innovations (CEPI)In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.For the three months ended March 31, 2023, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 2k (March 31, 2022: EUR 6k) as “other operating income”. As of March 31, 2023, EUR 307k in grant funds received have been deferred and are presented within other liabilities (December 31, 2022: EUR 309k). Bill & Melinda Gates Foundation (BMGF)For the three months ended March 31, 2023, CureVac recognized EUR 0k (March 31, 2022: EUR 63k) from the amortization of the grants on a straight-line basis into other operating income. As of March 31, 2023, EUR 1,712k in grant funds received have been deferred and presented within other liabilities (December 31, 2022: EUR 1,712k).

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Belgium</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">GSK</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 23,746</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 6,473</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Switzerland</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">CRISPR</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 180</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 209</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Netherlands</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Genmab</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 447</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 447</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 24,373</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,129</td></tr></table>

23746000

6473000

180000

209000

447000

24373000

7129000

4148000

18243000

132000

103000

2849000

6027000

6473000

10000000

423000

4725000

3321000

23746000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">Upfront and</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">Upfront and</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">Revenue recognized from</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">milestones payments included</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">milestones payments included</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"> upfront and milestones payments </td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;">Upfront and milestone </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">in contract</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">in contract</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">for three months ended</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;">payments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> liabilities at</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> liabilities at</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Customer</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">(EUR k)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;">(EUR k)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;">(EUR k)</td></tr><tr><td style="vertical-align:bottom;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;">GSK </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;background:#cceeff;margin:0pt;padding:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 102,804</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 99,180</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 17,719</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 3,624</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;">CRISPR </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;margin:0pt;padding:0pt;">USD 3,000k (EUR 2,524k)*</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 929</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"> 852</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 77</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 77</td></tr><tr><td style="vertical-align:bottom;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;">Genmab </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:20.34%;background:#cceeff;margin:0pt;padding:0pt;">USD 10,000k (EUR 8,937k)*</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 3,575</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"> 3,128</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 447</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 447</td></tr><tr><td style="vertical-align:bottom;width:14.52%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 107,308</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 103,160</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,243</td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,148</td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div>* Translated at the currency exchange rate prevailing on the transaction date. 205000000 10000000 102804000 99180000

17719000

3624000

3000000 2524000 929000 852000

77000

10000000 8937000 3575000 3128000

447000

107308000 103160000

18243000

4148000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;">December 31,</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;">March 31,</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;">Trade receivables</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 6,295</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"> 3,379</td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;">Contract assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> 2,707</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,464</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;">Contract liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 107,308</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"> 103,160</td></tr></table>

6295000

3379000

2707000

2464000

107308000

103160000

The cost of sales consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (7,937)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (8,188)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> (22,828)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"> (4,534)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (964)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (5,453)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Maintenance and lease</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"> (231)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"> (580)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"> (5,168)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"> (1,170)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (104)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (710)</td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (37,232)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (20,634)</td></tr></table>Selling and distribution expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (197)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (716)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (17)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (57)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (108)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (271)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (824)</td></tr></table>R&D expenses consists of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (17,287)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (3,489)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (7,054)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (11,037)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,013)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (1,725)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Patents and fees to register a legal right</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (1,855)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (857)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 16,800</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> (4,692)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Maintenance and lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> (36)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> (1,766)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (341)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (684)</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (10,786)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,251)</td></tr></table>General and administrative expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Personnel</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (9,781)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (9,098)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Maintenance and lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> (1,300)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> (1,301)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Third-party services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (5,283)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (7,002)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Legal and other professional services</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> (2,325)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> (1,629)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Amortization and depreciation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> (2,938)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> (3,106)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,939)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,152)</td></tr><tr><td style="vertical-align:bottom;width:73.28%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (24,566)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (23,287)</td></tr></table>

7937000 8188000

22828000

4534000

964000 5453000 231000 580000

5168000

1170000

104000 710000

37232000

20634000

197000 716000

17000

57000 108000

271000

824000

675000

129000

41000

68000

17287000

3489000

7054000 11037000

1013000

1725000

1855000 857000 -16800000 4692000 36000 1766000 341000 684000

10786000

24251000

6800000 25059000

10885000

6864000

152000

190000

9781000 9098000 1300000 1301000 5283000 7002000

2325000

1629000

2938000

3106000

2939000 1152000

24566000

23287000

7768000

7803000

1330000

1978000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31,</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Compensation for CMO/Material transfer</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 33,012</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 1,544</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Sale of equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"> 310</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"> 308</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"> 69</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;margin:0pt;padding:0pt;"> 2</td></tr><tr><td style="vertical-align:bottom;width:73.19%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152</td></tr><tr><td style="vertical-align:bottom;width:73.19%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,436</td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,006</td></tr></table>

33012000 1544000 310000 308000 69000 2000 45000 152000

33436000

2006000

20500000 12000000 25059000 8300000 15300000

2000

6000

307000

309000

63000

1712000

4. Issued Capital and ReservesAccording to the Company’s articles of association, the Company’s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a nominal value of EUR 0.12. As of March 31, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders’ equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company’s articles of association.In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to USD 600.0 million. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 17.5 million in net proceeds; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program amounts to $497.5 million.In February 2023, the Group completed a follow-on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Group from these transactions were EUR 219,832k. Additional offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.The number of shares issued and outstanding developed as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;">Common shares issued and outstanding at December 31, 2022</td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> 194,997,091</td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;">At-the-market offering program issuances</td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> 1,748,218</td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;">Share issuances as part of the public offering</td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"> 27,027,028</td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;">Share issuances for exercises between Jan to Mar 2023</td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> 112,089</td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;">Treasury shares</td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (32,913)</td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;">Common shares issued and outstanding at March 31, 2023</td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"> 223,851,513</td></tr></table>

386250000

0.12

600000000.0 1748218

17500000

497500000 27027028 9.25

219832000

14580000

194997091 1748218 27027028 112089 -32913 223851513

5. Share-based paymentsDuring the three months ended March 31, 2023 and 2022, the Group recognized share-based based payments expenses of EUR 1,578k and EUR 2,273k, respectively, as follows:Three months ended March 31,<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">Research and development expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 152</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Selling and distribution expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 67</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 41</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,978</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,330</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Other operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,273</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,578</td></tr></table>Expense recognized for the equity-settled programs was as follows:Three months ended March 31,<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Program</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">LTIP Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 1,824</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 975</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">RSU Supervisory Board</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 37</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 55</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">New VSOP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 103</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 57</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Prior VSOP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 92</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> (51)</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">LTIP RSUs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 216</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 542</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,273</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,578</td></tr></table>On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the Group’s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 options during 2022.On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options granted to the COO were exercised at that date. The CDO has left the Group and, under the terms of his LTIP agreement, his options had expired as of December 31, 2022.On March 1, 2021, CureVac granted 2,000 options to a key employee and on January 1, 2022, CureVac granted 9,500 options to a key employee. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.On March 1, 2022, CureVac granted 130,000 options to the Executive Board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.On April 1, 2022, CureVac granted 700 options to a key employee. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of March 31, 2023, none of the options were exercised at that date.The expenses recognized for employee services received under the LTIP Stock Options during the three months ended March 31, 2023, is in an amount of EUR 975k (2022; EUR 1,824k) and is included in general and administrative expenses and selling and distribution expenses.In 2021, as part of the LTIP program, the group awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, the group awarded 10,956 RSUs to Supervisory Board members and on December 23, 2021, the group awarded 63,095 RSUs to the Executive Board and various key employees. Up to March 31, 2023, 47,424 RSU’s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient’s costs are classified.On January 01, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses. For the three months period ended March 31, 2023, all RSUs were settled.On January 31, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO) and 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses.On June 22, 2022, the group awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. On November 30, 2022, the group awarded further 7,633 RSU awards to key employees who joined the Group during fiscal 2022. The related RSU expense is recorded in the functional cost category to which the award recipient’s costs are classified. Up to March 31, 2023, 73,056 RSUs were settled.Effective July 1, 2022 (‘closing date’), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (‘Frame Pharmaceuticals’), now CureVac Netherlands BV. On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees. The related RSU expense is recorded in the functional cost category to which the award recipients’ costs are classified.The expenses recognized for employee services received under the LTIP RSUs during the three months ended March 31, 2023, is in an amount of EUR 542k (2022: EUR 216k) and is included in research and development expenses, general and administrative expenses and selling and distribution expenses.The remaining expense of EUR 57k (2022: EUR 103k) results from grants under the New VSOP and the consideration of the Prior VSOP program leads to an earning of EUR 51k (2022: expense of EUR 92k) in the three-month period ended March 31, 2023.As the CEO left as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.Exercise of optionsUnder the New VSOP plan, 36,516 options were exercised within the first three months of 2023 at a weighted average share price of USD 10.42.

1578000

2273000

Three months ended March 31,<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">Research and development expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 152</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Selling and distribution expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 67</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 41</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,978</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,330</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Other operating expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 37</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,273</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,578</td></tr></table> 189000 152000 67000 41000 1978000 1330000 37000 55000 2273000 1578000 Three months ended March 31,<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Program</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;">EUR k</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;">EUR k</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">LTIP Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 1,824</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 975</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">RSU Supervisory Board</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 37</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> 55</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">New VSOP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"> 103</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 57</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Prior VSOP</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"> 92</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"> (51)</td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;">LTIP RSUs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 216</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 542</td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,273</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,578</td></tr></table> 1824000 975000 37000 55000 103000 57000 92000 -51000 216000 542000 2273000 1578000

266155

266156

6303

20000

30000

2000

9500

130000

700000

975000

1824

10956

63095

47424

36000

5000

30000

37868

193340

7633

73056

89655

542000 216000

57000

103000

51000

92000

36516

10.42

6. Fixed Assets6.1 Intangible assetsDuring the three months ended March 31, 2023, the Group acquired intangible assets of EUR 134k (three months ended March 31, 2022: EUR 448k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those.6.2 Property, plant and equipmentDuring the three months ended March 31, 2023, the increase in property, plant and equipment was attributable to the purchase of technical equipment and machines and other equipment of EUR 3,206k (March 31, 2022: EUR 1,551k) as well as additional amounts recognized as construction in progress of EUR 12,631k (March 31, 2022: EUR 20,533k) primarily related to the Company-owned GMP IV facility EUR 11,845k.

134000

448000

3206000

1551000

12631000

20533000

11845000

7. Assets held for saleIn 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO-Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell. Criteria for the determination of the fair value were defined based on certain sales scenarios considering different sales campaigns. All sales activities are scheduled for 2023 and as of March 31, 2023 Assets held for sale with a net book value of EUR 257k were sold through an external service provider.

29531000 19064000

10467000

257000

8. InventoriesThe inventories include only raw materials and supplies amounting to EUR 24,678k (December 31, 2022: EUR 23,989k), which are recoverable under the Company’s agreements with its collaboration partners. During the three months ended March 31, 2023, the increase in inventory of EUR 688k is due primarily to the purchases of raw material.

24678000

688000 9. Prepaid expenses and other assets (current)Prepaid expenses and other current assets as of March 31, 2023 amounted to EUR 25,597k (December 31, 2022: 40,287k) and mainly include receivables for the GSK compensation of EUR 3,658k (December 31, 2022; EUR 5,595k). For more details, refer to note 3.6. In addition, other assets include tax claims against the tax authorities of EUR 8,540k (December 31, 2022: EUR 24,840k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.

25597000

40287000

3658000 5595000

8540000

24840000

10. Financial assets and financial liabilitiesFair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the three months ended March 31, 2023 and 2022.

11. Trade and other payablesTrade and other payables are all due within one year amounting to EUR 14,973k (December 31, 2022: EUR 73,463k). During the three months ended March 31, 2023, the decrease of EUR 58,490k in trade and other payables was primarily due payments to raw material suppliers for invoices received before December 31, 2022.

14973000

73463000

58490000 12. Other liabilities and provisionsDuring the three months ended March 31, 2023, the decrease of EUR 2,776k in other liabilities was primarily due to lower accruals for outstanding invoices. During the three months ended March 31, 2023, the decrease of EUR 588k in provisions was primarily due to a consumption of the CRO provision for onerous losses. 2776000

588000

13. Income taxFor the three months ended March 31, 2023 and 2022, the Group recorded a consolidated income tax expense (March 31, 2022: income tax benefit) of EUR 1k (March 31, 2022: EUR 96k), respectively. The consolidated income tax expense (March 31, 2022: income tax benefit) for the three months ended March 31, 2023, resulted from income tax expense from CureVac Swiss AG of EUR 1k.

1000

-96000

-1000

14. Disclosure of financial instruments and risk managementAs the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the three months ended March 31, 2023, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.Refer to note 16 to the consolidated financial statements as of December 31, 2022 for additional information on the Group’s risk management activities. As of March 31, 2023, the Group held cash and cash equivalents of USD 76,186k and CHF 124k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds.

76186000

124000

15. Earnings per shareEarnings per share is calculated pursuant to IAS 33 Earnings per Share by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.The weighted number of shares outstanding for the three months ended March 31, 2023 was 211,444,899 (March 31, 2022: 186,993,831). This has led to a basic loss per share for the three months ended March 31, 2023 and 2022 of EUR 0.27 and EUR 0.08, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the three months ended March 31, 2023 and 2022.

211444899

186993831

-0.27

-0.08

16. Related party disclosuresDietmar HoppDuring fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH & Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group’s largest shareholder, purchased EUR 100,000k of the Group’s common shares at a price of USD 16.00 per share.Antony BlancIn 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfill a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac N.V., Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid in 2023 until March 2023 an amount of EUR 21k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.BePharBel Manufacturing S.A.In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group’s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean Stéphenne, Chairman of our Supervisory Board, holds directly and indirectly 15.61% of BePharBel Manufacturing’s equity and is a director of BePharBel Manufacturing, and Baron Jean Stéphenne’s son, Vincent Stéphenne, holds 1.43% of BePharBel Manufacturing’s equity and is a managing director of BePharBel Manufacturing.Franz-Werner HaasIn Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.Alexander ZehnderIn Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.Barker BioMedical GmbHIn Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was entered into. Barker BioMedical GmBH is a wholly-owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V.. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.Craig ToomanIn Q1 2023, a consulting agreement between CureVac SE and Craig Tooman was entered into. For the three-month period ended March 31, 2023 no costs have been incurred under this agreement.

100000

16.00

100000 21000

3900000

4016000

0.1561

0.0143

51000

17. Subsequent eventsThe Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company identified no subsequent event that requires disclosure in the financial statements.

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 149 205 1 false 60 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.curevac.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Sheet http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Statements 2 false false R3.htm 00200 - Statement - Interim Condensed Consolidated Statements of Financial Position Sheet http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition Interim Condensed Consolidated Statements of Financial Position Statements 3 false false R4.htm 00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity Interim Condensed Consolidated Statements of Changes in Shareholders' Equity Statements 4 false false R5.htm 00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows Sheet http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows Interim Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - Corporate Information Sheet http://www.curevac.com/role/DisclosureCorporateInformation Corporate Information Notes 6 false false R7.htm 10201 - Disclosure - Basis of preparation Sheet http://www.curevac.com/role/DisclosureBasisOfPreparation Basis of preparation Notes 7 false false R8.htm 10301 - Disclosure - Notes to the consolidated financial statements Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements Notes to the consolidated financial statements Notes 8 false false R9.htm 10401 - Disclosure - Issued Capital and Reserves Sheet http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves Issued Capital and Reserves Notes 9 false false R10.htm 10501 - Disclosure - Share-based payments Sheet http://www.curevac.com/role/DisclosureShareBasedPayments Share-based payments Notes 10 false false R11.htm 10601 - Disclosure - Fixed Assets Sheet http://www.curevac.com/role/DisclosureFixedAssets Fixed Assets Notes 11 false false R12.htm 10701 - Disclosure - Assets held for sale Sheet http://www.curevac.com/role/DisclosureAssetsHeldForSale Assets held for sale Notes 12 false false R13.htm 10801 - Disclosure - Inventories Sheet http://www.curevac.com/role/DisclosureInventories Inventories Notes 13 false false R14.htm 10901 - Disclosure - Prepaid expenses and other assets (current) Sheet http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent Prepaid expenses and other assets (current) Notes 14 false false R15.htm 11001 - Disclosure - Financial assets and financial liabilities Sheet http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities Financial assets and financial liabilities Notes 15 false false R16.htm 11101 - Disclosure - Trade and other payables Sheet http://www.curevac.com/role/DisclosureTradeAndOtherPayables Trade and other payables Notes 16 false false R17.htm 11201 - Disclosure - Other liabilities and provisions Sheet http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions Other liabilities and provisions Notes 17 false false R18.htm 11301 - Disclosure - Income tax Sheet http://www.curevac.com/role/DisclosureIncomeTax Income tax Notes 18 false false R19.htm 11401 - Disclosure - Disclosure of financial instruments and management of financial risks Sheet http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks Disclosure of financial instruments and management of financial risks Notes 19 false false R20.htm 11501 - Disclosure - Earnings per share Sheet http://www.curevac.com/role/DisclosureEarningsPerShare Earnings per share Notes 20 false false R21.htm 11601 - Disclosure - Related party disclosures Sheet http://www.curevac.com/role/DisclosureRelatedPartyDisclosures Related party disclosures Notes 21 false false R22.htm 11701 - Disclosure - Subsequent events Sheet http://www.curevac.com/role/DisclosureSubsequentEvents Subsequent events Notes 22 false false R23.htm 20202 - Disclosure - Basis of preparation (Policies) Sheet http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies Basis of preparation (Policies) Policies 23 false false R24.htm 30303 - Disclosure - Notes to the consolidated financial statements (Tables) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables Notes to the consolidated financial statements (Tables) Tables http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements 24 false false R25.htm 30403 - Disclosure - Issued Capital and Reserves (Tables) Sheet http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables Issued Capital and Reserves (Tables) Tables http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves 25 false false R26.htm 30503 - Disclosure - Share-based payments (Tables) Sheet http://www.curevac.com/role/DisclosureShareBasedPaymentsTables Share-based payments (Tables) Tables http://www.curevac.com/role/DisclosureShareBasedPayments 26 false false R27.htm 40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails Notes to the consolidated financial statements - Revenue from contract with customers (Details) Details 27 false false R28.htm 40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails Notes to the consolidated financial statements - Additional Information (Details) Details 28 false false R29.htm 40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) Details 29 false false R30.htm 40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails Notes to the consolidated financial statements - Contract balances (Details) Details 30 false false R31.htm 40305 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails Notes to the consolidated financial statements - Cost of sales (Details) Details 31 false false R32.htm 40306 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails Notes to the consolidated financial statements - Selling and distribution expenses (Details) Details 32 false false R33.htm 40307 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails Notes to the consolidated financial statements - Research and development expenses (Details) Details 33 false false R34.htm 40308 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails Notes to the consolidated financial statements - General and administrative expenses (Details) Details 34 false false R35.htm 40309 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails Notes to the consolidated financial statements - Other operating income (Details) Details 35 false false R36.htm 40310 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details) Notes http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details) Details 36 false false R37.htm 40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details) Sheet http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails Issued Capital and Reserves - Overview and General Remarks (Details) Details 37 false false R38.htm 40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details) Sheet http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails Issued Capital and Reserves - At-the-market offering (Details) Details 38 false false R39.htm 40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details) Sheet http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails Issued Capital and Reserves - Impact of share split (Details) Details 39 false false R40.htm 40501 - Disclosure - Share-based payments - Expenses (Details) Sheet http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails Share-based payments - Expenses (Details) Details 40 false false R41.htm 40502 - Disclosure - Share-based payments - Equity-settled programs (Details) Sheet http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails Share-based payments - Equity-settled programs (Details) Details 41 false false R42.htm 40503 - Disclosure - Share-based payments (Details) Sheet http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails Share-based payments (Details) Details http://www.curevac.com/role/DisclosureShareBasedPaymentsTables 42 false false R43.htm 40601 - Disclosure - Fixed Assets - Intangible assets (Details) Sheet http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails Fixed Assets - Intangible assets (Details) Details 43 false false R44.htm 40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details) Sheet http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails Fixed Assets - Property, plant and equipment (Details) Details 44 false false R45.htm 40701 - Disclosure - Assets held for sale (Details) Sheet http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails Assets held for sale (Details) Details http://www.curevac.com/role/DisclosureAssetsHeldForSale 45 false false R46.htm 40801 - Disclosure - Inventories (Details) Sheet http://www.curevac.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.curevac.com/role/DisclosureInventories 46 false false R47.htm 40901 - Disclosure - Prepaid expenses and other assets (current) (Details) Sheet http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails Prepaid expenses and other assets (current) (Details) Details http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent 47 false false R48.htm 41001 - Disclosure - Financial assets and financial liabilities (Details) Sheet http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails Financial assets and financial liabilities (Details) Details http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities 48 false false R49.htm 41101 - Disclosure - Trade and other payables (Details) Sheet http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails Trade and other payables (Details) Details http://www.curevac.com/role/DisclosureTradeAndOtherPayables 49 false false R50.htm 41201 - Disclosure - Other liabilities and provisions (Details) Sheet http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails Other liabilities and provisions (Details) Details http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions 50 false false R51.htm 41301 - Disclosure - Income tax (Details) Sheet http://www.curevac.com/role/DisclosureIncomeTaxDetails Income tax (Details) Details http://www.curevac.com/role/DisclosureIncomeTax 51 false false R52.htm 41401 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details) Sheet http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details) Details 52 false false R53.htm 41501 - Disclosure - Earnings per share (Details) Sheet http://www.curevac.com/role/DisclosureEarningsPerShareDetails Earnings per share (Details) Details http://www.curevac.com/role/DisclosureEarningsPerShare 53 false false R54.htm 41601 - Disclosure - Related party disclosures (Details) Sheet http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails Related party disclosures (Details) Details http://www.curevac.com/role/DisclosureRelatedPartyDisclosures 54 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: ifrs-full:ParValuePerShare, ifrs-full:RawMaterials, ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities - cvac-20230331xex99d1.htm 9 cvac-20230331x6k.htm cvac-20230331xex99d1.htm cvac-20230331.xsd cvac-20230331_cal.xml cvac-20230331_def.xml cvac-20230331_lab.xml cvac-20230331_pre.xml cvac-20230331xex99d2.htm cvac-20230331xex99d1001.jpg http://xbrl.sec.gov/dei/2022 https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvac-20230331x6k.htm cvac-20230331xex99d1.htm": { "axisCustom": 4, "axisStandard": 16, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 8, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 373 }, "contextCount": 149, "dts": { "calculationLink": { "local": [ "cvac-20230331_cal.xml" ] }, "definitionLink": { "local": [ "cvac-20230331_def.xml" ] }, "inline": { "local": [ "cvac-20230331x6k.htm", "cvac-20230331xex99d1.htm" ] }, "labelLink": { "local": [ "cvac-20230331_lab.xml" ] }, "presentationLink": { "local": [ "cvac-20230331_pre.xml" ] }, "schema": { "local": [ "cvac-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 626, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 6, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 14, "total": 20 }, "keyCustom": 62, "keyStandard": 143, "memberCustom": 42, "memberStandard": 17, "nsprefix": "cvac", "nsuri": "http://www.curevac.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cvac-20230331x6k.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.curevac.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "cvac-20230331x6k.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Share-based payments", "menuCat": "Notes", "order": "10", "role": "http://www.curevac.com/role/DisclosureShareBasedPayments", "shortName": "Share-based payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfFixedAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fixed Assets", "menuCat": "Notes", "order": "11", "role": "http://www.curevac.com/role/DisclosureFixedAssets", "shortName": "Fixed Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfFixedAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Assets held for sale", "menuCat": "Notes", "order": "12", "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSale", "shortName": "Assets held for sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Inventories", "menuCat": "Notes", "order": "13", "role": "http://www.curevac.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Prepaid expenses and other assets (current)", "menuCat": "Notes", "order": "14", "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent", "shortName": "Prepaid expenses and other assets (current)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Financial assets and financial liabilities", "menuCat": "Notes", "order": "15", "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities", "shortName": "Financial assets and financial liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Trade and other payables", "menuCat": "Notes", "order": "16", "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayables", "shortName": "Trade and other payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Other liabilities and provisions", "menuCat": "Notes", "order": "17", "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions", "shortName": "Other liabilities and provisions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Income tax", "menuCat": "Notes", "order": "18", "role": "http://www.curevac.com/role/DisclosureIncomeTax", "shortName": "Income tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Disclosure of financial instruments and management of financial risks", "menuCat": "Notes", "order": "19", "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks", "shortName": "Disclosure of financial instruments and management of financial risks", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)", "menuCat": "Statements", "order": "2", "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss", "shortName": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Earnings per share", "menuCat": "Notes", "order": "20", "role": "http://www.curevac.com/role/DisclosureEarningsPerShare", "shortName": "Earnings per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Related party disclosures", "menuCat": "Notes", "order": "21", "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures", "shortName": "Related party disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Subsequent events", "menuCat": "Notes", "order": "22", "role": "http://www.curevac.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Basis of preparation (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies", "shortName": "Basis of preparation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Notes to the consolidated financial statements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables", "shortName": "Notes to the consolidated financial statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Issued Capital and Reserves (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables", "shortName": "Issued Capital and Reserves (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Share-based payments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables", "shortName": "Share-based payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)", "menuCat": "Details", "order": "27", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "shortName": "Notes to the consolidated financial statements - Revenue from contract with customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_MrZSLVYsA0-RIpS-pgJkfQ", "decimals": "-3", "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromIssuingShares", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Notes to the consolidated financial statements - Additional Information (Details)", "menuCat": "Details", "order": "28", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "shortName": "Notes to the consolidated financial statements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_Y_PqBnk9MUOv4J4moD0JaQ", "decimals": "-3", "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_m11bCV96y0yrB385ikyHJg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)", "menuCat": "Details", "order": "29", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails", "shortName": "Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_m11bCV96y0yrB385ikyHJg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Interim Condensed Consolidated Statements of Financial Position", "menuCat": "Statements", "order": "3", "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition", "shortName": "Interim Condensed Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Notes to the consolidated financial statements - Contract balances (Details)", "menuCat": "Details", "order": "30", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "shortName": "Notes to the consolidated financial statements - Contract balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "lang": null, "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2022_To_12_31_2022_uS1gQCepeE-fBvDXgZ5mEw", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ImpairmentOfAssetsHeldForSale", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)", "menuCat": "Details", "order": "31", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "shortName": "Notes to the consolidated financial statements - Cost of sales (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_4lYXLXEIwE-a5819GCYTkA", "decimals": "-3", "lang": null, "name": "cvac:PersonnelExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember__fPZXSJpjkiaXrMr44IjSg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:PersonnelExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40306 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)", "menuCat": "Details", "order": "32", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails", "shortName": "Notes to the consolidated financial statements - Selling and distribution expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember__fPZXSJpjkiaXrMr44IjSg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:PersonnelExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:IfrsProvisionForLossOnContracts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40307 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)", "menuCat": "Details", "order": "33", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "shortName": "Notes to the consolidated financial statements - Research and development expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:IfrsProvisionForLossOnContracts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_yU-hcmKXzECbdCRcsJnklg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:PersonnelExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40308 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)", "menuCat": "Details", "order": "34", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "shortName": "Notes to the consolidated financial statements - General and administrative expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_yU-hcmKXzECbdCRcsJnklg", "decimals": "-3", "first": true, "lang": null, "name": "cvac:PersonnelExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40309 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)", "menuCat": "Details", "order": "35", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "shortName": "Notes to the consolidated financial statements - Other operating income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_4ZMIQGokBkaf-V1dtKXoqA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40310 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)", "menuCat": "Details", "order": "36", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "shortName": "Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_4ZMIQGokBkaf-V1dtKXoqA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-5", "first": true, "lang": null, "name": "cvac:RemainingAuthorizedForSaleValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GpOVAPRPH0GCJ_UvyptjNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)", "menuCat": "Details", "order": "37", "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "shortName": "Issued Capital and Reserves - Overview and General Remarks (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-5", "first": true, "lang": null, "name": "cvac:RemainingAuthorizedForSaleValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GpOVAPRPH0GCJ_UvyptjNg", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromIssuingShares", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)", "menuCat": "Details", "order": "38", "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "shortName": "Issued Capital and Reserves - At-the-market offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_eevPnEc8Y0S4I7tCLIpN_w", "decimals": "-5", "lang": null, "name": "cvac:AggregateGrossProceedsReceivableFromIssuingShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GpOVAPRPH0GCJ_UvyptjNg", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "INF", "first": true, "lang": null, "name": "cvac:CommonSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0bPvmFYtxkSsGTqoQZnyrA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)", "menuCat": "Details", "order": "39", "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "shortName": "Issued Capital and Reserves - Impact of share split (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "INF", "first": true, "lang": null, "name": "cvac:CommonSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0bPvmFYtxkSsGTqoQZnyrA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_HGR7SkBsyUGaWBWXuEG52A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "4", "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_HGR7SkBsyUGaWBWXuEG52A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Share-based payments - Expenses (Details)", "menuCat": "Details", "order": "40", "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails", "shortName": "Share-based payments - Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpenseRecognizedForEmployeeServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Share-based payments - Equity-settled programs (Details)", "menuCat": "Details", "order": "41", "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails", "shortName": "Share-based payments - Equity-settled programs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpenseRecognizedForEmployeeServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Share-based payments (Details)", "menuCat": "Details", "order": "42", "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "shortName": "Share-based payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "cvac:DisclosureOfFixedAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_0QOF_QLVgUiuECTTE-Kb7A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fixed Assets - Intangible assets (Details)", "menuCat": "Details", "order": "43", "role": "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "shortName": "Fixed Assets - Intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cvac:DisclosureOfFixedAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_0QOF_QLVgUiuECTTE-Kb7A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)", "menuCat": "Details", "order": "44", "role": "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails", "shortName": "Fixed Assets - Property, plant and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cvac:DisclosureOfFixedAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_zUbY6V4ie0WCAMdKdiaASg", "decimals": "-3", "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:GrossBookValueOfCmoEquipmentHeldForSale", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Assets held for sale (Details)", "menuCat": "Details", "order": "45", "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails", "shortName": "Assets held for sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_12_31_2022_Er9w6lIBAUG8O5CsHqCjmA", "decimals": "-3", "first": true, "lang": null, "name": "cvac:GrossBookValueOfCmoEquipmentHeldForSale", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Inventories (Details)", "menuCat": "Details", "order": "46", "role": "http://www.curevac.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Prepaid expenses and other assets (current) (Details)", "menuCat": "Details", "order": "47", "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails", "shortName": "Prepaid expenses and other assets (current) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "lang": null, "name": "cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Financial assets and financial liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails", "shortName": "Financial assets and financial liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_h-826aZe30iQPDfXWlGx9g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Trade and other payables (Details)", "menuCat": "Details", "order": "49", "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails", "shortName": "Trade and other payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "lang": null, "name": "cvac:ChangeInTradeAndOtherPayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "5", "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows", "shortName": "Interim Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForFinanceIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "cvac:OtherLiabilitiesAndProvisionsTextBlock", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ChangeInOtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Other liabilities and provisions (Details)", "menuCat": "Details", "order": "50", "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails", "shortName": "Other liabilities and provisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cvac:OtherLiabilitiesAndProvisionsTextBlock", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ChangeInOtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Income tax (Details)", "menuCat": "Details", "order": "51", "role": "http://www.curevac.com/role/DisclosureIncomeTaxDetails", "shortName": "Income tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_zMiasmSA7EKTqFmufqw7WQ", "decimals": "-3", "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_tgGqM0ucxE6kB1uzwDDmiQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GpOVAPRPH0GCJ_UvyptjNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)", "menuCat": "Details", "order": "52", "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails", "shortName": "Disclosure of financial instruments and management of financial risks - Foreign currency risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "As_Of_3_31_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_tgGqM0ucxE6kB1uzwDDmiQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GpOVAPRPH0GCJ_UvyptjNg", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0bPvmFYtxkSsGTqoQZnyrA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Earnings per share (Details)", "menuCat": "Details", "order": "53", "role": "http://www.curevac.com/role/DisclosureEarningsPerShareDetails", "shortName": "Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0bPvmFYtxkSsGTqoQZnyrA", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpensesToHandleFutureServiceAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Related party disclosures (Details)", "menuCat": "Details", "order": "54", "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "shortName": "Related party disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": "-3", "first": true, "lang": null, "name": "cvac:ExpensesToHandleFutureServiceAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_Eq3oOJql60a8K4A3v9G1nw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:CorporateInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Corporate Information", "menuCat": "Notes", "order": "6", "role": "http://www.curevac.com/role/DisclosureCorporateInformation", "shortName": "Corporate Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:CorporateInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Basis of preparation", "menuCat": "Notes", "order": "7", "role": "http://www.curevac.com/role/DisclosureBasisOfPreparation", "shortName": "Basis of preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Notes to the consolidated financial statements", "menuCat": "Notes", "order": "8", "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements", "shortName": "Notes to the consolidated financial statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Issued Capital and Reserves", "menuCat": "Notes", "order": "9", "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves", "shortName": "Issued Capital and Reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cvac-20230331xex99d1.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dp-exmFa7UyM4Pmv3mLApQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "country_BE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Belgium", "terseLabel": "Belgium" } } }, "localname": "BE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland", "terseLabel": "Switzerland" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Germany", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "country_NL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Netherlands", "terseLabel": "Netherlands" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHF" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EUR" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GBP" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued liability for other taxes consists of real estate transfer taxes.", "label": "Accrued Liability For Other Taxes Consists Of Real Estate Transfer Taxes", "terseLabel": "Accrued liability for other taxes consists of real estate transfer taxes" } } }, "localname": "AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AccruedOtherLiabilityForUpFrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued other liability for up-front payment.", "label": "Accrued Other Liability for Up-front Payment", "terseLabel": "Additional depreciation expense", "verboseLabel": "Accrued other liability for up-front payment" } } }, "localname": "AccruedOtherLiabilityForUpFrontPayment", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AdditionalDevelopmentMilestonePaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional development milestone payment received.", "label": "Additional Development Milestone Payments Received", "terseLabel": "Additional development milestone payments" } } }, "localname": "AdditionalDevelopmentMilestonePaymentsReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional offering costs recognized as reduction to capital reserve.", "label": "Additional Offering Costs Recognized As Reduction To Capital Reserve", "terseLabel": "Additional offering costs recognized as reduction to capital reserve" } } }, "localname": "AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AdjustmentsForDecreaseIncreaseInAssetHeldForSale": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustments for decrease increase in asset held for sale.", "label": "Adjustments For Decrease Increase in Asset Held for Sale", "terseLabel": "Decrease / (increase) in asset held for sale" } } }, "localname": "AdjustmentsForDecreaseIncreaseInAssetHeldForSale", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners", "terseLabel": "Decrease / (increase) in assets held for sale" } } }, "localname": "AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.", "label": "Adjustments For Increase Decrease In Other Current Financial And Other Liabilities", "terseLabel": "(Decrease) / increase in other current financial liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Non Cash Income From Release Of Provisions", "negatedLabel": "Non-cash income from release of provisions" } } }, "localname": "AdjustmentsForNonCashIncomeFromReleaseOfProvisions", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_AdjustmentsTransferToAssetHeldForSale": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer to assets held for sale.", "label": "Adjustments Transfer To Asset Held For Sale", "terseLabel": "Impairment of assets held for sale" } } }, "localname": "AdjustmentsTransferToAssetHeldForSale", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_AdvancePaymentsIntangibleAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payments, intangible asset.", "label": "Advance Payments [Member]", "terseLabel": "Goodwil" } } }, "localname": "AdvancePaymentsIntangibleAssetMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Advance Purchase Agreement with European Commission", "label": "Advance Purchase Agreement with European Commission" } } }, "localname": "AdvancedPurchaseAgreementWithEuropeanCommissionMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_AggregateGrossProceedsReceivableFromIssuingShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of aggregate gross proceeds receivable from issuance of shares.", "label": "Aggregate Gross Proceeds Receivable From Issuing Shares", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "AggregateGrossProceedsReceivableFromIssuingShares", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmortizationOfGovernmentGrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of amortization of the grants.", "label": "Amortization of the Government Grants", "terseLabel": "Amortization of the grants" } } }, "localname": "AmortizationOfGovernmentGrants", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount pertaining to grants deducted from the carrying amount of qualifying assets.", "label": "Amount Deducted From Carrying Amount Of Qualifying Assets", "terseLabel": "Amount deducted from the carrying amount of qualifying assets" } } }, "localname": "AmountDeductedFromCarryingAmountOfQualifyingAssets", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountEligibleToReceiveAsCommercialMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount eligible to receive commercial milestone payments.", "label": "Amount Eligible to Receive as Commercial Milestone Payments", "terseLabel": "Commercial milestone payments" } } }, "localname": "AmountEligibleToReceiveAsCommercialMilestonePayments", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount eligible to receive development and regulatory milestone payments.", "label": "Amount Eligible to Receive as Development and Regulatory Milestone Payments", "terseLabel": "Development and regulatory milestone payments" } } }, "localname": "AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.", "label": "Amount Eligible to Receive as One-Time Reimbursable Payment For Manufacturing Capacity Reservation", "terseLabel": "One-time reimbursable payment" } } }, "localname": "AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountOfLiabilityCashClaimAwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized in financial statements towards cash claim of Awards.", "label": "Amount of Liability, Cash Claim Awards", "terseLabel": "Amount of liability, cash claim awards" } } }, "localname": "AmountOfLiabilityCashClaimAwards", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AmountOfRestrictedStockUnitsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Restricted Stock Units Received.", "label": "Amount of Restricted Stock Units Received", "terseLabel": "Amount of restricted stock units received" } } }, "localname": "AmountOfRestrictedStockUnitsReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AntonyBlancMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Antony Blanc.", "label": "Antony Blanc [Member]", "terseLabel": "Antony Blanc" } } }, "localname": "AntonyBlancMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_ArrangementsAndNonArrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Non-arrangement Transactions [Member]" } } }, "localname": "ArrangementsAndNonArrangementTransactionsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_AssetsHeldForSaleNetBookValueSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net book value sold of assets held for sale.", "label": "Assets Held for Sale, Net Book Value Sold", "terseLabel": "Assets held for sale with a net book value sold" } } }, "localname": "AssetsHeldForSaleNetBookValueSold", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "cvac_AtMarketOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to at the market offering program.", "label": "ATM Offering Program" } } }, "localname": "AtMarketOfferingProgramMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "domainItemType" }, "cvac_BaronJeanStephenneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Baron Jean Stephenne.", "label": "Baron Jean Stephenne [Member]", "terseLabel": "Baron Jean Stephenne" } } }, "localname": "BaronJeanStephenneMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_BenefitExpenseRecognizedForShareBasedPayment": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit expense benefit recognized for share-based payment.", "label": "Benefit Expense Recognized For Share Based Payment", "totalLabel": "Total" } } }, "localname": "BenefitExpenseRecognizedForShareBasedPayment", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_BepharbelManufacturingS.aMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BePharBel Manufacturing S.A.", "label": "BePharBel Manufacturing S.A [Member]", "terseLabel": "BePharBel Manufacturing S.A" } } }, "localname": "BepharbelManufacturingS.aMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_BillAndMelindaGatesFoundationBmgfMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for grants from Bill & Melinda Gates Foundation (BMGF).", "label": "Bill & Melinda Gates Foundation (BMGF)" } } }, "localname": "BillAndMelindaGatesFoundationBmgfMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for grants from Bill & Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.", "label": "Bill & Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine" } } }, "localname": "BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for grants from Bill & Melinda Gates Foundation (BMGF) for malaria vaccine.", "label": "Bill & Melinda Gates Foundation (BMGF), Grant for malaria vaccine" } } }, "localname": "BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_BmbfMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BMBF", "label": "BMBF", "terseLabel": "BMBF" } } }, "localname": "BmbfMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_BoehringerIngelheimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Boehringer Ingelheim.", "label": "Boehringer Ingelheim", "terseLabel": "Boehringer Ingelheim" } } }, "localname": "BoehringerIngelheimMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_BundesministeriumFurBildungUndForschungMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Bundesministerium fr Bildung und Forschung.", "label": "Bundesministerium fr Bildung und Forschung" } } }, "localname": "BundesministeriumFurBildungUndForschungMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_CapitalIncreaseByGenmabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Genmab, capital increase.", "label": "Genmab Investment", "terseLabel": "Genmab Investment" } } }, "localname": "CapitalIncreaseByGenmabMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA.", "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]", "terseLabel": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amoun" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cvac_ChangeInExpenseByNature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in expense by nature.", "label": "Change in Expense By Nature", "terseLabel": "Increase in cost of sales" } } }, "localname": "ChangeInExpenseByNature", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ChangeInOtherLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in other liabilities.", "label": "Change in Other Liabilities", "verboseLabel": "Decrease in other liabilities" } } }, "localname": "ChangeInOtherLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ChangeInTradeAndOtherPayables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of change in trade and other payables.", "label": "Change in Trade and Other Payables", "terseLabel": "Amount of decrease in trade and other payables" } } }, "localname": "ChangeInTradeAndOtherPayables", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ChangesInWorkingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Changes in Working Capital [Abstract]", "terseLabel": "Working capital changes" } } }, "localname": "ChangesInWorkingCapitalAbstract", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Chief Business Officer and Chief Commercial Officer.", "label": "Chief Business Officer and Chief Commercial Officer", "terseLabel": "Chief Business Officer and Chief Commercial Officer" } } }, "localname": "ChiefBusinessOfficerAndChiefCommercialOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ChiefBusinessOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Chief Business Officer.", "label": "Chief Business Officer [Member]", "terseLabel": "Chief Business Officer" } } }, "localname": "ChiefBusinessOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ChiefDevelopmentOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Chief Development Officer", "label": "Chief Development Officer", "terseLabel": "Chief Development Officer" } } }, "localname": "ChiefDevelopmentOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person with designation of Chief operating officer and Chief development officer.", "label": "Chief Operating Officer and Chief Development Officer", "terseLabel": "Chief Operating Officer and Chief Development Officer" } } }, "localname": "ChiefOperatingOfficerAndChiefDevelopmentOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ChiefScientificOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Chief Scientific Officer.", "label": "Chief Scientific Officer", "terseLabel": "Chief Scientific Officer" } } }, "localname": "ChiefScientificOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ClarentisSrlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.", "label": "Clarentis SRL [Member]", "terseLabel": "Clarentis SRL" } } }, "localname": "ClarentisSrlMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_CoalitionForEpidemicPreparednessInnovationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for grants related to Coalition for Epidemic Preparedness Innovations.", "label": "Coalition for Epidemic Preparedness Innovations" } } }, "localname": "CoalitionForEpidemicPreparednessInnovationsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.", "label": "Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines" } } }, "localname": "CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cvac_CollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for termination of exclusive collobaration and license agreement.", "label": "Collaboration And License Agreement [Member]", "terseLabel": "Collaboration and License Agreement" } } }, "localname": "CollaborationAndLicenseAgreementMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cvac_CommonSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued and outstanding for during the period.", "label": "Common Shares Issued And Outstanding", "periodEndLabel": "Common shares issued and outstanding ending", "periodStartLabel": "Common shares issued and outstanding beginning" } } }, "localname": "CommonSharesIssuedAndOutstanding", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_CompanyOwnedGmpIvFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for company-owned GMP IV facility.", "label": "Company-owned GMP IV facility", "terseLabel": "Company-owned GMP IV facility" } } }, "localname": "CompanyOwnedGmpIvFacilityMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "domainItemType" }, "cvac_CompensationForContractManufacturingOrganizationsTransfer": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 3.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.", "label": "Compensation for Contract Manufacturing organizations Transfer", "terseLabel": "Compensation for CMO/Materials transfer" } } }, "localname": "CompensationForContractManufacturingOrganizationsTransfer", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.", "label": "Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities", "terseLabel": "Compensation consist for set-up activities" } } }, "localname": "CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.", "label": "Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses", "terseLabel": "Reimbursement of prepayments" } } }, "localname": "CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_CorporateInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Corporate Information" } } }, "localname": "CorporateInformationAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_CorporateInformationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on corporate information.", "label": "Corporate Information [Text Block]", "terseLabel": "Corporate Information" } } }, "localname": "CorporateInformationTextBlock", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureCorporateInformation" ], "xbrltype": "textBlockItemType" }, "cvac_CostOfReimbursementClaim": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 2.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cost of reimbursement claim.", "label": "Cost of reimbursement claim", "terseLabel": "Reimbursement claim" } } }, "localname": "CostOfReimbursementClaim", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvac_CrisprMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for CRISPR.", "label": "CRISPR", "terseLabel": "CRISPR" } } }, "localname": "CrisprMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_CrisprTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for CRISPR Therapeutics", "label": "CRISPR Therapeutics" } } }, "localname": "CrisprTherapeuticsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_CumulativeAmortizationAndImpairmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accumulated depreciation, amortization and impairment.", "label": "Cumulative Amortization And Impairment [Member]", "terseLabel": "Cumulative Amortization And Impairment", "verboseLabel": "Cumulative amortization and impairment charges" } } }, "localname": "CumulativeAmortizationAndImpairmentMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cvac_CurevacSwissAgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for CureVac Swiss AG.", "label": "Curevac Swiss Ag [Member]", "terseLabel": "CureVac AG" } } }, "localname": "CurevacSwissAgMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "domainItemType" }, "cvac_CurrentGrantReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of grant receivable, classified as current.", "label": "Current Grant Receivable", "terseLabel": "Current grant receivable" } } }, "localname": "CurrentGrantReceivable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "cvac_CurrentValueAddedTaxAndOtherTaxesPayables": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 5.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current value added tax and other taxes payables.", "label": "Current Value Added Tax And Other Taxes Payables", "terseLabel": "VAT and other taxes (real estate transfer taxes)" } } }, "localname": "CurrentValueAddedTaxAndOtherTaxesPayables", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents for decrease in number of shares due to treasury of shares.", "label": "Decrease In Number Of Shares Due To Treasury Of Shares", "terseLabel": "Treasury shares" } } }, "localname": "DecreaseInNumberOfSharesDueToTreasuryOfShares", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_Deductibletemporarydifferencesnotrecognizedtrhoughprofiorlossofreportingperiod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deductible temporary differences not recognized through P&L pertaining to reporting period.", "label": "DeductibleTemporaryDifferencesNotRecognizedTrhoughProfiOrLossOfReportingPeriod", "terseLabel": "Amount of deductible temporary differences not recognized through P&L pertaining to reporting period" } } }, "localname": "Deductibletemporarydifferencesnotrecognizedtrhoughprofiorlossofreportingperiod", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "cvac_Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred tax assets related to items credited (charged) directly to equity.", "label": "DeferredTaxAssetsRelatingToItemsChargedOrCreditedDirectlyToEquity", "terseLabel": "The amount of deferred tax assets related to items credited (charged) directly to equity" } } }, "localname": "Deferredtaxassetsrelatingtoitemschargedorcrediteddirectlytoequity", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Covid-19 impact.", "label": "Description of Accounting Policy for Covid-19 Impact, Explanatory", "terseLabel": "Impact of COVID-19 and the Russia-Ukraine Conflict" } } }, "localname": "DescriptionOfAccountingPolicyForCovid19ImpactExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" ], "xbrltype": "textBlockItemType" }, "cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Pre-launch products.", "label": "Description of Accounting Policy for Pre-Launch Products, Explanatory", "terseLabel": "Pre-launch products" } } }, "localname": "DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" ], "xbrltype": "textBlockItemType" }, "cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.", "label": "Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]", "terseLabel": "New standards, interpretations and amendments adopted by the Group" } } }, "localname": "DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" ], "xbrltype": "textBlockItemType" }, "cvac_DietmarHoppMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH & Co. KG , a majority shareholder of the entity, a related party.", "label": "Dietmar Hopp [Member]", "terseLabel": "Dietmar Hopp" } } }, "localname": "DietmarHoppMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Dievini Hopp BioTech holding GmbH & Co. KG.", "label": "Dievini Hopp BioTech holding GmbH & Co. KG [Member]", "terseLabel": "Dievini Hopp BioTech holding GmbH & Co. KG" } } }, "localname": "DieviniHoppBiotechHoldingGmbhCo.KgMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_DiluteEffectOfOrdinarySharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed issuance of new shares.", "label": "Dilute Effect Of Ordinary Shares Issued", "terseLabel": "New issue of shares for the purpose of calculating earning per share" } } }, "localname": "DiluteEffectOfOrdinarySharesIssued", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "cvac_DisclosureOfBasisOfPreparationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statement.", "label": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statement.", "label": "Disclosure of Basis of Preparation Explanatory [Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationExplanatoryTextBlock", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparation" ], "xbrltype": "textBlockItemType" }, "cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of expense recognized for employee services explanatory.", "label": "Disclosure of Expense Recognized For Employee Services Explanatory", "terseLabel": "Schedule of share-based payments expenses" } } }, "localname": "DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "cvac_DisclosureOfFixedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Fixed Assets" } } }, "localname": "DisclosureOfFixedAssetsAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_DisclosureOfFixedAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for fixed assets.", "label": "Disclosure Of Fixed Assets, Explanatory", "terseLabel": "Fixed Assets" } } }, "localname": "DisclosureOfFixedAssetsExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssets" ], "xbrltype": "textBlockItemType" }, "cvac_DisclosureOfGovernmentGrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Disclosure Of Government Grants [Line Items]", "terseLabel": "Notes to the consolidated financial statements" } } }, "localname": "DisclosureOfGovernmentGrantsLineItems", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfGovernmentGrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of government grants.", "label": "Disclosure Of Government Grants [Table]" } } }, "localname": "DisclosureOfGovernmentGrantsTable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the consolidated financial statements" } } }, "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents of disclosure of notes to the consolidated financial statements.", "label": "Disclosure Of Notes To The Consolidated Financial Statements [Line Items]", "terseLabel": "Notes to the consolidated financial statements" } } }, "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsLineItems", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of notes to the consolidated financial statements.", "label": "Disclosure Of Notes To The Consolidated Financial Statements [Table]" } } }, "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsTable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfOtherLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Disclosure of Other liabilities [Line Items]", "terseLabel": "Other liabilities and provisions" } } }, "localname": "DisclosureOfOtherLiabilitiesLineItems", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfOtherLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other liabilities.", "label": "Disclosure of Other liabilities [table]" } } }, "localname": "DisclosureOfOtherLiabilitiesTable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "stringItemType" }, "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Prepaid expenses and other assets (current)" } } }, "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current assets.", "label": "Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory", "terseLabel": "Prepaid expenses and other assets (current)" } } }, "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" ], "xbrltype": "textBlockItemType" }, "cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about upfront payments and related revenues recognized.", "label": "Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory", "terseLabel": "Summary of upfront payments and related revenues recognized" } } }, "localname": "DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "cvac_Dr.IngmarHrrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Dr. Ingmar Hrr.", "label": "Dr. Ingmar Hrr [Member]", "terseLabel": "Dr. Ingmar Hrr" } } }, "localname": "Dr.IngmarHrrMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_Effectsondeferredtaxassetsduetoenactedincreasesintradetaxlevyratebycitycounciloftuebingen": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effects On Deferred Tax Assets Due To The Enacted Increases In The Trade Tax Levy Rate By The City Council Of Tuebingen.", "label": "EffectsOnDeferredTaxAssetsDueToEnactedIncreasesInTradeTaxLevyRateByCityCouncilOfTuebingen", "terseLabel": "Effects on deferred tax assets" } } }, "localname": "Effectsondeferredtaxassetsduetoenactedincreasesintradetaxlevyratebycitycounciloftuebingen", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "cvac_EliLillyAndCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Eli Lilly and Company.", "label": "Eli Lilly.", "terseLabel": "Eli Lilly." } } }, "localname": "EliLillyAndCompanyMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_EliLillyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Eli Lilly", "label": "Eli Lilly" } } }, "localname": "EliLillyMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for equipment physically located at the CMO facilities.", "label": "Equipment physically located at the CMO facilities", "terseLabel": "Equipment physically located at the CMO facilities" } } }, "localname": "EquipmentPhysicallyLocatedAtCmoFacilitiesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cvac_EuropeanCommissionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for European Commission.", "label": "European Commission", "terseLabel": "European Commission" } } }, "localname": "EuropeanCommissionMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_EuropeanUnionAdvancePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to EU APA.", "label": "EU APA", "terseLabel": "EU APA" } } }, "localname": "EuropeanUnionAdvancePurchaseAgreementMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_ExecutiveBoardMembersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for executive board members.", "label": "Executive board members", "terseLabel": "Executive board members" } } }, "localname": "ExecutiveBoardMembersMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ExerciseOfGreenshoeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise of Greenshoe.", "label": "Exercise \"Greenshoe\"", "terseLabel": "Exercise \"Greenshoe\"" } } }, "localname": "ExerciseOfGreenshoeMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_ExerciseOfOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for exercise of options.", "label": "Exercise of options", "terseLabel": "Exercise of options" } } }, "localname": "ExerciseOfOptionsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": { "order": 1.0, "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.", "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses", "verboseLabel": "General and administrative expenses" } } }, "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": { "order": 4.0, "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in other operating expenses.", "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Other Operating Expenses", "verboseLabel": "Other operating expenses" } } }, "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": { "order": 3.0, "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.", "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses", "verboseLabel": "Research and development expenses" } } }, "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ExpenseRecognizedForEmployeeServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense recognized for employee services.", "label": "Expense Recognized For Employee Services", "totalLabel": "Total" } } }, "localname": "ExpenseRecognizedForEmployeeServices", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets Rsu. [Refer: Expense from share-based payment transactions]", "label": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhicGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsin Rsu", "verboseLabel": "Expenses recognized with RSU" } } }, "localname": "ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": { "order": 2.0, "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.", "label": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSalesAndMarketingExpenses", "terseLabel": "Selling and distribution expenses" } } }, "localname": "Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ExpensesToHandleFutureServiceAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses to handle future service agreement.", "label": "Expenses To Handle Future Service Agreement", "terseLabel": "Expenses to handle future service agreement" } } }, "localname": "ExpensesToHandleFutureServiceAgreement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "cvac_FinancialInstrumentsAndRiskManagementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure of financial instruments and management of financial risks" } } }, "localname": "FinancialInstrumentsAndRiskManagementAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_FlorianVonDerMlbeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Florian von der Mlbe.", "label": "Florian von der Mlbe [Member]", "terseLabel": "Florian von der Mlbe" } } }, "localname": "FlorianVonDerMlbeMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to follow on public offering.", "label": "Follow-on public offering, incl. Greenshoe" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "domainItemType" }, "cvac_FormerFrameEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Frame employee's", "label": "Former Frame Employee’s [Member]", "terseLabel": "Former Frame employee's" } } }, "localname": "FormerFrameEmployeesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_GenmabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Genmab.", "label": "Genmab", "terseLabel": "Genmab" } } }, "localname": "GenmabMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_GermanFederalMinistryOfEducationAndResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for German Federal Ministry of Education and Research.", "label": "German Federal Ministry of Education and Research", "terseLabel": "German Federal Ministry of Education and Research" } } }, "localname": "GermanFederalMinistryOfEducationAndResearchMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_GlaxosmithklineCovidAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.", "label": "GlaxoSmithKline COVID Agreement" } } }, "localname": "GlaxosmithklineCovidAgreementMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cvac_GlaxosmithklineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for GlaxoSmithKline.", "label": "GSK [Member]", "terseLabel": "GSK" } } }, "localname": "GlaxosmithklineMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_GovernmentGrantsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to government grants.", "label": "Government Grants [Axis]" } } }, "localname": "GovernmentGrantsAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "stringItemType" }, "cvac_GovernmentGrantsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to government grants.", "label": "Government Grants [Domain]" } } }, "localname": "GovernmentGrantsDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_GrossBookValueOfCmoEquipmentHeldForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of gross book value of CMO-Equipment held for sale.", "label": "Gross book value of CMO-Equipment held for sale" } } }, "localname": "GrossBookValueOfCmoEquipmentHeldForSale", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "cvac_GrossCarryingAmountOfAcquisitionCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.", "label": "Gross Carrying Amount of Acquisition Cost [Member]", "terseLabel": "Acquisition costs" } } }, "localname": "GrossCarryingAmountOfAcquisitionCostMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cvac_Gsk2ndGenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for GSK 2nd Gen.", "label": "GSK 2nd Gen", "terseLabel": "GSK 2nd Gen" } } }, "localname": "Gsk2ndGenMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_GskAgreement2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for GSK Agreement 2020.", "label": "2020 GSK AGREEMENT" } } }, "localname": "GskAgreement2020Member", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "IfrsCashAndCashEquivalentsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "IFRS Contractual Obligation", "terseLabel": "Contractual obligation amount" } } }, "localname": "IfrsContractualObligation", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsCostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of sales", "terseLabel": "Cost of sales" } } }, "localname": "IfrsCostOfSalesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsCurrentGrantReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of current grant receivables.", "label": "IFRS Current Grant Receivables", "terseLabel": "Grant receivable" } } }, "localname": "IfrsCurrentGrantReceivables", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsDecreaseThroughGovernmentalContractLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The decrease in contract liabilities resulting from governmental contract liabilities.", "label": "IFRS Decrease Through Governmental Contract Liabilities", "terseLabel": "Decrease in outstanding balance due to release of government contractual liabilities" } } }, "localname": "IfrsDecreaseThroughGovernmentalContractLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of development milestone payment included in contract liabilities", "label": "IFRS Development Milestone Payment Included In Contract Liabilities", "terseLabel": "Development milestone payment included in contract liabilities" } } }, "localname": "IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsGeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative expenses", "terseLabel": "General and administrative expenses" } } }, "localname": "IfrsGeneralAndAdministrativeExpenseMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsIncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Ifrs Income Statement Location [Axis]" } } }, "localname": "IfrsIncomeStatementLocationAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "stringItemType" }, "cvac_IfrsIncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Ifrs Income Statement Location [Domain]" } } }, "localname": "IfrsIncomeStatementLocationDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Ifrs Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Decrease / (increase) in prepaid expenses and other assets" } } }, "localname": "IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase in expense related to in-effective set-up activities and settlement costs", "label": "IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs", "terseLabel": "Recognition of expenses related to ineffective set-up activities and settlement costs" } } }, "localname": "IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsInventoryFinishedGoodsWriteDown": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognised related to the write-down of inventories, finished goods.", "label": "IFRS Inventory, Finished Goods, Write down", "terseLabel": "Finished goods written down" } } }, "localname": "IfrsInventoryFinishedGoodsWriteDown", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsMilestonePaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment received.", "label": "IFRS Milestone Payment Received", "terseLabel": "Milestone payment received" } } }, "localname": "IfrsMilestonePaymentReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares received from the participants.", "label": "IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity", "terseLabel": "Number of shares received" } } }, "localname": "IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "cvac_IfrsOptionFeePaymentIncludedInContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of Option fee payment included in contract liabilities", "label": "IFRS Option Fee Payment Included In Contract Liabilities", "terseLabel": "Option fee payment included in contract liabilities" } } }, "localname": "IfrsOptionFeePaymentIncludedInContractLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other liabilities and provisions." } } }, "localname": "IfrsOtherLiabilitiesAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_IfrsOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option", "terseLabel": "Over-Allotment Option" } } }, "localname": "IfrsOverAllotmentOptionMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product" } } }, "localname": "IfrsProductMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsProvisionForLossOnContracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of provision for loss on contracts.", "label": "Ifrs Provision For Loss on Contracts", "terseLabel": "Estimated contract termination provisions" } } }, "localname": "IfrsProvisionForLossOnContracts", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsRemainingGrantIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of remaining grant income classified as other operating income.", "label": "IFRS Remaining Grant Income", "terseLabel": "Remaining grant income" } } }, "localname": "IfrsRemainingGrantIncome", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development expenses", "terseLabel": "Research and development expenses" } } }, "localname": "IfrsResearchAndDevelopmentExpenseMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Restricted stock unit.", "label": "RSU Supervisory Board", "terseLabel": "RSU Supervisory Board" } } }, "localname": "IfrsRestrictedStockUnitMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsSaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "localname": "IfrsSaleOfStockAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "cvac_IfrsSaleOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]", "terseLabel": "IFRS Sale of Stock" } } }, "localname": "IfrsSaleOfStockDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsShareBasedPaymentArrangementTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "First tranche", "terseLabel": "First tranche" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_IfrsSharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Ifrs Shares Issued, Price Per Share", "terseLabel": "Price per shares issued in follow-on public offering" } } }, "localname": "IfrsSharesIssuedPricePerShare", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "perShareItemType" }, "cvac_IfrsStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Ifrs Stock Issued During Period, Shares, New Issues", "verboseLabel": "Shares issued as part of the at-the-market offering program" } } }, "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_IfrsStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from at the market shares issued during the period.", "label": "Ifrs Stock Issued During Period Value New Issues", "negatedLabel": "Proceeds from at-the-market offering program (net of transaction costs)" } } }, "localname": "IfrsStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Share split ratio" } } }, "localname": "IfrsStockholdersEquityNoteStockSplitConversionRatio", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "pureItemType" }, "cvac_IfrsVestingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "localname": "IfrsVestingAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "cvac_IfrsVestingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "localname": "IfrsVestingDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ImpairmentOfAssetsHeldForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss on assets held for sale.", "label": "Impairment of Assets Held for Sale", "terseLabel": "Impairment of assets held for sale" } } }, "localname": "ImpairmentOfAssetsHeldForSale", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ImpairmentsOfInventoryAndPrepayments": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairments of inventory and prepayments", "label": "Impairments of inventory and prepayments", "terseLabel": "Impairment of inventory and prepayments" } } }, "localname": "ImpairmentsOfInventoryAndPrepayments", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_IncomeTaxAndSocialSecurityLiabilityReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax and social security liability receivable.", "label": "Income Tax and Social Security Liability Receivable", "terseLabel": "Income tax and social security liability receivable" } } }, "localname": "IncomeTaxAndSocialSecurityLiabilityReceivable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Income tax [line Items]", "terseLabel": "Income tax" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "stringItemType" }, "cvac_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of Income tax", "label": "Income tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "stringItemType" }, "cvac_IncreaseDecreaseInInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in inventory during the period.", "label": "Increase (Decrease) In Inventory", "terseLabel": "Increase in inventory" } } }, "localname": "IncreaseDecreaseInInventory", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_IncreaseInNumberOfSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase in the number of shares outstanding.", "label": "Increase In Number Of Shares Outstanding", "terseLabel": "Capital Investment" } } }, "localname": "IncreaseInNumberOfSharesOutstanding", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in PPE off set by impairment in equipment.", "label": "Increase In Property and Equipment Off Set By Impairment of Equipment", "terseLabel": "Partial offset of increase in property, plant and equipment" } } }, "localname": "IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "cvac_InitialPublicOfferingAndPrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for initial public offering and private placement.", "label": "Initial Public Offering and Private Placement", "terseLabel": "Initial Public Offering and Private Placement" } } }, "localname": "InitialPublicOfferingAndPrivatePlacementMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_InventoriesLineItem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Inventories [Line item", "terseLabel": "Inventories", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "InventoriesLineItem", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails", "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "stringItemType" }, "cvac_InventoriesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Inventories [Table]" } } }, "localname": "InventoriesTable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails", "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "stringItemType" }, "cvac_KeyEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for key employees.", "label": "Key employees", "terseLabel": "Key employees" } } }, "localname": "KeyEmployeesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_LaboratoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for laboratories.", "label": "Laboratories [Member]", "terseLabel": "Laboratories" } } }, "localname": "LaboratoriesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_LicenseFeePayable": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of license fee payables.", "label": "License Fee Payable", "terseLabel": "License fees payable" } } }, "localname": "LicenseFeePayable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_LicensesSoftwareAndPrepaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "licenses, software and prepayments", "label": "licenses, software and prepayments [Member]" } } }, "localname": "LicensesSoftwareAndPrepaymentsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvac_LockUpPeriodAfterInitialListing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lock-up period, which is days after the initial listing.", "label": "lock Up Period, After Initial Listing", "terseLabel": "Lock-up period" } } }, "localname": "LockUpPeriodAfterInitialListing", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "cvac_LongTermIncentivePlanAndRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-Term Incentive Plan and Restricted stock units.", "label": "LTIP RSU" } } }, "localname": "LongTermIncentivePlanAndRestrictedStockUnitMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "domainItemType" }, "cvac_LongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-Term Incentive Plan.", "label": "LTIP", "terseLabel": "LTIP Stock Options" } } }, "localname": "LongTermIncentivePlanMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "domainItemType" }, "cvac_MaintenanceAndLeaseExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 4.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maintenance and lease expenses incurred by the company during the period.", "label": "Maintenance And Lease Expenses", "negatedLabel": "Maintenance and lease" } } }, "localname": "MaintenanceAndLeaseExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ManagementBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Member stands for management board of the entity's key management personnel.", "label": "Management Board", "terseLabel": "Management Board" } } }, "localname": "ManagementBoardMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_MariolaFotinMleczekMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Mariola Fotin-Mleczek.", "label": "Mariola Fotin-Mleczek [Member]", "terseLabel": "Mariola Fotin-Mleczek" } } }, "localname": "MariolaFotinMleczekMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_MaximumGrantToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of maximum grant receivable.", "label": "Maximum Grant To Be Received", "terseLabel": "Maximum grant" } } }, "localname": "MaximumGrantToBeReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_MaximumUnspentFundsReimbursable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of maximum unspent funds reimbursable.", "label": "Maximum Unspent Funds Reimbursable", "terseLabel": "Maximum unspent funds reimbursable" } } }, "localname": "MaximumUnspentFundsReimbursable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_Maximumtaxprofitthatcanbeoffsetagainsttaxlosscarryforwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of tax profits that can be offset against tax losses carryforwards", "label": "MaximumTaxProfitThatCanBeOffsetAgainstTaxLossCarryforwards", "terseLabel": "Maximum amount of tax profits that can be offset against tax loss carryforwards" } } }, "localname": "Maximumtaxprofitthatcanbeoffsetagainsttaxlosscarryforwards", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for person or persons designated as part of Executive board and various key employees.", "label": "Members of executive board and various key employees", "terseLabel": "Members of executive board and various key employees" } } }, "localname": "MembersOfExecutiveBoardAndVariousKeyEmployeesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_MilestoneRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for milestone revenues.", "label": "Milestone revenues" } } }, "localname": "MilestoneRevenuesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cvac_MiscellaneousOtherOperatingIncomeOther": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 6.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of miscellaneous other operating income, classified as other.", "label": "Miscellaneous Other Operating Income, Other", "terseLabel": "Other" } } }, "localname": "MiscellaneousOtherOperatingIncomeOther", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvac_MonetaryAssetsInForeignCurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Monetary Assets In Foreign Currency" } } }, "localname": "MonetaryAssetsInForeignCurrencyMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_MonetaryLiabilitiesInForeignCurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "\"This member stands for a type\n of market risk representing the\n risk that the fair value or future\n cash flows of a financial\n instrument will fluctuate\n because of changes in foreign\n exchange rates.\"", "label": "Monetary Liabilities In Foreign Currency" } } }, "localname": "MonetaryLiabilitiesInForeignCurrencyMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.", "label": "Net Loss", "terseLabel": "Net loss" } } }, "localname": "NetLoss", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvac_NetValueOfInventoryTransferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net value of inventory transferred during the period.", "label": "Net Value Of Inventory Transferred", "terseLabel": "Net inventory transferred" } } }, "localname": "NetValueOfInventoryTransferred", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_NewVirtualStockOptionsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Virtual stock option plan II.", "label": "New VSOP.", "verboseLabel": "New VSOP" } } }, "localname": "NewVirtualStockOptionsPlanMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "domainItemType" }, "cvac_NumberOfAdditionalGrantsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional grants received by the company.", "label": "Number Of Additional Grants Received", "terseLabel": "Number of additional grants received" } } }, "localname": "NumberOfAdditionalGrantsReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "integerItemType" }, "cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.", "label": "Number Of Collaboration Partners That Owed Hundred Percent Of All Receivables And Contract Assets Outstanding", "terseLabel": "Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding" } } }, "localname": "NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.", "label": "Number Of Collaboration Partners With Balances Greater Than Ten Percent Of All Receivables And Contract Assets", "terseLabel": "Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets" } } }, "localname": "NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.", "label": "Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement", "terseLabel": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement" } } }, "localname": "NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "integerItemType" }, "cvac_NumberOfKeyEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of key employees.", "label": "Number of Key Employees", "terseLabel": "Number of key employees" } } }, "localname": "NumberOfKeyEmployees", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "integerItemType" }, "cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments settled in a share-based payment arrangement.", "label": "Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement", "terseLabel": "Number of RSUs settled" } } }, "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options vested in a share-based payment arrangement.", "label": "Number Of Share Options Vested In Share-Based Payment Arrangement", "verboseLabel": "Number of options vested" } } }, "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "cvac_NumberOfSharesIssuedForRsuDeliveries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued for RSU deliveries.", "label": "Number of Shares Issued for RSU Deliveries", "terseLabel": "Number of shares issued for RSU deliveries" } } }, "localname": "NumberOfSharesIssuedForRsuDeliveries", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued for RSU deliveries.", "label": "Number of Shares Issued on Exercise of Options and RSU Deliveries", "terseLabel": "Shares issued for LTIP option exercises and RSU deliveries" } } }, "localname": "NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_OptionFeePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of Option fee Payment received.", "label": "Option Fee payment", "terseLabel": "Option fee payment received" } } }, "localname": "OptionFeePayment", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_OptionsGrantedToThenChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).", "label": "Former Chief Executive Officer Grant", "terseLabel": "Former Chief Executive Officer Grant" } } }, "localname": "OptionsGrantedToThenChiefExecutiveOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "domainItemType" }, "cvac_OtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Other customers.", "label": "Others", "terseLabel": "Others" } } }, "localname": "OtherCustomersMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "cvac_OtherExpense": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 9.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of other expense.", "label": "Other Expense", "negatedLabel": "Other" } } }, "localname": "OtherExpense", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_OtherLiabilitiesAndProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other liabilities and provisions" } } }, "localname": "OtherLiabilitiesAndProvisionsAbstract", "nsuri": "http://www.curevac.com/20230331", "xbrltype": "stringItemType" }, "cvac_OtherLiabilitiesAndProvisionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of other liabilities and provisions.", "label": "Other Liabilities and Provisions [Text Block]", "terseLabel": "Other liabilities and provisions" } } }, "localname": "OtherLiabilitiesAndProvisionsTextBlock", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" ], "xbrltype": "textBlockItemType" }, "cvac_OtherLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 6.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other current liabilities.", "label": "Other Liability, Current", "terseLabel": "Other" } } }, "localname": "OtherLiabilityCurrent", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_OtherMiscellaneousNonCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherNoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of other miscellaneous non-current liabilities.", "label": "Other Miscellaneous Non-current Liabilities", "terseLabel": "Other (e.g. license liabilities, Deferred Tax Liability)" } } }, "localname": "OtherMiscellaneousNonCurrentLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_OtherOperatingIncomeGovernmentGrants": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 5.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of other operating income recognized in relation to government agencies and similar bodies.", "label": "Other Operating Income, Government Grants", "terseLabel": "Other operating income related the grants from government agencies and similar bodies", "verboseLabel": "Grants and other reimbursements from government agencies and similar bodies" } } }, "localname": "OtherOperatingIncomeGovernmentGrants", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_OutstandingInvoicesCurrent": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 3.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current outstanding invoices.", "label": "Outstanding Invoices, Current", "terseLabel": "Outstanding invoices" } } }, "localname": "OutstandingInvoicesCurrent", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PartnershipAgreementMaximumAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount agreed under the partnership agreement.", "label": "Partnership Agreement, Maximum Amount", "terseLabel": "Maximum amount under the partnership agreement" } } }, "localname": "PartnershipAgreementMaximumAmount", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PartnershipAgreementPeriodOfCostsToBeCovered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for which the costs are to be covered by the funds received under the partnership agreement.", "label": "Partnership Agreement, Period Of Costs To Be Covered", "terseLabel": "Period for which the costs are to be covered" } } }, "localname": "PartnershipAgreementPeriodOfCostsToBeCovered", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "durationItemType" }, "cvac_PartnershipAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of the partnership agreement.", "label": "Partnership Agreement, Term", "terseLabel": "Term of the partnership agreement" } } }, "localname": "PartnershipAgreementTerm", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "durationItemType" }, "cvac_PatentsAndFeesToRegisterLegalRight": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 7.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred by the company for registering a legal right.", "label": "Patents And Fees To Register Legal Right", "negatedLabel": "Patents and fees to register a legal right" } } }, "localname": "PatentsAndFeesToRegisterLegalRight", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PaymentOnProceedsFromTreasurySharesAndExerciseOfOptions": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow or outflow from the exercise of options and treasury shares.", "label": "Payment on Proceeds From Treasury Shares and Exercise Of Options" } } }, "localname": "PaymentOnProceedsFromTreasurySharesAndExerciseOfOptions", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_Percenatgeofeffectsondeferredtaxassetstransferredtoequity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PercenatgeOfEffectsOnDeferredTaxAssetsTransferredToEquity", "label": "PercenatgeOfEffectsOnDeferredTaxAssetsTransferredToEquity", "terseLabel": "Percenatge of effects on deferred tax assets credited to equity" } } }, "localname": "Percenatgeofeffectsondeferredtaxassetstransferredtoequity", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "cvac_Percenatgeofeffectsondeferredtaxassetstransferredtoprofitorloss": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percenatge Of Effects On Deferred Tax Assets Transferred To Profit or Loss.", "label": "PercenatgeOfEffectsOnDeferredTaxAssetsTransferredToProfitOrLoss", "terseLabel": "Percenatge of effects on deferred tax assets credited to profit or loss" } } }, "localname": "Percenatgeofeffectsondeferredtaxassetstransferredtoprofitorloss", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "cvac_PercentageOfTaxProfitsSubjectToTaxableInExcessOfFiftyLakhs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of tax profits subject to taxable in excess of $5000k", "label": "Percentage Of Tax Profits Subject To Taxable In Excess Of Fifty Lakhs", "terseLabel": "Percentage of tax profits subject to taxable in excess of $5000k" } } }, "localname": "PercentageOfTaxProfitsSubjectToTaxableInExcessOfFiftyLakhs", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "cvac_Percentageoftaxprofitscanbeoffsetagainstremaininglosscarryforwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of tax profits that can be set off against remaining loss carryforwards", "label": "PercentageOfTaxProfitsCanBeOffsetAgainstRemainingLossCarryforwards", "terseLabel": "Taxable profit" } } }, "localname": "Percentageoftaxprofitscanbeoffsetagainstremaininglosscarryforwards", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "cvac_PersonnelAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of personnel accrued liabilities.", "label": "Personnel Accrued Liabilities", "terseLabel": "Personnel accrued liabilities (e.g. bonus, vacation)" } } }, "localname": "PersonnelAccruedLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PersonnelExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 1.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of personnel expenses incurred by the company during the period.", "label": "Personnel Expenses", "negatedLabel": "Personnel" } } }, "localname": "PersonnelExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PlanNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "stringItemType" }, "cvac_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of prepaid compensation for contract manufacturing organizations transfer.", "label": "Prepaid Compensation for Contract Manufacturing organizations Transfer", "terseLabel": "Prepayments for compensation" } } }, "localname": "PrepaidCompensationForContractManufacturingOrganizationsTransfer", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PriorVirtualStockOptionsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Virtual stock option plan I.", "label": "Prior VSOP", "terseLabel": "Prior VSOP" } } }, "localname": "PriorVirtualStockOptionsPlanMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" ], "xbrltype": "domainItemType" }, "cvac_PrivatePlacementIsa2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for private Placement \"ISA 2020\".", "label": "2020 Private Investment", "terseLabel": "2020 Private Investment" } } }, "localname": "PrivatePlacementIsa2020Member", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_ProceedFromIssuingOtherEquityInstrument": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Proceed From Issuing Other Equity Instrument", "label": "Proceed From Issuing Other Equity Instrument", "terseLabel": "Payment on / Proceeds from Treasury Shares" } } }, "localname": "ProceedFromIssuingOtherEquityInstrument", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of proceed from issuing other equity instrument or exercise of options.", "label": "Proceed From Issuing Other Equity Instrument Or Exercise of Options", "terseLabel": "Payment on / proceeds from treasury shares/exercise of options" } } }, "localname": "ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProceedsFromPaymentsForSaleOfOtherFinancialAssetsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash flow from sale / purchase of other financial assets classified as investing activities.", "label": "Proceeds from (Payments For) Sale of Other Financial Assets, Investing Activities", "terseLabel": "Proceeds from sale of other financial assets" } } }, "localname": "ProceedsFromPaymentsForSaleOfOtherFinancialAssetsInvestingActivities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]", "label": "Proceeds from (Repayments of) borrowings, classified as financing activities", "terseLabel": "Proceeds from (repayment of) the EIB loan" } } }, "localname": "ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProceedsOnExerciseOfOptions": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds on exercise of options.", "label": "Proceeds On Exercise Of Options", "negatedLabel": "Proceeds on exercise of options" } } }, "localname": "ProceedsOnExerciseOfOptions", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProceedsOrPaymentsFromExerciseOfOptions": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash inflow or outflow from the exercise of options.", "label": "Proceeds Or Payments From Exercise Of Options", "negatedLabel": "Payments from the exercise of options" } } }, "localname": "ProceedsOrPaymentsFromExerciseOfOptions", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ProfessionalFessCurrent": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 4.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current professional fees.", "label": "Professional Fess, Current", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFessCurrent", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ProvisionForEmployerTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for employer taxes arising according to US regulations for future exercises.", "label": "Provision for Employer Taxes", "verboseLabel": "Provision for employer taxes" } } }, "localname": "ProvisionForEmployerTaxes", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvac_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to follow on public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_RealEstateTransferTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of real estate transfer taxes.", "label": "Real Estate Transfer Taxes", "terseLabel": "Real estate transfer taxes" } } }, "localname": "RealEstateTransferTaxes", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from government grants and similar bodies.", "label": "Receipts from Government Grants Classified as Operating Activities", "terseLabel": "Receipts from grants from government agencies and similar bodies", "verboseLabel": "Grant amount received/eligible to receive" } } }, "localname": "ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cvac_ReimbursementOfApprovedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reimbursement of approved expenses", "label": "Reimbursement of Approved Expenses", "terseLabel": "Reimbursement of approved expenses" } } }, "localname": "ReimbursementOfApprovedExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_RelatedPartyTransactionConsultingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consulting fees incurred as a part of related party transaction.", "label": "Related Party Transaction, Consulting Fees", "terseLabel": "Consulting fees" } } }, "localname": "RelatedPartyTransactionConsultingFees", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of notice for termination of the agreement at the option of the party.", "label": "Related Party Transaction, Notice Period for Termination of Agreement", "terseLabel": "Notice period for termination at the option" } } }, "localname": "RelatedPartyTransactionNoticePeriodForTerminationOfAgreement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "durationItemType" }, "cvac_RelatedPartyTransactionNumberOfLoansReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of loans received from a related party.", "label": "Related Party Transaction, Number of Loans Received", "terseLabel": "Number of convertible loans" } } }, "localname": "RelatedPartyTransactionNumberOfLoansReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "integerItemType" }, "cvac_RemainingAuthorizedForSaleValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of remaining authorized for sale value.", "label": "Remaining Authorized For Sale Value", "terseLabel": "Remaining authorized for sale value" } } }, "localname": "RemainingAuthorizedForSaleValue", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development services combined with an IP license.", "label": "Research and development Services Combined With Ip License [Member]" } } }, "localname": "ResearchAndDevelopmentServicesCombinedWithIpLicenseMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "cvac_ResearchAndDevelopmentServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development services.", "label": "Research and development services" } } }, "localname": "ResearchAndDevelopmentServicesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "cvac_ResearchServicesCombinedWithIpLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research services combined with an IP license.", "label": "Research services combined with an IP license", "terseLabel": "Research services combined with an IP license" } } }, "localname": "ResearchServicesCombinedWithIpLicenseMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "cvac_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Restricted stock Units", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "domainItemType" }, "cvac_ReversalOfProvisionForOnerousContracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.", "label": "Reversal of Provision for Onerous Contracts", "terseLabel": "Reversal of provision of onerous contracts" } } }, "localname": "ReversalOfProvisionForOnerousContracts", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.", "label": "Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over", "terseLabel": "Reversal of provision recognized" } } }, "localname": "ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ReversalOfProvisionsForPersonnelExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 4.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of personnel expenses reversed during the period.", "label": "Reversal Of Provisions For Personnel Expenses", "verboseLabel": "Income from reversal of provisions" } } }, "localname": "ReversalOfProvisionsForPersonnelExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvac_RightToExercisePercentageOfVestedVirtualShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the right to exercise percentage of vested virtual shares.", "label": "Right To Exercise Percentage Of Vested Virtual Shares", "terseLabel": "Right to exercise percentage of vested virtual shares" } } }, "localname": "RightToExercisePercentageOfVestedVirtualShares", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "cvac_RittershausRechtsanwaelteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Member stands for Rittershaus Rechtsanwaelte , a related party.", "label": "Rittershaus Rechtsanwaelte [Member]", "terseLabel": "Rittershaus Rechtsanwaelte" } } }, "localname": "RittershausRechtsanwaelteMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_SaleOfEquipment": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": 1.0, "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of sale of equipment in operating income.", "label": "Sale of equipment", "terseLabel": "Sale of equipment" } } }, "localname": "SaleOfEquipment", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of expense recognized for the programs.", "label": "Schedule of Expense Recognized for the Programs [Table Text Block]", "terseLabel": "Schedule for expense recognized for the equity-settled programs" } } }, "localname": "ScheduleOfExpenseRecognizedForProgramsTableTextBlock", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "cvac_SellingAndDistributionExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for selling and distribution expenses.", "label": "Selling and distribution expenses", "terseLabel": "Selling and distribution expenses" } } }, "localname": "SellingAndDistributionExpensesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "domainItemType" }, "cvac_SeriesCSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Series C shares.", "label": "Series C", "terseLabel": "Series C" } } }, "localname": "SeriesCSharesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_SeriesSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Series A shares.", "label": "Series A", "terseLabel": "Series A" } } }, "localname": "SeriesSharesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "cvac_SettlementOfShareBasedPaymentAwardsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of share based payment awards settled in cash.", "label": "Settlement Of Share Based Payment Awards , Amount", "terseLabel": "Settlement of share-based payment awards" } } }, "localname": "SettlementOfShareBasedPaymentAwardsAmount", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Share-based payment expense (incl. deferred taxes)", "label": "Share-based payment expense (incl. deferred taxes)", "terseLabel": "Share-based payments (net of taxes)" } } }, "localname": "ShareBasedPaymentExpenseIncl.DeferredTaxes", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvac_ShareOptionExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share option exercises.", "label": "Share Option Exercises", "terseLabel": "Share option exercises" } } }, "localname": "ShareOptionExercises", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_SoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The member stands for software.", "label": "Software [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvac_StockIssuanceDuringPeriodForExistingShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period for existing shareholders.", "label": "Stock Issuance During Period For Existing Shareholders", "terseLabel": "Shares issued to former shareholders of Frame Pharmaceuticals" } } }, "localname": "StockIssuanceDuringPeriodForExistingShareholders", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_StockIssuedDuringPeriodForExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period, upon exercises.", "label": "Stock Issued During Period, For Exercises", "terseLabel": "Share issuances for exercises" } } }, "localname": "StockIssuedDuringPeriodForExercises", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "sharesItemType" }, "cvac_SupervisoryBoardMembersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for supervisory board members.", "label": "Supervisory board members", "terseLabel": "Supervisory board members" } } }, "localname": "SupervisoryBoardMembersMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for technical equipment and machines and other equipment.", "label": "Technical equipment and machines [Member]", "terseLabel": "Technical equipment and machines" } } }, "localname": "TechnicalEquipmentAndMachinesAndOtherEquipmentMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cvac_TechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity.", "label": "Technology [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvac_Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries]", "label": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVenture", "terseLabel": "Indefinetly reinvested and associated with invested in subsadiries, deferred tax liabilities have not been recognized" } } }, "localname": "Temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventure", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for termination of exclusive collobaration and license agreement.", "label": "Termination of Exclusive Collaboration And License Agreement" } } }, "localname": "TerminationOfExclusiveCollaborationAndLicenseAgreementMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cvac_ThenChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Dan Menichella, then Chief Executive Officer.", "label": "Dan Menichella, then Chief Executive Officer", "terseLabel": "Dan Menichella, then Chief Executive Officer" } } }, "localname": "ThenChiefExecutiveOfficerMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_ThirdPartyServiceExpenses": { "auth_ref": [], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 3.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred by the company for third party services during the period.", "label": "Third Party Service Expenses", "negatedLabel": "Third-party services" } } }, "localname": "ThirdPartyServiceExpenses", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_TradeAndOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for trade and other payables.", "label": "Trade and other payables and provision" } } }, "localname": "TradeAndOtherPayablesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_TradeAndOtherPayablesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Trade And Other Payables One" } } }, "localname": "TradeAndOtherPayablesOneMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_TradeAndOtherPayablesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Trade And Other Payables Two" } } }, "localname": "TradeAndOtherPayablesTwoMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_TradeAndOtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Trade And Other Receivables" } } }, "localname": "TradeAndOtherReceivablesMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "cvac_TypeOfArrangementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "stringItemType" }, "cvac_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of upfront payment revenue recognized from termination of agreement.", "label": "Upfront Payment Revenue Recognized From Termination of Agreement", "terseLabel": "Upfront payment revenue recognized from termination of agreement" } } }, "localname": "UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvac_UpfrontPaymentsIncludedInContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of upfront payments of the company included in contract liabilities.", "label": "Upfront Payments Included In Contract Liabilities", "terseLabel": "Upfront and milestones payments included in contract liabilities" } } }, "localname": "UpfrontPaymentsIncludedInContractLiabilities", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "cvac_UpfrontPaymentsReceivedOrReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of upfront payments received or receivable by the company.", "label": "Upfront Payments Received Or Receivable", "terseLabel": "Upfront and milestone payments received or receivable" } } }, "localname": "UpfrontPaymentsReceivedOrReceivable", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "cvac_VincentStphenneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Vincent Stphenne.", "label": "Vincent Stphenne [Member]", "terseLabel": "Vincent Stphenne" } } }, "localname": "VincentStphenneMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cvac_VirtualSharesProgramIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Virtual shares program I.", "label": "Prior VSOP [Member]", "terseLabel": "Prior VSOP" } } }, "localname": "VirtualSharesProgramIMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "domainItemType" }, "cvac_VirtualSharesProgramIiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Virtual shares program II (New VSOP).", "label": "New VSOP", "terseLabel": "New VSOP" } } }, "localname": "VirtualSharesProgramIiMember", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "cvac_WriteOffOfRawMaterials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of raw materials written off during the period.", "label": "Write Off Of Raw Materials", "terseLabel": "Write off of raw materials" } } }, "localname": "WriteOffOfRawMaterials", "nsuri": "http://www.curevac.com/20230331", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.curevac.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive income", "terseLabel": "Other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r261" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventory" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other assets", "terseLabel": "Decrease / (increase) in other assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in trade receivables and contract assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDeferredTaxExpense": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for deferred tax expense", "terseLabel": "Decrease / (increase) in deferred taxes" } } }, "localname": "AdjustmentsForDeferredTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r262" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense", "terseLabel": "Depreciation and impairment of property, plant and equipment and right-of-use assets" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r263" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance costs", "terseLabel": "Finance expense" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income", "negatedLabel": "Finance income" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } }, "en-us": { "role": { "label": "Adjustments for gain (loss) on disposals, property, plant and equipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment of property, plant and equipment" } } }, "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r264" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "(Decrease) / increase in trade and other payables, other liabilities and contract liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": { "auth_ref": [ "r259" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for losses (gains) on disposal of non-current assets", "terseLabel": "Loss on disposal of fixed assets" } } }, "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForProvisions": { "auth_ref": [ "r262" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for provisions", "terseLabel": "Releases in provision for onerous contracts" } } }, "localname": "AdjustmentsForProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments to reconcile loss before tax to net cash flows" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r262" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based payment expense" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r23", "r127", "r133", "r134", "r150", "r173", "r174", "r176", "r182", "r197", "r218", "r219" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r79" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Amortization" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r21", "r114", "r115", "r118", "r164", "r167" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetsAbstract", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r69", "r70" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Net loss per share basic" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureEarningsPerShareDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r120", "r141", "r176", "r207", "r208", "r267" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BuildingsMember": { "auth_ref": [ "r251" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Buildings [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalReserve": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the capital reserves." } }, "en-us": { "role": { "label": "Capital reserve.", "terseLabel": "Capital reserve" } } }, "localname": "CapitalReserve", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalReserveMember": { "auth_ref": [ "r241" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } }, "en-us": { "role": { "label": "Capital reserve" } } }, "localname": "CapitalReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r15", "r92", "r108" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents.", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r86", "r93" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash flow provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r86", "r93" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash flow (used in) investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r86", "r93" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash flow (used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities", "negatedLabel": "Acquisition of subsidiary, net of cash acquired" } } }, "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInOtherProvisions": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Increase (decrease) in other provisions", "terseLabel": "Decrease in provisions" } } }, "localname": "ChangesInOtherProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r72", "r74", "r119", "r132" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r72", "r119", "r132" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r153", "r155", "r156", "r157" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r153", "r155", "r156", "r157" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "auth_ref": [ "r257" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "ClassesOfInventoriesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Commitments made by entity, related party transactions", "terseLabel": "Settlement amount" } } }, "localname": "CommitmentsMadeByEntityRelatedPartyTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r3", "r34", "r98", "r100", "r106", "r206" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Total comprehensive income (loss)", "totalLabel": "Total comprehensive loss for the period" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r251" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Construction in progress [Member]", "terseLabel": "Assets under construction" } } }, "localname": "ConstructionInProgressMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r121", "r124" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract liabilities", "verboseLabel": "Contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r1", "r39" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales.", "negatedLabel": "Cost of sales" } } }, "localname": "CostOfSales", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r160", "r177", "r178", "r179", "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign currency risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAdvancesToSuppliers": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } }, "en-us": { "role": { "label": "Current advances to suppliers", "terseLabel": "Prepayments for future service agreements and goods" } } }, "localname": "CurrentAdvancesToSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r24", "r102", "r206" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CurrentAssetsAbstract", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractAssets": { "auth_ref": [ "r121" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current contract assets. [Refer: Contract assets]" } }, "en-us": { "role": { "label": "Current contract assets", "terseLabel": "Contract assets", "verboseLabel": "Contract assets" } } }, "localname": "CurrentContractAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "CurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentGovernmentGrants": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Current government grants", "terseLabel": "Grants from government agencies and similar bodies" } } }, "localname": "CurrentGovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r130" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r25", "r104", "r206" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepaid expenses and other assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r18" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 7.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "terseLabel": "Provisions" } } }, "localname": "CurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } }, "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "terseLabel": "Outstanding VAT refund claims" } } }, "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } }, "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Income tax expenses" } } }, "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxLiabilities": { "auth_ref": [ "r20" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Current tax liabilities", "verboseLabel": "Income taxes payable" } } }, "localname": "CurrentTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r187", "r189" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "CurrentTradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]" } }, "en-us": { "role": { "label": "Decrease through classified as held for sale, property, plant and equipment", "negatedLabel": "Assets held for sale" } } }, "localname": "DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": { "auth_ref": [ "r215", "r216", "r220" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Decrease through derecognition, financial assets", "terseLabel": "Loss on derecognition of fixed assets" } } }, "localname": "DecreaseThroughDerecognitionFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences", "terseLabel": "Deferred tax (income) expenses on taxable temporary differences" } } }, "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r2", "r39", "r110", "r162", "r169", "r184" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 5.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "negatedLabel": "Amortization and depreciation", "negatedTerseLabel": "Amortization and depreciation" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r55" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Depreciation" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r268", "r269" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r69", "r70" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Net loss per share diluted" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued Capital and Reserves" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "verboseLabel": "Schedule of total shares" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Issued Capital and Reserves" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "terseLabel": "Schedule of revenue from contract with customers recognized" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Notes to the consolidated financial statements" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Subsequent events" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial assets and financial liabilities" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial assets and financial liabilities" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Disclosure of financial instruments and management of financial risks" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisks" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income tax" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of inputs used in the measurement of the fair value at grant date" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Fixed Assets" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for inventories." } }, "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DisclosureOfInventoriesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "verboseLabel": "Disclosure of financial instruments and management of financial risks" } } }, "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "auth_ref": [ "r151", "r152" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } }, "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } } }, "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent events" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": { "auth_ref": [ "r148" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations." } }, "en-us": { "role": { "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]", "terseLabel": "Assets held for sale" } } }, "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSale" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } }, "en-us": { "role": { "label": "Disclosure of notes and other explanatory information [text block]", "terseLabel": "Notes to the consolidated financial statements" } } }, "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of reconciliation of outstanding awards" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Disclosure of other operating expense [text block]", "terseLabel": "Schedule of other operating expenses" } } }, "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Disclosure of other operating income [text block]", "terseLabel": "Schedule of other operating income" } } }, "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "verboseLabel": "Fixed Assets" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related party disclosures" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "verboseLabel": "Issued Capital and Reserves" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based payments" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based payments" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Share-based payments" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r142" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Trade and other payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]", "terseLabel": "Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end" } } }, "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party disclosures" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Related party disclosures" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "negatedLabel": "Disposals" } } }, "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Earnings per share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r88", "r89" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Currency translation gains (losses) on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r65", "r67", "r113" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r21", "r27", "r97", "r99", "r114", "r115", "r118" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity.", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r21" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total equity and liabilities" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquityAndLiabilitiesAbstract", "terseLabel": "Equity and liabilities" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpenseByNature": { "auth_ref": [ "r39" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity." } }, "en-us": { "role": { "label": "Expenses, by nature", "negatedTotalLabel": "Total" } } }, "localname": "ExpenseByNature", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r145" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Expenses recognized" } } }, "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r145" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Expenses from share-based payments" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "terseLabel": "Share-based based payments expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]" } }, "en-us": { "role": { "label": "Explanation of significant changes in contract assets and contract liabilities [text block]", "terseLabel": "Schedule of contract balances" } } }, "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r35" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Finance expenses" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r248" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinishedGoods": { "auth_ref": [ "r190", "r253" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current finished goods", "terseLabel": "Finished goods" } } }, "localname": "FinishedGoods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r242" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r171", "r196", "r210", "r226" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r171", "r196", "r210", "r226" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GoodwillMember": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Goodwill [Member]", "terseLabel": "Goodwil" } } }, "localname": "GoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government grants", "terseLabel": "Grants received and deferred" } } }, "localname": "GovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r47", "r76", "r84", "r85", "r146", "r154", "r156", "r217", "r270", "r271" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Acquisition costs", "terseLabel": "Acquisition costs" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails", "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLoss": { "auth_ref": [ "r73", "r74" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 8.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Impairment loss", "negatedLabel": "Impairment of equipment" } } }, "localname": "ImpairmentLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r50" ], "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, property, plant and equipment", "verboseLabel": "Impairment" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InAccordanceWithIFRS9Member": { "auth_ref": [ "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for the information reported in accordance with IFRS 9." } }, "en-us": { "role": { "label": "Effects from the first-time adoption of IFRS 9" } } }, "localname": "InAccordanceWithIFRS9Member", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r36", "r42", "r43", "r44", "r63", "r111", "r163" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax benefit/ (expense)" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r265" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } }, "en-us": { "role": { "label": "Income taxes paid, classified as operating activities", "negatedLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers." } }, "en-us": { "role": { "label": "Effects from the first-time adoption of IFRS 15" } } }, "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r92" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Shares issued on exercise of option", "terseLabel": "Exercise of options" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Currency translation" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Currency translation" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment", "terseLabel": "Reclassifications" } } }, "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers, intangible assets other than goodwill", "terseLabel": "Reclassifications" } } }, "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers, property, plant and equipment", "terseLabel": "Attributions" } } }, "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } }, "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Repurchase of common shares" } } }, "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance expense", "terseLabel": "Insurance expense" } } }, "localname": "InsuranceExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "auth_ref": [ "r257" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill [member]" } } }, "localname": "IntangibleAssetsAndGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r11", "r81" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "verboseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r14", "r56", "r187" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } } }, "localname": "Inventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InventoriesAtFairValueLessCostsToSell": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of inventories carried at fair value less costs to sell. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Inventories, at fair value less costs to sell", "terseLabel": "Inventories fair value costs to sell" } } }, "localname": "InventoriesAtFairValueLessCostsToSell", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InventoryWritedown2011": { "auth_ref": [ "r38", "r58" ], "lang": { "en": { "role": { "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Inventory write-down", "verboseLabel": "Raw materials write-offs and scrap" } } }, "localname": "InventoryWritedown2011", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "auth_ref": [ "r13", "r112", "r165" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } }, "en-us": { "role": { "label": "Investments accounted for using equity method", "terseLabel": "Equity investment" } } }, "localname": "InvestmentAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "verboseLabel": "Issuance of share capital (net of transaction costs)" } } }, "localname": "IssueOfEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r191" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital.", "terseLabel": "Issued capital" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r133", "r134", "r182", "r218", "r221", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "2022", "terseLabel": "2022" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r21", "r114", "r115", "r118", "r164", "r168" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LicencesMember": { "auth_ref": [ "r258" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Licence [Member]", "terseLabel": "Licenses" } } }, "localname": "LicencesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income tax" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersAxis": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Major customers [axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MajorCustomersMember": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } }, "en-us": { "role": { "label": "Customers [member]" } } }, "localname": "MajorCustomersMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r193" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Share transaction", "terseLabel": "Share transaction" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r23", "r127", "r133", "r134", "r150", "r158", "r173", "r174", "r176", "r182", "r197", "r218" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "auth_ref": [ "r242" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 7.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Miscellaneous other operating expense", "negatedLabel": "Other operating expenses" } } }, "localname": "MiscellaneousOtherOperatingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "auth_ref": [ "r242" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 6.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Other operating income", "totalLabel": "Total" } } }, "localname": "MiscellaneousOtherOperatingIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetDeferredTaxAssets": { "auth_ref": [ "r250" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "NetDeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r24", "r103", "r206" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Total non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NoncurrentAssets", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": { "auth_ref": [ "r16" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 7.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]" } }, "en-us": { "role": { "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners", "terseLabel": "Assets held for sale", "verboseLabel": "Written down value of equipment" } } }, "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets held for sale" } } }, "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentContractLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "NoncurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r130" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r25", "r105", "r206" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NoncurrentLiabilitiesAbstract", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r18" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "terseLabel": "Provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r22", "r133", "r134", "r182", "r218", "r221" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Within one year", "terseLabel": "Within one year" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r213", "r214" ], "lang": { "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Number of awards granted" } } }, "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r144", "r266" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of RSU's awarded" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Options exercisable", "terseLabel": "Thereof exercisable" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "terseLabel": "Number of options exercised" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted", "verboseLabel": "Number of share options granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r28" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Number of shares authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "verboseLabel": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r69", "r247" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Common shares [Member]", "terseLabel": "Common shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r6", "r33", "r37", "r107" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r26", "r37" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation", "terseLabel": "Foreign currency adjustments" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentFinancialAssets": { "auth_ref": [ "r12" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } }, "en-us": { "role": { "label": "Other current financial assets", "terseLabel": "Other financial assets" } } }, "localname": "OtherCurrentFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentFinancialLiabilities": { "auth_ref": [ "r19", "r109" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]" } }, "en-us": { "role": { "label": "Other current financial liabilities" } } }, "localname": "OtherCurrentFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherLiabilities", "weight": 1.0 }, "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other liabilities", "totalLabel": "Other liabilities (current)" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Miscellaneous liabilities" } } }, "localname": "OtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherLiabilities": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other liabilities", "totalLabel": "Total other liabilities (current & non-current)" } } }, "localname": "OtherLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other assets.", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentLiabilities": { "auth_ref": [ "r244" ], "calculation": { "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherLiabilities", "weight": 1.0 }, "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } }, "en-us": { "role": { "label": "Other non-current liabilities.", "terseLabel": "Other liabilities", "totalLabel": "Other liabilities (non-current)" } } }, "localname": "OtherNoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "auth_ref": [ "r251" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Other property, plant and equipment [Member]", "terseLabel": "Other equipment, furniture and fixtures:" } } }, "localname": "OtherPropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "verboseLabel": "Notional value per share" } } }, "localname": "ParValuePerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "auth_ref": [ "r246" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } }, "en-us": { "role": { "label": "Payables on social security and taxes other than income tax", "terseLabel": "Payroll-related taxes and social-security liabilities" } } }, "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r205" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Payments on lease obligations" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": { "auth_ref": [ "r203" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to acquire or redeem entity's shares." } }, "en-us": { "role": { "label": "Payments to acquire or redeem entity's shares", "negatedLabel": "Payment on treasury shares" } } }, "localname": "PaymentsToAcquireOrRedeemEntitysShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PreferenceSharesMember": { "auth_ref": [ "r247" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Preferred shares", "terseLabel": "Preferred shares" } } }, "localname": "PreferenceSharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PreviouslyStatedMember": { "auth_ref": [ "r4", "r94", "r95", "r96" ], "lang": { "en": { "role": { "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)." } }, "en-us": { "role": { "label": "Previously stated" } } }, "localname": "PreviouslyStatedMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r260" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Proceeds from the exercise of options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Proceeds from government grants, classified as financing activities", "verboseLabel": "Government grants" } } }, "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities": { "auth_ref": [ "r254" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from government grants, classified as investing activities. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Proceeds from government grants, classified as investing activities", "terseLabel": "Proceeds from asset-related grants" } } }, "localname": "ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": { "auth_ref": [ "r260" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of bonds, notes and debentures." } }, "en-us": { "role": { "label": "Proceeds from issue of bonds, notes and debentures", "verboseLabel": "Proceeds from the convertible loan" } } }, "localname": "ProceedsFromIssueOfBondsNotesAndDebentures", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "auth_ref": [ "r202" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Proceeds from issuing other equity instruments", "negatedLabel": "Payment on treasury shares" } } }, "localname": "ProceedsFromIssuingOtherEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r202" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Cash received from issuance of shares", "verboseLabel": "Proceeds from the issuance of shares (net of transaction costs)" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r170", "r209" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r170", "r209" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r242" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 6.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "negatedLabel": "Legal and other professional services" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r32", "r87", "r98", "r100", "r164", "r166", "r206", "r224", "r227" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "totalLabel": "Net loss for the period", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r147", "r184", "r185", "r222", "r223" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Loss before income tax", "totalLabel": "Loss before income tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r199", "r248" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r10", "r53" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r54", "r200", "r212" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "auth_ref": [ "r64", "r66", "r101" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Equity interest held" } } }, "localname": "ProportionOfOwnershipInterestInAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } }, "en-us": { "role": { "label": "Purchase of other long-term assets, classified as investing activities", "negatedLabel": "Purchases of financial assets" } } }, "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedTerseLabel": "Purchase of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r120", "r141", "r176", "r207", "r208", "r267" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r120", "r141", "r176", "r207", "r208", "r267" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]", "terseLabel": "Ranges" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RawMaterials": { "auth_ref": [ "r190", "r253" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current raw materials", "verboseLabel": "Raw materials" } } }, "localname": "RawMaterials", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "auth_ref": [ "r39", "r184" ], "calculation": { "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": { "order": 2.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]" } }, "en-us": { "role": { "label": "Raw materials and consumables used", "negatedTerseLabel": "Materials", "terseLabel": "Materials" } } }, "localname": "RawMaterialsAndConsumablesUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } }, "en-us": { "role": { "label": "Receivables from taxes other than income tax", "terseLabel": "Tax claims" } } }, "localname": "ReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfBondsNotesAndDebentures": { "auth_ref": [ "r260" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for repayments of bonds, notes and debentures." } }, "en-us": { "role": { "label": "Repayments of bonds, notes and debentures", "negatedLabel": "Repayments of convertible loan" } } }, "localname": "RepaymentsOfBondsNotesAndDebentures", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r204" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "verboseLabel": "Amount paid" } } }, "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r60", "r186" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Currency translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RestatedMember": { "auth_ref": [ "r4", "r94", "r95", "r96", "r175", "r243" ], "lang": { "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } }, "en-us": { "role": { "label": "Currently stated [member]" } } }, "localname": "RestatedMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r191", "r192" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r9", "r186" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "auth_ref": [ "r4", "r94", "r95", "r96" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Retrospective application and retrospective restatement [axis]" } } }, "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r122", "r123" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Total revenues", "terseLabel": "Revenue", "totalLabel": "Total revenues", "verboseLabel": "Revenue recognized" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Income from government grants", "verboseLabel": "Income from release of governmental contract liabilities" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue that was included in contract liability balance at beginning of period", "terseLabel": "Revenue recognized from upfront payments", "verboseLabel": "Revenue recognized from contract liabilities" } } }, "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r131" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsMember": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right of use-assets", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Risk exposure associated with instruments sharing characteristic", "terseLabel": "Exposure in (foreign) currency" } } }, "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r248" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Selling and distribution expenses" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "terseLabel": "Offering costs for legal, accounting, printing and registration fees" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r142" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services." } }, "en-us": { "role": { "label": "Short-term employee benefits expense", "terseLabel": "Salary and salary-related expenses", "verboseLabel": "Salary and salary-related expenses" } } }, "localname": "ShorttermEmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r65", "r67", "r113" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Statement of changes in equity" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Condensed Consolidated Statements of Financial Position" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense": { "auth_ref": [ "r195" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]" } }, "en-us": { "role": { "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense", "verboseLabel": "Deferred tax benefits (expense) from net operating loss carryforwards" } } }, "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": { "auth_ref": [ "r45" ], "lang": { "en": { "role": { "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]" } }, "en-us": { "role": { "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised", "terseLabel": "Deferred tax assets" } } }, "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r17" ], "calculation": { "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade and other payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other payables." } } }, "localname": "TradeAndOtherCurrentPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r188", "r246" ], "calculation": { "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers into Level 3 of fair value hierarchy, assets", "terseLabel": "Transfers into Level 3, Assets" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers into Level 3 of fair value hierarchy, liabilities", "terseLabel": "Transfers into Level 3, Liabilities" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period", "terseLabel": "Transfer from Level 1 to Level 2, Assets" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period", "terseLabel": "Transfer from Level 1 to Level 2, Liabilities" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period", "terseLabel": "Transfer from Level 2 to Level 1, Assets" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period", "terseLabel": "Transfer from Level 2 to Level 1, Liabilities" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 3 of fair value hierarchy, assets", "terseLabel": "Transfers out of Level 3, Assets" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 3 of fair value hierarchy, liabilities", "terseLabel": "Transfers out of Level 3, Liabilities" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TravelExpense": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from travel." } }, "en-us": { "role": { "label": "Travel expense", "terseLabel": "Travel expenses" } } }, "localname": "TravelExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r68", "r191" ], "calculation": { "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares.", "negatedLabel": "Treasury Shares" } } }, "localname": "TreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury share", "terseLabel": "Treasury share" } } }, "localname": "TreasurySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfContractsAxis": { "auth_ref": [ "r211", "r225" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of contracts [axis]" } } }, "localname": "TypesOfContractsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfContractsMember": { "auth_ref": [ "r211", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of contracts [member]" } } }, "localname": "TypesOfContractsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r149", "r151", "r152", "r177", "r178", "r179", "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r149", "r151", "r152", "r177", "r178", "r179", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r142" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails", "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "stringItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Average share price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Price per share" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding", "terseLabel": "Weighted number of shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.curevac.com/role/DisclosureEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Operating Officer", "terseLabel": "Chief Operating Officer" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndManagementOfFinancialRisksForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureInventoriesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsAdditionalInformationDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails", "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureIncomeTaxDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractBalancesDetails", "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails", "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "C8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Section": "Presentation and disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_j&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r185": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r186": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r187": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r188": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r189": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r191": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r192": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r193": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r194": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r195": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r196": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r197": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r198": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_21_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r199": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r2": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r201": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r202": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r203": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r204": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r205": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r207": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r208": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r213": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r214": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r215": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r216": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r217": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r218": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r223": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r224": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r225": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r226": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r227": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r228": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r229": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r231": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r232": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r233": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r234": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r235": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r236": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r237": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r238": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r239": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r241": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r242": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r243": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r244": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r245": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r246": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r247": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r248": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r249": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r250": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r251": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r252": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r253": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r254": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r255": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r256": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r257": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r258": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r259": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r260": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r261": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r262": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r263": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r264": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r265": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r266": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r267": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r268": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r269": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r270": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r271": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r28": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "29", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "49", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 72 0001410578-23-001384-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-23-001384-xbrl.zip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

#DY9#$P,#$N:G!G4$L! A0#% @ \X&^5E?T M4T!U@0 @L0# !@ ( ! ,T" &-V86,M,C R,S S,S%X97@Y =.60R+FAT;5!+!08 "0 ) &(" "K3@, ! end